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Phosphatase of regenerating liver (PRL-1) has gained attention as an important 
therapeutic target because of its involvement in cancer and metastasis, where it promotes 
proliferation and cell motility. The protein is found at high concentration in numerous cancer 
tissues and when over-expressed induces cellular transformation. Elevated levels of PRL-1 have 
been shown to trigger metastasis and to promote cellular transformation and tumorigenesis. 
Because its enzyme activity contributes to both tumorigenesis and metastasis, this protein is an 
attractive target for therapeutic intervention. The problem with ubiquitously inhibiting PRL-1 is 
that this enzyme is also essential to cell survival and tissue regeneration under normal 
physiological conditions. Inhibition may result in nonspecific and unwanted cell death of healthy 
tissues. Targeting only the overactive form of an enzyme would provide a reasonable resolution 
to this problem, but it is currently unknown how PRL-1 prompts proliferation in some cells and 
differentiation in others. The long-term goal of this project is to identify the crucial structural and 
dynamic features that support the enzymatic activity of PRL-1 and characterize the different 
forms to identify ones appropriate to target for therapeutic intervention. In this work, we have 
shown that the full-length unmodified form of PRL-1 is primarily inactive based on its 
determined reduction potential (-364.3 ± 1.5 mV) and that in vivo, activation is likely conferred 
through a posttranslational modification at the C-terminus. Using an assortment of biophysical 
techniques, we have also shown that a mutant form of PRL-1 (PRL-1-C170S/C171S) is reduced 
and active and can serve as a model for posttranslationally modified PRL-1 at this site. 
A second goal of this dissertation project is to use PRL-1 as a model system for studying 
protein stability. An understanding of the forces that contribute to protein stability is crucial to 
the development of new biotechnology products with improved half-lives and lower 
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immunogenicity. Because proteins are held together by numerous weak interactions, 
understanding the mechanisms by which stabilization is achieved is important to the design of 
new biotechnology products that better resist unfolding and aggregation. Mechanistic 
information describing how specific interactions influence stability is lacking, in part because the 
techniques typically used to study inherent stability do not provide sufficient detail. We used 
high-resolution solution NMR to examine the details of one aspect of stability in PRL-1. It is 
well-established that the oxidation state of cysteine residues in proteins are critical to overall 
physical stability. The presence of disulfide bonds most often imparts thermodynamic stability, 
and as such, engineered disulfide bonds have become a means for improving the viability of 
protein therapeutics. In some cases, however, disulfide bonds can diminish stability. PRL-1 has 
two discernable stable states, one of which contains a disulfide bond (oxidized, inactive) and is 
slightly less stable than the one that does not (reduced, active). To understand how the reduced 
form compensates for the loss of the disulfide bond, a series of mutants were analyzed that 
disrupted disulfide bond formation in distinct ways. The physical stability of each variant is 
unique with respect to the others, indicating that the stability of the whole protein depends on a 
combination of local, synergistic interactions with the Cys side chains. High-resolution solution 
NMR was used to provide site-specific and mechanistic information about how each interaction 
influences the protein’s physical stability. This analysis reveals several key structural 
components that contribute to PRL-1’s overall stability in the absence this disulfide bond. The 
results provide insight to explain how the reduced protein compensates for the loss of this 
structural feature, which has implications for its function in vivo, and how local instability may 
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CHAPTER 1. INTRODUCTION 
 
1.1. PRL-1 AS A NOVEL THERAPEUTIC TARGET 
 In drug discovery research, a drug “target” is a molecule for which there is a reasonable 
amount of understanding of how it functions in both normal physiology and a diseased state. 
Upon identification of a target, a lengthy process ensues to validate the significance of the target 
with respect to the disorder or disease, which is often one of the most critical steps in the 
development of new therapeutics.1 Target validation requires more than identifying its 
expression at the genetic level because many genes often produce different protein isoforms, 
which can have subtly different functions, or encode posttranslational modification motifs that 
also give rise to variation in protein function. The ultimate goal is to identify a potent molecule 
(usually small in size) that modifies the actions of the target and promotes restoration of normal 
cellular physiology. High-throughput screening experiments rely on the use of large libraries of 
small molecule candidate compounds that may bind to and modify the activity of the target, most 
commonly a protein, thereby assessing the “druggability” of a target. 
Not all targets can be deemed druggable. Traditionally, classification of a protein as a 
druggable target is based on the fulfillment of three requirements: 1) the protein must have the 
ability to bind a small molecule with the appropriate “rule-of-five”∗ properties, 2) bind to the 
molecule with reasonable potency and 3) be disease modifying. Using this definition, it is 
suggested that between 600 and 3000 genes in the human genome code for potential druggable 
                                                
∗The so-called “rule-of-five” predicts that poor absorption or permeation is more likely when 1) 
there are more than five hydrogen-bond (H-bond) donors, 2) there are more than ten H-bond 
acceptors 3) the molecular weight (MW) is greater than 500 Daltons (Da), 4) the calculated Log 
P is greater than 5 (indicates increased lipophilicity) and 5) compound classes that are substrates 
for biological transporters are exceptions to the rule.2  
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targets.3 This definition does not, however, factor in specificity. Just because a small molecule 
drug with good physicochemical properties can be developed that modulates the activity of a 
protein target does not mean specificity can be achieved. Proteins of the same genomic family 
usually have functional similarities and conserved structural features within the binding-site, 
suggesting that if one member of the family were able to bind a drug, other members would also 
be able to bind the same compound. Furthermore, a single protein may regulate multiple 
pathways and inhibition or increased activation of the protein may lead to unwanted side effects. 
In this context structural characterization is an important facet of target validation experiments 
because the three-dimensional structure can permit identification of both allosteric and active 
binding sites, which provides further information about the biological role the target plays and 
facilitates structure based drug design. 
This problem of specificity is exemplified by the protein tyrosine kinase (PTK) family of 
enzymes, which have been studied and targeted for drug design for many years.4 PTKs play 
important roles in virtually all aspects of the cellular physiology and malfunction or deletion of 
these enzymes can lead to diseased states. Nearly all PTK inhibitors function by competing for 
the highly conserved adenosine triphosphate (ATP) binding site in vivo. Specificity, in part, 
comes from the fact that only a portion of the drug interacts with the residues that bind to ATP, 
while the rest of the molecule makes contacts with other residues situated outside the ATP-
binding pocket. Although a reasonable degree of specificity among related proteins with as much 
as 60% sequence identity can be achieved with this approach, it has been shown that even more 
distantly related proteins with less homology can still interact with the same inhibitor.4 
Furthermore, many kinases will alter the phosphorylation state of many protein substrates, which 
may lead to other undesirable outcomes. A better approach is to target a modified or unique form 
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of the protein involved in the promotion of a disease but not in normal cell function. This was 
successfully demonstrated with Gleevaec, a drug developed using structure-based rational design 
to solely inhibit the aberrant form of Abl kinase and effectively treat chromic mylogenous 
leukemia (CML).5,6  
In this work, a similar approach has been initiated to facilitate the design of a specific 
inhibitor to phosphatase of regenerating liver (PRL-1). PRL-1 is a unique protein tyrosine 
phosphatase (PTPases) that, together with the opposing actions of PTKs, plays an important role 
in maintaining appropriate tyrosine phosphorylation levels in the cell during development and 
tissue regeneration.7 PRLs are normally expressed at low levels in most mature cells, while 
higher expression levels are observed during embryonic development8 and during cellular 
proliferation9-13 or differentiation9,14-16 depending on the cell type. PRL-1 has gained attention as 
an important therapeutic target because of its involvement in cancer and metastasis, where it 
promotes proliferation and cell motility when active.17,18 Because its enzyme activity contributes 
to both tumorigenesis and metastasis, this protein is an attractive target for therapeutic 
intervention. The problem with ubiquitously inhibiting PRL-1 is that this enzyme is also essential 
to cell survival and tissue regeneration under normal physiological conditions. Therefore, its 
complete inhibition may result in nonspecific, unwanted cell death of healthy tissues. Targeting 
only the overactive form of the enzyme would provide a reasonable resolution to this problem, 
but it is currently unknown how PRL-1 prompts proliferation in some cells and differentiation in 
others. Our working hypothesis is that aberrant modification of PRL-1 results in misregulation of 
phosphatase activity, thereby promoting proliferation and/or motility of transformed cells. 
Posttranslational modifications may affect the activity of PRL-1 both directly, by altering the 
conformation of the protein to better prime the active site, and indirectly by altering its 
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subcellular location where it may act on different downstream effectors. A cartoon of PRL-1 is 
shown in Figure 1.1, which summarizes known and/or predicted sites of modification. The 
primary aim of my doctoral research project was to characterize the unmodified, full-length 
protein and understand how its C-terminal region contributes to the unique regulation of the 
catalytic activity of PRL-1. The research results described in this dissertation also provide a basis 
for subsequent development of potential therapeutics by either high-throughput screening or 
























1.2. PRL-1 AS A MODEL PROTEIN TO STUDY PROTEIN STABILITY 
 Commercial pressure often forces the pharmaceutical industry to direct their efforts 
towards development of small molecule drugs. Small compounds are far less expensive to make 
and are often much more stable than protein therapeutics but it can be quite difficult to obtain the 
desired specificity from a small molecule drug. Proteins offer a very high degree of selectivity in 
Figure 1.1. Cartoon of PRL-1. The potential posttranslational modifications that may 
regulate PRL-1 are shown with respect to the active site (C104VAGLGR) and WPFDD loop 
(see section 2.4). Those modifications that were investigated in this work are designated 
with a *.  
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their mode of action, and as such, these macromolecular molecules are also being pursued as 
potential drug candidates. Macromolecular drugs are quite diverse and range from peptides and 
proteins to nucleic acids and vaccines. Protein drugs often include monoclonal antibodies and 
recombinant proteins like insulin or human growth hormone that target the cell surface or 
extracellular sites.  
Protein molecules do have disadvantages when it comes to their use as therapeutics. Due 
to the inherent complexity of the molecule, they are often far less stable and susceptible to many 
pathways of both chemical and physical degradation, often leading to immunogenic responses in 
vivo.19 It follows that they are far more expensive to make and difficult to formulate than small 
molecules. Because of these problems, an understanding of the forces that contribute to protein 
stability is crucial to the development of new biotechnology products having improved half-lives 
and lower immunogenicity. It is often too expensive and too lengthy a process to conduct such 
research on viable protein drug candidates because of the need to rapidly identify stabilizing 
conditions for formulation purposes. In this context, basic research plays a pivotal role in the 
drug development process. Often times, model proteins (a novel protein target and/or a 
ubiquitously expressed cell signaling protein) that are well characterized at the molecular level 
can be used to answer fundamental questions regarding protein stability. Such questions can be 
conducted much faster with model proteins because the three-dimensional structure has often 
already been determined and the basic set of assays to produce and characterize the protein are 
usually known. This approach is used in the present work in which a novel drug target (PRL-1) 
was used to determine how stabilization or destabilization was achieved in various protein forms 
with or without a disulfide bond present. PRL-1 serves as an excellent model for this purpose 
because the information described in the following chapters indicate that this protein strongly 
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favors the oxidized state in vitro, but equilibrium control of the redox state is easily modulated 
using a redox buffer system to generate the reduced form. Second, a major conformational 
change occurs upon reduction of the protein, providing well-resolved, site-specific measurable 
differences between the two states using solution NMR spectroscopy. Additionally, the 
structures of both reduced and oxidized PRL-1 have been determined previously using X-ray 
crystallography, which facilitates interpretation of the changes observed in the NMR data with 
respect to the three-dimensional structure.20,21  
 
1.3. OUTLINE  
The following chapters describe the assays used to characterize full-length PRL-1 in both 
inactive and active states. Chapter 2 is used to describe the identification of a constitutively 
reduced and active form of PRL-1 to use as a positive control, followed by Chapter 3, which 
describes the methods used to obtain sequential backbone NMR assignments of reduced and 
active PRL-1 and the results therein. Chapter 4 is geared towards quantifying the propensity of 
PRL-1 to be modulated by redox conditions. The conclusions presented in this section provide 
the first evidence of how direct modification of PRL-1 can lead to both direct and indirect 
changes in its activity through structural changes and/or changes in the subcellular location. In 
Chapter 5, the focus is shifted from understanding the biology of PRL-1 to its stability. In this 
work, PRL-1 was used as a model to determine how modulation of a disulfide bond in different 
ways leads to increased or decreased stability and to elucidate the mechanism by which 
stabilization or destabilization was achieved in the various protein forms. The results of this 
investigation have provided key insight into how disulfide bonds stabilize proteins in general, 
which is important information that can be applied to the design of future protein therapeutics 
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with better physicochemical properties. The final chapter is largely discussion based, as the 
implications of the findings in this dissertation with respect to the larger goals of this project are 
considered as well as preliminary data presented that provides a foundation for subsequent 
studies in the Laurence lab. Two appendices are included in this document to facilitate the 
understanding of the various methods used. Appendix A focuses on the in vitro activity assays 
used. Appendix B provides a sequence alignment of the PRL family members. Appendix C is a 
comprehensive summary of NMR methods that can be used to facilitate drug design. Appendix 
D provides supplementary data for Chapter 5 and Appendix E summarizes a new method for 
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CHAPTER 2.  
IDENTIFYING A STABLE, REDUCED AND ACTIVE FORM OF PRL-1 
 
2.1. INTRODUCTION 
2.1.1. PRL-1 Belongs to the PTPase Family of Enzymes  
Tyrosine phosphorylation (pTyr) is a major protein posttranslational modification that 
cells utilize in signal transduction to regulate numerous cellular functions including (but not 
limited to) cell growth, differentiation, cell migration and apoptosis. The opposing activities of 
protein tyrosine kinases (PTKs), which promote phosphorylation, and protein tyrosine 
phosphatases (PTPases), which promote dephosphorylation, govern cellular pTyr levels in a 
reversible and dynamic manner to maintain homeostasis, and imbalances can lead to various 
diseased states.2,3 PRL-1 belongs to the PTPase family of enzymes and plays a critical role in 
normal proliferation during development and regeneration of damaged tissues. Although the 
biochemical pathways by which PRL-1 functions remain to be determined, mutagenesis studies 
have shown that the phosphatase activity of PRL-1 is required for normal mitotic progression, 
cellular proliferation, enhanced cellular motility and metastatic cancer formation, indicating that 
the active form of PRL-1 is the relevant target for development of anticancer therapeutics.4-11  
Although members of the PTPase family share an identical catalytic mechanism, the 
family is subclassified into three groups based on their structure or sequence homology and 
substrate preference: tyrosine-specific (ts), dual-specific (ds) and low molecular weight (lmw) 
PTPases. tsPTPases (such as PTP1B) strictly target pTyr substrates, while the dsPTPases can 
catalyze the hydrolysis of pSer and pThr as well as pTyr. The lmw and dsPTPases display little 
amino acid sequence identity with classic PTPases beyond the conserved residues in the active 
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site.12,13 Although the three subfamilies have little sequence similarity and display differences in 
substrate specificity, the three-dimensional structures of PTPase catalytic domains have the same 
general topology with a parallel β-sheet in the central portion of the protein bordered by α-
helices on both sides (Figure 2.1). The active site is located within a crevice on the protein 
surface, which is much deeper for the tsPTPases than for the dsPTPases. The deeper active site 
pocket in tsPTPases permits selectivity towards pTyr containing substrates.13,14 
The unique feature that is characteristic of all PTPases is the CX5R (single-letter code for 
amino acids) signature motif in the active site, where the X represents any amino acid. All 
PTPases dephosphorylate their pTyr substrates using a common two-step mechanism. Unlike 
alkaline phosphatases and Ser/Thr phosphatases, this reaction requires no metal ions and is 
nucleophilic in nature.12 First, the conserved Cys initiates the catalytic reaction by attacking the 
phosphorous on the incoming substrate, while the phosphate binding loop (P-loop) and 
conserved Arg residue bind and position the phosphate group (Figure 2.2). The thiolate of the 
conserved Cys is utilized as an attacking nucleophile to form a cysteinyl-phosphate enzyme 
Figure 2.1. Subclasses of the PTPase Family Members. A representative member of each 
PTPase subfamily is presented. The PDB files 2B4S, 1D5R and 1XWW were used to 
generate the illustrations of PTP1B, PTEN and LMWPTP, respectively. The active site is 












Figure 2.2. Classic PTPase Catalytic Mechanism. A. Simplified PTPase Reaction 
Scheme. B. Mechanism of Catalysis. Although the nature of the chemical reaction transition 
states is not discussed here, an illustration for each step was included for reference. For a 
detailed account of how PTPases achieve transition state stabilization, the reader is directed to 
an excellent review.12 This figure was created based on Figure 3 from reference 12, with 
modifications. It should be noted that significant differences between what is illustrated here 




intermediate (E-P), and substitution of the conserved Cys completely abrogates enzyme activity. 
12,15 In the second step, enzyme dephosphorylation is accomplished by hydrolysis. A sequentially 
distal but spatially proximal Asp residue facilitates both steps of catalysis by serving as a general 
acid during E-P formation, transferring a proton to the leaving tyrosine group, and by serving as 
a general base during hydrolysis that abstracts a proton from the nucleophilic water molecule 
(Figure 2.2). Mutation of the Asp residue results in a substrate-trapping enzyme because release 
of the leaving group is dramatically slowed.16-19 The conserved Asp residue is located in a 
flexible loop known as the WPD-loop, which undergoes a major conformational change upon 
substrate binding.20,21 In unligated PTPases (closed conformation), the conserved Asp moves as 
much as 20 Ǻ away from the active site. Previous studies have shown that the invariant Trp in 
the WPD-loop is an important hinge residue that hydrogen bonds to the conserved Arg to 
correctly position it in the active site for substrate binding in the open, active conformation. 
Mutation of the Trp residue completely disables general acid catalysis and diminishes the affinity 
of the active site for substrate.18 A conserved Ser or Thr is also often found immediately 
following the active site motif (CX5RS/T) and mutation of this residue dramatically slows 
catalysis. The hydroxyl group of this residue facilitates catalysis by stabilizing the negative 
charge on the leaving thiolate group during E-P hydrolysis.12,22,23 The PTPase catalytic 
mechanism has been extensively studied and readers are directed to some excellent reviews for a 
more detailed description of this information.12,13 
2.1.2. Oxidation of PTPases 
Although the PTPase family members display a range of regulatory mechanisms that are 
specific for each subclass, they do share one common mode of inactivation: reversible oxidation 
of the catalytic Cys residue, which has been shown to occur in vivo.24,25 Unlike most Cys 
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residues in proteins that have –SH pKa values near eight, the side chain of the PTPase catalytic 
Cys is typically deprotonated (pKa≈3-6) due to the partially positive microenvironment of the 
active site, making it extremely reactive at physiological pH.26 The exceptional reactivity of the 
thiol group is required for enzyme activity but also renders the catalytic Cys highly susceptible to 
oxidation.27-29 Members of each PTPase subfamily have previously been shown to be oxidized 
by treatment with H2O2 including the tsPTPases, PTP1B and LAR (leukocyte antigen-
related),28,30 human LMWPTP,31 and dsPTPases, VHR (vaccinia H1-related), PTEN and 
Cdc45.28,32,33 Oxidation of the catalytic Cys occurs via the formation of sulfenic acid, which 
inhibits catalysis because the reaction is mediated by the actions of a nucleophilic thiolate side 
chain.28 Oxidation of Cys residues to sulfenic acid is reversible upon incubation with thiol 
compounds. Extreme oxidizing conditions can lead to further oxidation of Cys residues to form 
sulfinic or sulfonic acid, both of which are irreversible (Figure 2.3).34 The mechanism common 
to all PTPases is to prevent further and irreversible oxidation by forming an S-S bridge 
containing the catalytic Cys. In the case of PTP1B, the sulfenyl-amide intermediate that forms 
upon oxidation can be glutathionylated to form a mixed disulfide.35-37 In other cases, 
intramolecular disulfide bond formation can occur between two Cys residues located within the 
Figure 2.3. PTPase Oxidation Scheme. The 
PTPase catalytic thiolate group can react 
with reactive oxygen species to form a 
sulfenic acid intermediate. The addition of 
one or two more oxygen atoms leads to the 
formation of sulfinic or sulfonic acid, which 
are irreversible modifications. On the other 
hand, the sulfenic acid intermediate can also 
react with nearby –SH side chains to form a 
disulfide bond. Disulfide bonds can be re-





active site, as for LMWPTP,31 or between two distant Cys residues, as for Cdc25,33 PTEN32 and 
SHP-1.38 This process is important because disulfide bond formation inhibits PTPase activity but 
protects itself from irreversible oxidation, permitting PTPase reactivation under favorable 
conditions. Most importantly, the differences in the pKa values of the catalytic Cys26 and the 
structural distance between the two Cys residues will dramatically influence the propensity of an 
individual PTPase to be rapidly oxidized and regulated by transient changes in intracellular 
redox conditions. 
The previously published crystal structure of wild-type PRL-1 reveals that a disulfide 
bond forms between the active site Cys (C104) and nearby partner C49, which was subsequently 
confirmed by Trypsin digestion followed by Mass Spectrometry analysis. Disulfide bond 
formation is accompanied by substantial changes in the conformation of the catalytically 
important residues that inhibit the ability of PRL-1 to bind substrate, and the formation of the -S-
S- bridge directly prevents formation of the phosphoenzyme intermediate.39,40 This indicates the 
reduced form of the PRL-1 protein is the relevant target for drug development. The chemically 
reduced wild-type protein (PRL-1 in the presence of a reducing agent) is not a good candidate for 
this purpose for several reasons. First, using the chemically reduced wild type may lead to a 
higher number of false positives or negatives in drug screening assays because 1) the reducing 
agent transiently interacts with the active-site residues of PRL-1, which may interfere with the 
binding of molecules of modest affinity, and/or 2) the reducing agent could interact (either 
chemically or physically) with other chemicals in the screening library. Furthermore, many of 
the commercially available reducing agents like dithiothreitol (DTT), β-mercaptoethanol (BME) 
and reduced glutathione (GSH) are readily susceptible to oxidation to form the oxidized 
counterparts (oxDTT, oxBME and GSSG), the formation of which limits the time during which 
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the protein remains active. Finally, PRL-1 may require a posttranslational modification in vivo 
for activation, and as such, the chemically reduced wild type would be dramatically different 
from the biologically relevant form. It follows that in order to conduct biologically relevant in 
vitro drug screening assays, identification of a stable, constitutively active (reduced) form of 
PRL-1 is needed, which is the subject of the current study. 
Several approaches were used to generate a constitutively reduced mimic of PRL-1, 
including direct modulation of the disulfide bond via mutagenesis. Mutations to C104 cannot be 
used because a change at this position renders the protein inactive,5 whereas mutation of C49 
would abolish disulfide bond formation but preserve the catalytic thiolate group essential for 
activity. Additionally, the residues at the predicted Src kinase phosphorylation site (Y53) and 
residues at the predicted farnesylation site were all tested for their indirect affect on disulfide 
bond formation (see Figure 1.1). In this approach, protein engineering was used to mutate 
residues of the respective posttranslational modification sites instead of in vitro modification 
because these reactions can be expensive and practically very difficult to complete. A summary 
of the findings is described in the following sections. 
 
2.2. METHODS 
2.2.1. Protein Expression and Purification 
The PRL-1 gene was cloned into the pET-30 Xa LIC vector as described previously.41 
The PRL-1 wild-type DNA was mutated to C104S, C49S and Y53E using the PCR-based 
Quickchange method. The primers used to generate these mutants were 5’- 
ggttgtattgctgttcatTCCgttgcaggccttgg-3’, 5’- ggagttaccacaatagtaagagtatGtgaagcaacttatgacac-3’ 
and  5’-gagtatgtgaagcaactGaAgacactactcttgtgg-3’, respectively, with capital letters indicating the 
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mutated base. The C170S-C171S 
double mutant was created using two 
rounds of mutagenesis with the  
primers for the C170S and C171S 
mutations, 5’-ggtcatagaaacaactCttgcat 
tcaataaggatc-3’ and 5’-ggtcatagaaacaa 
ctgttCcattcaataaggctgtaactc-3’, 
respectively (Integrated DNA Technologies, Coralville, IA). PCR reactions were treated with 
DpnI (Promega) for 1.5 hours at 37°C, directly transformed into NovaBlue GigaSingles 
Compentent cells (Novagen) and spread on LB agar plates containing 30 mg/mL kanamycin  
(Kan30) to select for transformed cells. Individual colonies were cultured overnight in LB Kan30 
at 37 °C. The resultant DNA was purified using the Wizard Plus MiniPrep System (Promega). 
The mutated DNA was confirmed to have the correct sequence by bidirectional sequencing using 
the T7 promoter and T7 terminator primers (Northwoods DNA, Inc., Bemidjii, MN). The 
plasmid was transformed into BL21 (DE3) competent cells and selected based on Kan30 
resistance. The PRL-1 variants were expressed and purified using the same procedure as 
described previously for the wild-type protein.41 All solutions used in the purification and 
analysis of samples involved in this study were sparged with Ar gas to minimize oxidation 
derived from O2. Purity of the final protein samples was assessed by SDS-PAGE and protein 
concentrations were determined by UV absorbance at 280 nm using an extinction coefficient of 
19420 M-1 cm-1. The extinction coefficient was calculated based on the reduced protein using the 
ProtParam program from ExPASy.42,43 Final samples were concentrated to 30 mg/mL and stored 
Table 2.1 Purpose of PRL-1 Mutants 
PRL-1 Variant Purpose 
Wild Type Permits chemical modulation of the disulfide bond with reducing agents 
C104S Abolishes disulfide bond formation; inactive 
C49S Abolishes disulfide bond formation; catalytic Cys preserved 
Y53E Mimics phosphorylation of Y53 
C170S-C171S Mimics modification of the CaaX box at C-terminus 
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at 4 °C in 50 mM HEPES, pH 7.5 until analysis. Table 2.1 summarizes the purpose of studying 
each mutant. 
2.2.2. SDS-PAGE 
Protein samples were diluted to a final concentration of 1 mg/mL in 50 mM sodium 
phosphate, pH 7.5, with 100 mM NaCl and were incubated for 1 hour with varying amounts of 
reduced or oxidized DTT. Oxidized DTT was obtained by incubating H2O2 with DTT at a 3:1 
concentration ratio (H2O2:DTT) and was confirmed to be complete by monitoring the absorbance 
at 283 nm.44,45 After incubation, non-reducing SDS-PAGE loading buffer was added. Samples 
were then heated for 6 minutes and finally run on a 12% acrylamide gel. Gels were stained using 
Coomassie (R-250) and the protein bands were used to assess the relative amounts of reduced or 
oxidized PRL-1. Because H2O2 also oxidizes 
Met residues rapidly, oxidized DTT was used 
to study thiol-specific chemistry changes. 
2.2.3. PTPase Activity Assays 
A standard phosphatase activity assay 
with p-nitrophenyl phosphate (pNPP) was 
used to determine the activity of PRL-1 
variants according to the scheme illustrated in Figure 2.4.46 Attempts to fit the activity of PRL-1 
to the Michaelis-Menten rate equation were unsuccessful. The details of the work to delineate the 
reason for this observation are outlined in Appendix A. Instead, the relative activity of PRL-1 at 
one substrate concentration was evaluated using assay mixtures that contained 50 mM HEPES, 
pH 7.5, 20 mM freshly prepared pNPP and 0-100 mM freshly prepared DTT. Reactions were 
initiated by the addition of PRL-1 at a final concentration of 1 mg/mL and monitored for 





absorption at 405 nm and 37 °C using a Cary 100 UV-Vis spectrophotometer with temperature 
controller. Reactions were run in triplicate and on a minimum of two independently produced 
protein samples, totaling at least n=6 replicates. Relative activity was determined at 60 minutes 




2.3.1. Nonreduced Full-length PRL-1 Wild Type is Primarily Inactive 
The pNPP activity assay performed on non-reduced, purified wild-type protein revealed 











0 1 mM DTT
Figure 2.5. PRL-1 WT Activity A. 
Data are displayed as percent maximum 
activity (100%) based on the average of 
reduced PRL-1-C170S-C171S samples, 
following subtraction of the blank 
involving the inactive PRL-1-C104S 
mutant. No increase in activity was 
detected when 100 and 200 mM 
reduced DTT were added (data not 
shown). The average of the samples is 
shown in the figure and error bars 
represent one standard deviation of the 
mean. B. SDS-PAGE of Wild-type 
PRL-1. The higher intensity of the 
lower band indicates that untreated 




PRL-1 requires the addition of a thiol reducing agent for activity. Maximal activity is reached 
when 10 mM DTT is added to the solution of 1 mg/mL PRL-1. An eight-fold increase in activity 
is observed when 10 mM DTT is added to the assay mixture. As a negative control, the PRL-1-
C104S mutant was constructed. This mutant is completely inactive because the nucleophilic 
thiol, which is essential for activity, has been removed. Under reducing conditions our activity 
data is comparable to the previously published kinetic constants, where truncated forms of PRL-
1 were found to turn over generic PTPase substrates quite slowly.21,39 
Because activity was dramatically affected by the addition of reducing agents, we 
hypothesized that the lack of signal observed for the untreated PRL-1-WT was due to disulfide 
bond formation at the active site. To test this, we ran untreated PRL-1-WT on SDS-PAGE under 
nonreducing conditions. Disulfide bond formation can be visualized using nonreducing SDS-
PAGE. Oxidized protein, containing a disulfide bond, migrates faster than predicted because the 
structure is more compact. When left untreated, wild-type PRL-1 runs as two bands on an SDS-
PAGE gel, just below the 20-kDa marker (Figure 2.5.B, lane 1). For wild-type PRL-1, the lower 
band is much more intense, corresponding to a high degree of oxidation. When run under 
oxidizing conditions, only the lower band is detected (Figure 2.5.B, lane 2). The addition of four-
fold excess of reduced DTT to the oxidized sample restores the upper band or reduced species 
(Figure 2.5.B, lane 3). As a control, the C104S mutant was also examined. At 50 mM oxidized 
DTT, no band corresponding to the 20 kDa oxidized species was observed (data not shown), 
indicating the band at 20 kDa reflects formation of a disulfide bond between C104 and C49. This 
is consistent with the findings of Sun et al. (2005), who examined both the C104S and C49S 
mutant by SDS-PAGE.39 These studies by Sun et al., however, were conducted on truncated 
PRL-1 (1-160) and chemical oxidation was required to generate the lower band. As such, direct 
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confirmation that the presence of the C-terminus does not alter the number or position of 
disulfide bonds is needed. This is reported in Chapter 4 (4.3.1) but indicates that the bond 





2.3.2. PRL-1-C170S-C171S is Reduced and Active 
We next began examining the effects of various mutations on the activity of PRL-1. The 
purpose of each mutant studied is outlined in Table 2.1 As indicated by Figure 2.6, the activity of 
PRL-1-C49S is slightly greater than the oxidized wild type, but markedly less than the reduced 
wild type. Only modest activity was observed with the Y53 mutants. In both cases, the activity 
was approximately nine-fold lower than the reduced wild type but only five-fold higher than the 
C104S negative control. In stark contrast to untreated wild-type PRL-1, the untreated C170S-
C171S mutant exhibits an eight-fold increase in activity. The activity of PRL-1-C170S-C171S is 
Figure 2.6. Activity of PRL-1 Mutants. The data are expressed as the 
% activity of the C170S-C171S mutant after subtraction of the C104S 
inactive mutant. C170S-C171S is constitutively active and does not 
require the addition of reducing agents. Averages of the individual runs 




statistically identical to wild-type PRL-1 under reducing conditions, and the activity of this 
mutant is not modulated by the addition of reducing agents.  
 
2.4. DISCUSSION 
The crystal structure of PRL-1 in complex with sulfate is shown in Figure 2.7.A. The 
secondary structural features and overall topology of PRL-1 are most similar to those of the 
dsPTPase category. Overall, PRL enzymes share low sequence identity with other dsPTPases 
(<30%) but have the closest structural homology to VHR, Cdc14, MKP (mitogen-activated 
protein kinase phosphatase), KAP (kidney androgen-regulated protein) and PTEN.39,40 Both the 
catalytic Cys and Asp are present in PRL-1, and the P-loop parallels other dsPTPases in 
sequence conservation. The so-called WPD-loop of PRL-1 is divergent and the catalytic Asp is 
located in the +5 rather than +3 position relative to the Trp, which we refer to as the WPFDD-
loop. In the closed conformation (PRL-1-C104S; Figure 2.7.A), the active site Arg (R110) is 
engaged in apolar interactions with the phenyl ring of a nearby Phe (F70) and a polar interaction 
with the carbonyl oxygen of the same residue (Figure 2.7.B). This important contact positions 
the most C-terminal Asp residue (D72) to participate in catalysis, which has been confirmed with 
mutagenesis studies of PRL-3.21 A sequence alignment of the PRL family members is presented 
in Appendix B. The most important and unique characteristic of the published PRL-1 structures 
is the presence of a disulfide bond at the active site (Figure 2.7.C). This has implications for 
changes in both the structure and activity of the enzyme. Although, Sun et al. (2005) showed that 
disulfide bond formation occurs between C49 and C104 by mass spectrometry, this required the 
use of H2O2 and all activity assays were conducted under reducing conditions, which gives no 
indication of the extent of oxidation in this truncated PRL-1 variant. In Figure 2.7.C, the 
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structures of the reduced PRL-1-C104S mutant and oxidized wild type are aligned and oriented 
to focus on the active site. The crystal structure indicates that structural changes that result from 
disulfide bond formation are confined to the active site, nearby residues and/or increased 
flexibility of the WPFDD-loop. For example, the backbone NH groups of P-loop residues lining 
the active site pocket in PRL-1-C104S are rotated in PRL-1-WT with the carbonyl carbons now 
Figure 2.7. Crystal Structures of PRL-1. 
A. PDB file 1ZCL is illustrated in blue The 
active site of the protein is labeled and 
colored in red. B. The active site of PRL-1-
C104S was enlarged for enhanced 
visualization of the contacts the P-loop 
makes and other residues that are important 
for proper active site positioning (i.e. F70, 
V113, R137 and F141). C. The PDB files, 
1ZCL (C104S; Red) and 1ZCK (WT; Blue) 
were aligned using Pymol to identify 
structural purtubations that occur upon 
disulfide bond formation. In the oxidized 





pointing inwards preventing substrate coordination. Additionally, the residues of the WPFDD-
loop are absent from the oxidized crystal structure, presumably because of flexibility or disorder. 
In line with this description, this study shows that wild-type PRL-1 forms a disulfide bond 
readily in vitro, which inhibits its PTPase activity (Figure 2.6). 
It appears, however, that upon oxidation, the overall topology of PRL-1 remains the same 
and that disulfide bond formation is accommodated within the structure without causing 
considerable conformational changes (Figure 2.7.C). In fact, the rmsd value for alignment of the 
backbones of the two structures is approximately 0.636 for the two protein forms. Based on this 
information, it was predicted the C49S enzyme should have comparable activity to the 
chemically reduced wild type. This was not the case, as indicated by Figure 2.6, which shows 
that PRL-1-C49S is approximately 1.5-fold less active than the chemically reduced wild type. 
Closer inspection of the C49S progress curve (data not shown) shows C49S initially turns over 
substrate at a rate comparable to the reduced wild type. Prior to any significant reduction in the 
total pNPP concentration, however, the rate slows to that of background, indicating substrate 
turnover has ceased. It appears that C49S can initially rapidly react with pNPP to a reasonable 
extent but has diminished ability to release product. This type of behavior is characteristic of a 
substrate-trapping mutant, similar to the D72A mutant studied by other groups,21,39 suggesting 
that disulfide bond formation may cause a considerably larger change in the protein than 
indicated by the two crystal structures. 
Although maximal activity of wild-type PRL-1 is gained by the addition of 10 mM DTT 
(Figure 2.6.A), the chemically reduced enzyme still turns over substrate extremely slowly, 
comparable to the previously published kinetic rate constants.21,39 Unique structural features of 
PRL-1’s active site may explain this observation. Typical of other dsPTPases, a shallow active 
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site pocket is present at the surface of the protein, although the β2-α1 loop (loop two; L2) and 
the β3-α2 loop (loop three; L3) are considerably shorter in PRL-1 and give rise to an unusually 
wide (almost 9 Ǻ) and shallow catalytic pocket compared to other dsPTPases, which suggests 
that either PRL-1 may be able to accommodate a unique or broader range of substrates, or its 
specificity is derived from posttranslational modification and/or binding partners that alter its 
conformation.  
Also unique to the active site of PRL-1 is the substitution of an Ala (A111) for the 
conserved Ser/Thr in the CX5RS/T signature motif that facilitates E-P hydrolysis (Figure 2.7.B). 
Accordingly, it was predicted that this mutation was a major contributing factor to the 
inexplicably low in vitro activity of PRL-1 (and -3) towards generic substrates.21,39 As shown by 
Sun et al. (2005), substitution of Ala with Ser to create the PRL-1-A111S mutant increases the 
rate of activity by about 15 fold. Although a 15-fold rate enhancement is significant, it is rather 
small compared to the differences in reaction rates of other PTPases in which an Ala has been 
substituted for the Ser/Thr. Others have seen as much as a 100-fold reduction in enzymatic 
activity with this mutation in other PTPases.12 There are two additional residues that participate 
in unique interactions with the active site pocket that also contribute to PRL-1’s low in vitro 
activity, albeit to a reasonably small extent (Figure 2.7.B) First, position 113 is predicted (based 
on structural and sequence homology) to provide two H-bond donors to the carbonyl carbon of 
G109. The first comes from the backbone NH and the second comes from a conserved Thr side 
chain. In PRL-1, Val is substituted for the Thr. Furthermore, the NH of this residue is equally 
close in space to the carbonyl of R110, and it is difficult to predict to which atom it would prefer 
to donate. Sun et al. (2005) found that substitution of Val with Thr increases the enzyme activity 
by seven fold.39 In a subsequent study by the same group, it was shown that a double mutant 
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consisting of both the A111 to Ser and V113 to Thr mutations (PRL-1-A111S/V113T) exhibited 
a 24-fold increase in PTPase activity compared to the wild type.7 Second, position 137 is 
predicted (also based on structural and sequence homology) to provide two H-bond donors to the 
carbonyl groups of A106 and G107 of the P-loop. In other dsPTPases, this residue is an Arg and 
its position is stabilized via tertiary contacts with nearby Asp and Asn residues. While the 
corresponding Arg (R137) residue is present in PRL-1, its interactions with the P-loop are 
relatively weak because it lacks the appropriate nearby residues to stabilize its position. Instead 
of Asn or Asp, V10 and presumably A8 are situated in close proximity to R137. Despite missing 
the appropriate tertiary contacts, Sun et al. (2005) found that mutation of R137 to Ala causes a 
ten-fold reduction in enzyme activity indicating this residue does weakly interact with the active 
site.39  
Collectively, this information indicates that structural reorganization of the active site 
may be needed to confer activity. This could be provided from substrates or binding partners in 
vivo. For example, ATF-5 (activating transcription factor-5; mistakenly called ATF-7 in 
reference 47) was identified as a PRL-1 binding partner using a yeast two-hybrid system and 
confirmed using a variety of gel-shift assays in vitro.48 Although the unusually flat surface 
properties of L2, L3 and the active site is consistent with binding to a coiled-coiled protein such 
as ATF-5, further confirmation of the PRL-1 and ATF-5 interaction has yet to be described by 
other groups. 40 This may be due, in part, to the use of inappropriate (incorrectly 
posttranslationally modified) PRL-1 forms in the binding assays. In agreement with this idea, the 
majority of the conserved amino acids are located in or surrounding the active site. As such, it is 
likely that substrate specificity and/or active site rearrangement is determined by other unique 
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features, distal to the active site where amino acid substitutions among the PRLs are located, 
which may direct posttranslational modifications of the primary sequence.39,40  
Y53 is located within a predicted Src kinase motif and is predicted to be phosphorylated 
in vivo.49 To determine whether modification of this residue affects the activity of PRL-1, the 
Y53E mutant was constructed. As indicated by Figure 2.6, this mutant has markedly less activity 
than the reduced wild type and only moderately more activity than the C104S negative control. 
This finding indicates that phosphorylation (or other modifications of this residue) may 
negatively regulate PRL-1 activity. On the other hand, modification to residues C170 and C171 
dramatically enhanced the activity of PRL-1 and the C170S-C171S double mutant does not 
require a reducing agent for activity. The PRL enzymes are unique in that each isoform contains 
a C-terminal prenylation motif or CaaX box, where C stands for cysteine, a represents any 
aliphatic residue and X corresponds to any amino acid. The prenylation motif directs 
farnesylation at the conserved CaaX box Cys, followed by proteolytic cleavage of the aaX 
peptide and methylation of the terminal carboxyl moiety.50 Farnesylation has been shown to 
occur in vivo for the PRL enzymes.49,51 In PRL-1, this modification occurs at C170 and often 
affects its subcellular localization. Because farnesylation occurs on C170 and mutation of this 
residue increases the in vitro activity, we expect farnesylation will also alter the protein’s 
conformation to a more active state. This correlates well with biological studies, which found 
that when farnesylation is prevented, localization of PRL-1 is altered and its ability to promote 
proliferation is abrogated. For example, expression of a prenylation-defective mutant of PRL-1 
in HeLa cells causes mitotic defects4 and the loss of PRL-1 prenylation in HEK293 cells inhibits 
the ability of PRL-1 to promote cell growth and migration.7 
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 In summary, the data presented in this chapter show that alterations to two of the 
predicted posttranslational sites affect the enzyme activity of PRL-1, such that farnesylation at 
the C-terminus probably promotes catalysis, while phosphorylation at Y53 would inhibit it. 
These studies also indicate that the C170S-C171S mutant provides the most stable, reduced and 
active form of PRL-1 of those tested with which inhibition assays and screening for lead 
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CHAPTER 3.  
1H, 15N, 13C RESONANCE ASSIGNMENTS  
OF REDUCED AND ACTIVE PRL-1 
 
3.1. INTRODUCTION 
One of the most important uses of high-field solution nuclear magnetic resonance (NMR) 
in the pharmaceutical industry relies on its unique ability to examine protein-drug interactions at 
high resolution. NMR can be used to evaluate the structural, thermodynamic and kinetic aspects 
of even a weak binding reaction. The basis of NMR screening experiments is that binding causes 
a perturbation in the physical properties of both molecules. Unique properties of small and 
macromolecules allow selective detection of either the protein target or ligand, even in a mixture 
of compounds. This topic has been extensively reviewed in Appendix C, which outlines current 
methodologies used for assessing protein-ligand interactions from the perspectives of the protein 
target and ligand and delineates the fundamental principles for understanding NMR approaches 
in drug research.  
In order to conduct protein detected NMR drug screening assays and facilitate structure 
based drug design, sequence-specific backbone assignments of the protein target are needed. 
Previously, the 1H, 15N, and 13C resonance assignments were reported for PRL-1 under 
nonreducing conditions.1 Unfortunately, the protein is inactive under these conditions, as 
indicated by the results presented in Chapter 2. Consequently, a mutant form of PRL-1 (PRL-1-
C170S-C171S) has been identified that constitutively exists in the reduced and active state. 
Although the crystal structures of wild type and reduced but inactive C104S reveal the overall 
conformation of these two forms is approximately the same, our studies with the C49S mutant 
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indicate that, in solution, more substantial changes between the two states may be present. 
Furthermore, the 1H, 15N and 13C resonance assignments were reported for PRL-2 and PRL-3 
under reducing conditions.2,3 Comparison of these very closely related homologues (>76% 
identity) reveals large differences in conformation between the reduced and oxidized forms. See 
Appendix B for the sequence alignment of the PRL family members. Consequently, the majority 
of chemical shift positions of resonances from reduced PRL-1 are substantially altered compared 
to those of the previously reported oxidized form, precluding our ability to deduce assignments 
based on small chemical shift perturbations. We present here the 1H, 15N and 13C resonance 




3.2.1. Protein Expression and Purification 
 PRL-1-WT and C170S-C171S were expressed and purified as previously described in 
section 2.2.1. All solutions used in the purification and analysis of samples involved in this study 
were sparged with Ar gas to minimize oxidation derived from O2. Purity of the final protein 
samples was assessed by SDS-PAGE and protein concentrations were determined by UV 
Absorbance at 280 nm using an extinction coefficient of 19420 M-1 cm-1. The extinction 
coefficient was calculated based on the reduced protein using the ProtParam program from 
ExPASy.4,5 Purified protein samples were concentrated to approximately 2.0 mM in 50 mM 






3.2.2. NMR Experiments 
For making assignments, the NMR sample was at 2 mM concentration, contained 5% 
D2O, 50 mM sodium phosphate at pH 6.5 with 100 mM NaCl and was analyzed in a Shigemi 
tube. 2D 1H-15N HSQCs and 3D versions of the CBCA(CO)NH, HNCACB, C(CO)NH and 
HNCO experiments6 were carried out on a Bruker Avance 800 MHz NMR spectrometer using a 
cryogenic, triple-resonance probe equipped with pulse field gradients. Water suppression was 
accomplished using flip-back pulses. All spectra were obtained at 37 °C and referenced relative 
to DSS.7 Spectra were processed using nmrPipe 8 and peak picked using Sparky.9 Peak lists were 
submitted to the PINE Server through NMRFAM, University of Wisconsin, Madison.10 All 
automated assignments were manually verified using Sparky based on the strategies presented by 
Sattler et al. (1999).6 
For structural comparisons between PRL-1-WT and PRL-1-C170S-C171S, 1H-15N 
HSQC spectra were acquired on the same instrument listed above. All spectra were obtained at 
37 °C and acquired in 16 scans with 2048 points in the 1H dimension and 256 increments for the 





15N dimension. The sample concentrations were 1.0 mM and made up in the same buffer 
conditions described above. Sample reduction of PRL-1-WT was accomplished by the addition 
of 10 mM DTT at least 72 hours prior to spectral acquisition. All spectra were referenced as 
described above, processed using nmPipe and peak picked using Sparky for chemical shift 
analysis. 
3.3. RESULTS 
3.3.1. Completion of Assignments 
Greater than 90% of the NH, CO, Cα and Cβ resonances were assigned for PRL-1-
C170S-C171S. Complete sequential backbone assignments were achieved for residues V10-
Q173 with the exception of residues N27, E36, T52, E59, A111, R137 and R138 and two small 
regions including residues N142-K144 and R167-N169. Assignments for E36, T52, E59 and 
R137 are available for wild-type PRL-1, although no 13C chemical shift information is available 
for R137. N27, A111 and the C-terminal regions missing in PRL-1-C170S-C171S were also not 
assigned in the oxidized wild type and are likely undergoing conformational exchange. More 
importantly, the residues comprising the PTPase active site were fully assigned for PRL-1-
C170S-C171S. This information was missing in wild-type PRL-1 and should prove to be useful 
for NMR-based drug screening assays. More than 80% of the aliphatic side chains were assigned 
using the CCCONH experiment. Figure 3.1 shows the 1H-15N HSQC spectrum of PRL-1-C170S-
C171S with peaks labeled. 
3.3.2. Chemical Shift Comparisons 
The assignments for PRL-1-C170S-C171S correlate well with the assignments previously 
published for PRL-2 and PRL-3 under reducing conditions, indicating that the C170S-C171S 
mutant is, in fact, a reduced species. Comparison of PRL-1-C170S-C171S assignments to the 
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non-reduced wild type reveals a difference in conformation between the reduced and oxidized 
species, which is illustrated in Figure 3.2.A. Overall, more than 90% of the backbone amide 
resonances shift upon reduction, which is illustrated graphically in Figure 3.3. Exceptions 
include G123 and Y126, located at the opposite end of the central helix from the active site, and 
several peaks in the middle of the spectra. The backbone NH resonance of C49, which forms a 
disulfide bond with the active site residue C104, shifts significantly upfield by more than 9 ppm 
in nitrogen and 1 ppm in proton (Figure 3.3) with the C170S-C171S mutation, which is also 
observed in wild type upon chemical reduction. The NH chemical shift of the C49 residue 




WT (red) and C170S-
C171S (black). The 
C49 and C104 residues 
are highlighted by a 
black and red boxes, 
respectively.  
B. Reduced PRL-1-
WT (red) and C170S-
C171S (black). 
Reduction of the wild 
type was accomplished 
by the addition of 10 
mM DTT. The small 
number of unique peaks 
in the spectra are 
probably a result of 
dynamic differences that 
arise from chemical 





moving upfield just under 1 ppm in nitrogen and 0.1 ppm in proton (Figure 3.3). Cβ chemical 
shifts can indicate the redox state of cysteine residues 11, and accordingly, the Cβ chemical shifts 
of the C104 and C49 residues differ between the reduced and oxidized states. The Cβ shifts for 
C49 and C104 in non-reduced wild type are 35.21 and 36.36 ppm, respectively, while for 
C170S-C171S, the Cβ shift for C49 is 34.01 and the Cβ peak for C104 is 29.82 ppm. The upfield 
shift indicates the cysteine residues are in the reduced state in PRL-1-C170S-C171S, although 
trypsin digestion with mass spectrometry analysis is needed to confirm this and is presented in 
the next chapter. Lastly, the 1H-15N HSQC spectra of PRL-1-C170S-C171S overlays 
exceptionally well with chemically reduced wild type (Figure 3.2.B) and it does not change with 
the addition of thiol modulating agents (data not shown). This parallels the finding from the 




Figure 3.3. Redox State Based Chemical Shift Changes. A. Δδ (1H). B Δδ (15N). Δδ 
was calculated by subtracting δ (ppm) for PRL-1-C170S-C171S from δ (ppm) for oxidized 
PRL-1-WT. Residues denoted with ∗, ∘ and ✝, were either not assigned for both PRL-1 
variants, assigned for wild type but not the mutant or assigned for the mutant and not wild 
type, respectively. Consequently, a Δδ value for these residues was not calculated and 




addition of DTT (data not shown). Together, the data indicate that PRL-1-C170S-C171S 
represents the active form of this phosphatase, which can be used to facilitate NMR-based drug 
screening to identify molecules that inhibit its activity. 
3.3.3. Data Deposition 
The assignments have been deposited in the Biological Magnetic Resonance Databank 
(BMRB) under the accession number 15949 (http://www.bmrb.wisc.edu).  
 
3.4. DISCUSSION 
Although the solution NMR data reveal that substantial conformational changes occur in 
solution between the reduced and oxidized states, such large differences are not apparent in the 
crystal structures. The majority of the differences are located near the active site when 
comparing the two crystallized proteins, and these differences are obvious in the NMR data as 
well. The number and magnitude of changes, however, is much more substantial that would be 
predicted based on the crystal structures. One explanation for this discrepancy may be the 
absence of the C-terminus. Crystallized PRL-1 was truncated at residues 156 and 160 for the 
reduced and oxidized forms, respectively, but we have clearly shown that these residues are 
important for the structure and activity of the protein. Furthermore, the most dramatic change in 
the spectrum that occurs upon reduction of PRL-1 corresponds to the chemical shift changes of 
C49, which is expected. Such a large change can be advantageous for the purpose of studying the 
reduction potential of the disulfide bond because it provides a large, measurable difference 
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CHAPTER 4.  
ENZYME ACTIVITY OF PRL-1 IS CONTROLLED BY REDOX 
ENVIRONMENT AND ITS C-TERMINAL RESIDUES 
 
4.1. INTRODUCTION 
PTPases are subject to redox regulation, such that oxidation inhibits their activity and, as 
such, members of each PTPase subfamily have been shown to be oxidized both in vitro and in 
vivo.1 The mechanism common to all PTPases is to prevent further and irreversible oxidation by 
forming an S-S bridge containing the catalytic Cys. This process is important because disulfide 
bond formation inhibits PTPase activity but protects the enzyme from irreversible oxidation, 
permitting PTPase reactivation under favorable conditions. Intracellular reducing agents such as 
thioredoxin (TRX), glutaredoxin (GRX) and reduced glutathione (GSH) presumably play 
essential roles in the recovery of PTPase activity in vivo.2 The propensity for disulfide bond 
formation will be influenced not only by the pKa value of the catalytic Cys, but also the 
structural distance between the two partner Cys residues.3 Unfortunately, in vitro activity assays 
and structure analyses are often performed in the presence of high concentrations of reducing 
agents to prevent inactivation. Despite this precaution, crystallization of PRL-1 produced a 
structure of the inactive, oxidized form. No other PTPase structure has been reported in the 
inactive state and many remain active in the absence of reducing agents, suggesting that PRL-1 
may be more prone to oxidation than other family members.4 This is further supported by the 
data in Chapter 2 indicating that full-length PRL-1 WT is primarily inactive in vitro and forms a 
disulfide bond readily under mild oxidizing conditions. 
Disulfide bond formation in vivo depends on the presence of reactive oxidants as well as 
the redox environment of the cell, which is primarily determined by the amount of glutathione 
and the ratio of its reduced to oxidized forms [GSH:GSSG]. The reduction potential and capacity 
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of a cell vary with tissue type, age, health and most importantly, cellular compartment.2 The 
reported subcellular locations of PRL-1 are quite varied among the different research groups and 
depend on the presence of posttranslational modifications, especially farnesylation. The specific 
roles that PRL-1 plays at each of these locations has yet to be elucidated, but because PRL-1 is 
subject to redox modulation, it is likely that posttranslational modifications may affect the 
activity of PRL-1 both directly, by altering the conformation of the protein to better prime the 
active site (as indicated by the C170S-C171S mutant), and indirectly by altering its subcellular 
location where it may be more or less prone to inactivation by disulfide bond formation. The 
combination of these regulatory mechanisms provides a novel way for cells to differentially 
regulate enzymes that share a common mechanism of, but have a different propensity for, 
oxidative inactivation. In the present study, high-resolution NMR was used to determine the 
reduction potential of the active site disulfide bond in full-length PRL-1. Determining the 
reduction potential of the disulfide bond involving the catalytic Cys provides a basis for 
understanding how subcellular localization may regulate the phosphatase activity of PRL-1 in 
different types of cellular environments. 
 
4.2. METHODS 
4.2.1. Protein Expression and Purification 
All PRL-1 variants were purified as described in section 2.2.1. The primer used to 
generate the C98A mutant was 5’-cgtgaagaacctggtGCTtgtattgctgttcattgc-3’. Capital letters 
indicate the mutated bases. All sample buffers for analysis in this study were sparged with Ar gas 
to minimize oxidation derived from O2. Purity of the final protein samples was assessed by SDS-
PAGE and protein concentrations were determined by UV Absorbance at 280 nm using an 
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extinction coefficient of 19420 M-1 cm-1. The extinction coefficient was calculated based on the 
reduced protein using the ProtParam program from ExPASy.5,6 Purified protein samples were 
concentrated to approximately 1.5 mM and stored in 50 mM sodium phosphate at pH 7.5 with 
100 mM NaCl. 
4.2.2. Electrospray Ionization Mass Spectrometry∗  
ESI spectra were acquired on a Q-Tof-2 (Micromass Ltd, Manchester UK) Hybrid Mass 
Spectrometer operated in MS mode employing the time of flight analyzer de-tuned to 8000 
resolution (FWHH) for sensitivity. For whole protein ESI spectra, purified protein samples were 
diluted to 1 µg/µL in untreated (“oxidizing”) 20 mM ammonium bicarbonate, pH 8.2, and 
allowed to incubate at room temperature. Time points were taken on the first, fourth and seventh 
day post-purification and frozen at -80°C until ready for use. Samples were desalted on a short (3 
cm x 1 mm I.D.) reverse-phase (RP) HPLC column (Hamilton PRP1, Reno, NV). Samples were 
loaded onto the column from a 1% formic acid solution with protein (5 µg), washed in same 
solution, and eluted with 90% MeOH/0.5% formic acid directly into the ESI source. The cone 
voltage was 60 eV, and the voltage on the collision cell was 20 V. Spectra were acquired over 
the mass range 800 to 3000 u, accumulating data for 5 seconds per cycle. 
For tryptic digests, PRL-1-WT and PRL-1-C170S-C171S were diluted to 1 mg/mL in 
ammonium bicarbonate, pH 8.2, with or without 20 mM β-mercaptoethanol (BME), and trypsin 
(Promega) was added in a 1:50 ratio protease:protein (w/w) and incubated at 37 °C for 16 hours. 
To confirm complete digestion, samples at various time points were analyzed by SDS-PAGE and 
visualized by silver staining. Coupled to MS analysis, capillary HPLC separations were 
performed using a Zorbax SBC18 RP column (5 cm x 0.32 mm I.D., 3.5 µm bead size, 300 Å 
                                                
∗ This data was collected in collaboration with Anthony A. Vartia and Todd Williams.  
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pore size) packed by Micro-Tech Scientific (Sunnyvale, CA), with a chromatograph (Waters 
capLC XL, Milford, MA) that develops gradients at 10 µL/min. A linear gradient of 20 to 80% B 
was applied over 120 minutes. The solvents were: A) 99% H2O, 1% MeOH, B) 99% MeOH, 1% 
H2O, and both contained 0.08% formic acid. Argon was admitted to the collision cell at a 
pressure that attenuates the beam to about 20%. This corresponds to 16 psi on the supply 
regulator or 5.3 x 10-5 mBar on a penning gauge near the collision cell. The collision cell was 
operated at 8 V for maximum transmission, and spectra were acquired over the range 250 to 
2000 u, accumulating data for 8 seconds per cycle. 
4.2.3. SDS-PAGE 
Protein samples were diluted to 1 mg/mL concentration in 50 mM sodium phosphate, pH 
7.5, with 100 mM NaCl and were incubated for 1 hour with varying amounts of reduced or 
oxidized dithiothreitol (DTT). Oxidized DTT was obtained by incubating H2O2 with DTT at a 
3:1 concentration ratio (H2O2:DTT); oxidation was confirmed to be complete by monitoring the 
absorbance at 283 nm.7,8 After incubation, non-reducing SDS-PAGE loading buffer was added. 
Samples were then heated for 6 minutes and finally run on a 12% acrylamide gel. Gels were 
stained using Coomassie (R-250) and the protein bands were used to assess the relative amounts 
of reduced or oxidized PRL-1. To determine if PRL-1 could be reduced by GSH, a similar study 
was conducted using GSH as the reducing agent. The protein was incubated under the same 
conditions with GSH concentrations ranging from 0.1 mM to 200 mM. After incubation, non-
reducing SDS-PAGE loading buffer was added. Samples were then heated for 6 minutes and 
finally run on a 12% acrylamide gel. Gels were stained using Coomassie (R-250) and the protein 




4.2.4. Phosphatase Activity Assays 
A standard phosphatase activity assay with p-nitrophenyl phosphate (pNPP) was used to 
determine the relative activity of PRL-1 variants.9 All samples were exchanged at least 105 fold 
by dialysis or using Amicon Ultra 10 kDa centrifugal filters (Millapore) into 50 mM HEPES, pH 
7.5 before being tested for phosphatase activity. Assay mixtures contained 50 mM HEPES, pH 
7.5, 20 mM p-nitrophenyl phosphate (pNPP-freshly prepared) and 0-10 mM reduced DTT. 
Reactions were initiated by the addition of PRL-1 at a final concentration of 1 mg/mL and 
monitored for absorption at 405 nm and 37 °C using a Cary 100 UV-Vis spectrophotometer with 
temperature controller. Reactions were run in triplicate and on a minimum of two independently 
produced protein samples, totaling at least n=6 replicates. Relative activity was determined at 60 
minutes by calculating the amount of p-nitrophenol produced (ε=1.78x10-4 M-1·cm-1).10 Averages 
and standard deviations of the of the individual runs are shown. 
4.2.5. NMR Experiments 
For structural comparisons of PRL-1 variants, samples were prepared in 50 mM sodium 
phosphate buffer, 100 mM NaCl, pH 6.5, containing 5% D2O. 1H-15N HSQC spectra were 
acquired on a Bruker Avance 800 MHz spectrometer using a cryogenic, triple resonance probe 
equipped with pulse field gradients. Water suppression was accomplished using flip-back pulses. 
The concentrations of PRL-1-WT and PRL-1-C98A were 1 mM and the spectra were collected 
with 2048 points in 1H and 256 increments in 15N. Sample reduction was accomplished by the 
addition of 10 mM DTT at least 72 hours prior to spectral acquisition. All spectra were obtained 
at 37 °C.  
For the redox titration, the method previously published by Piotukh et al. (2007) was 
followed.11 Briefly, PRL-1-C98A was prepared in 50 mM sodium phosphate, 100 mM NaCl, pH 
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7.5, containing 5% D2O at a final concentration of 0.3 mM. As judged by SDS-PAGE, PRL-1-
C98A was fully oxidized by adding 5 mM oxidized DTT (DTT oxidation was verified as 
described above). The sample was then titrated with increasing amounts of reduced DTT (1-200 
mM) and a 1H-15N HSQC spectrum was taken at each point. Spectra were collected on a Bruker 
Avance 800 spectrometer using a cryogenic, triple resonance probe equipped with pulse field 
gradients. All spectra were obtained at 37 °C and acquired in at least 16 scans with 2048 points 
in 1H and 256 increments in 15N. For both studies, 1H chemical shifts were referenced with 
respect to an external DSS standard in D2O. Indirect referencing relative to 1H was determined 
for 15N assuming the ratio 15N/1H = 0.101329118.12 nmrPipe and SPARKY were used for data 
processing and spectral analysis.13,14 
4.2.6. Determining the Reduction Potential of PRL-1  
Following the method by Piotukh et al. (2007) to determine the reduction potential of 
PRL-1, the heights of several well-resolved peaks in each NMR spectrum were obtained using 
SPARKY and plotted versus the corresponding half-cell potential of DTT 11. The half-cell 
















3  (1) 
where R is the universal gas constant (8.3145 J K-1 mol-1), T is the temperature in Kelvin, n=2 for 
the two-electron reduction, and F is the Faraday constant (9.6485x104 C mol-1). For the reduced 
and oxidized DTT pair, the standard midpoint potential, E0’, was previously determined to be      
-332 mV at pH 7.0 7. This value was adjusted to pH 7.5 according to the equation 2,11 
! 
EpH mV( ) = E
0 + pH " 7.0( ) #
$E
$pH
  (2) 
The ΔE/ΔpH value for DTT was taken as -61.5 2.   
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 PRL-1 undergoes a structural transition upon reduction and sequence assignments for the 
reduced and oxidized species are published elsewhere.15,16 This information was used to identify 
chemical shifts for the same residues in each state and to select reference peaks that have no 
change in chemical shift upon reduction (G123; 7.9 and 107.6 ppm and Y126; 9.3 and 124.3 
ppm). The reference peaks were used to control for dynamics changes between the two spectra. 
The correction factors were averaged for both reference peaks and then applied to the peaks 
selected for statistical analysis. 10% of the backbone NH resonances that change intensity 
significantly upon reduction were selected on the basis that they were well-resolved and assigned 
in both the reduced and oxidized spectra. These peaks were used to calculate E0’ of PRL-1. The 
peak heights of individual resonances were normalized, plotted against the half-cell potential and 





1+ x /E 0'( )p
+ B     (3) 
where A and B are the values for the initial and final plateaus of the sigmoidal decay function 
and p is the curve increase rate from the plot of each resonance. The resulting individual curves, 
depicting the relative amounts of the corresponding NH resonance in the reduced and oxidized 
states, intersect at 50% of the maximal intensity. This point defines the standard potential E’. 
Fifteen peaks were fit for an E’ value and then averaged to determine the reduction potential.  
 
4.3. RESULTS 
4.3.1. Purified Full-length PRL-1-WT is Inactive 
As indicated by our analysis of the full-length, unmodified wild type in Chapter 2, PRL-
1-WT is primarily inactive under nonreducing conditions. Because activity was dramatically 
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affected by the addition of reducing agents (Figure 2.6.A), we hypothesized that the lack of 
signal observed for the untreated PRL-1-WT was due to disulfide bond formation at the active 
site. To test this, we ran untreated PRL-1-WT on SDS-PAGE under non-reducing conditions 
(Figure 4.1.A, lane 2). When left untreated, wild-type PRL-1 runs as two bands on an SDS-
PAGE gel, just below the 20-kDa marker (Figure 1B, lane 1). For wild-type PRL-1, the lower 
band is much more intense, corresponding to a high degree of oxidation. When run under 
oxidizing conditions, only the lower band is detected (Figure 4.1.A, lane 2). The addition of a 
four-fold excess of reduced DTT to the oxidized sample restores the upper band or reduced 
species. Disulfide bond formation in PRL-1 has been observed by SDS-PAGE previously, but 
these studies were performed on a truncated version of PRL-1, and hydrogen peroxide was used 
to accomplish oxidation.4 Because H2O2 also oxidizes methionine residues rapidly, we chose to 
use a thiol-specific chemistry for this study. This approach has the advantage of employing an 
equilibrium reaction and enables quantitative analysis. Because glutathione (GSH) is the primary 
Figure 4.1. PRL-1-WT. A. 2 mg/mL PRL-1-WT was incubated with various amounts of 
oxidized or reduced DTT for approximately one hour. The higher intensity of the lower 
band indicates that untreated PRL-1-WT is primarily oxidized. B. 2 mg/mL PRL-1-WT 
was incubated with increasing concentrations of reduced glutathione (GSH) and run on 
SDS-PAGE. Although, only 10-50 mM GSH is shown here, concentrations spanning 0.1-






redox buffer in vivo, these experiments were also performed using the GSH/GSSG redox couple 
as a thiol-modulating agent. Although GSSG efficiently oxidized PRL-1 (data not shown), 
complete reduction by GSH was only accomplished at concentrations near 50 mM (Figure 
4.1.B). Because of this, DTT was used in all studies as both an oxidizing and reducing agent.  
To confirm the formation and position 
of disulfide bonds in the untreated full-length 
protein, PRL-1 was analyzed using mass 
spectrometry. Several peaks were observed in 
the mass spectra of intact protein, which 
indicate wild-type PRL-1 is oxidized. A mass 
shift of +2 is observed in the spectra of 
proteins subject to chemical reduction 
compared to the oxidized samples, suggesting 
that one disulfide bond has been broken. To 
identify the specific sites at which oxidation 
occurs, PRL-1 was digested with Trypsin and 
examined using LC-separated ESI-MS under 
both reducing and oxidizing conditions. 
Digests of wild-type PRL-1 protein in non-
reducing and reducing environments reveal 
differences in intensity for peaks associated 
with peptides containing C49 and C104. In the presence of oxygen, PRL-1-WT shows almost 
exclusively the presence of the C49- and C104-containing fragments joined by a disulfide bond 
Figure 4.2. Mass spectra of PRL-1 
fragments from a tryptic digest after 
LC/MS separation. The column on the left 
contains data corresponding to the mass 
series for the C49-containing peptide and 
the right shows the disulfide bound C49-
C104 containing peptides. WT PRL-1 is 
shown in row A and PRL-1-C170S-C171S 
in row B. Some spectra are expanded 
vertically and the expansion factor is 









(Figure 4.2.A). The disulfide-bound fragment is observed as a large m/z +1 peak at 3183.3 in the 
mass spectrum of oxidized PRL-1. The individual C49-containing fragment expected at m/z +1 
1470.6 in oxidized PRL-1-WT is present only as a trace peak. These two fragments are easily 
distinguished from other peaks because they are located in unpopulated regions of the spectrum. 
In contrast, the 1714 m/z +1 signal calculated for the C104-containing fragment is buried under 
other peaks and cannot be easily distinguished among numerous overlapping signals for this 
sample. Chemical reduction of PRL-1 with reducing agent results in complete loss of signal at 
3183.3, indicating the disulfide bond between the two peptides has been broken. Concomitantly, 
a large peak appears at 1470.6, which corresponds to the individual C49-containing peptide. 
Additionally, because the nucleophilic cysteine may be oxidized to sulfinic and sulfonic acids, 
MS data were mined for additional oxidation of the corresponding peptide with two and three 
oxygen atoms, respectively. Peaks at the predicted masses were not found in any of the samples, 
indicating that the redox inactivation of PRL-1 occurs predominantly through disulfide bond 
formation at the catalytic cysteine. Collectively, our data show that purified full-length PRL-1-
WT is oxidized and, consequently, requires a reducing agent to restore activity. 
4.3.2 Complete Oxidation of Full-length PRL-1-WT Leads to Precipitation  
NMR can be used to determine the reduction potential of a protein.11 An accurate 
calculation of the reduction potential of PRL-1 requires an accurate measurement of the NMR 
peak heights that correspond to the reduced and oxidized species. This necessitates conversion to 
either a completely oxidized or reduced species to perform a complete titration and to have an 
accurate reference baseline. We chose to completely oxidize PRL-1 because it is predominately 
oxidized following purification without treatment by oxidizing agents. Unexpectedly, incubation 
of wild-type PRL-1 with oxidizing agents (H2O2, GSSG and/or oxidized DTT) resulted in 
53 
 
complete precipitation of the protein at one hour. Attempts to re-oxidize PRL-1 following 
reduction with these components also led to precipitation (data not shown). SDS-PAGE analysis 
of the insoluble material revealed the precipitate is not mediated by disulfide cross linking (data 
not shown). Because the NMR experiments necessary to complete a redox titration require the 
protein to remain stable and soluble for a longer period of time, the wild-type protein was not a 
suitable candidate for this study.  
 We have previously shown that the C-terminal mutant, PRL-1-C170S-C171S is primarily 
reduced and active. Additionally, studies of PRL-1 by other groups indicate that the C-terminus 
affects solubility.4,17 As such, we anticipated that precipitation could be avoided by using a C-
terminal mutant, to perform the redox titration. As shown in Figure 2.6 (Chapter 2), the untreated 
C170S-C171S mutant exhibits an eight-fold increase in activity compared to the untreated wild-
type protein. Furthermore, the activity of PRL-1-C170S-C171S is statistically identical to wild-
type PRL-1 under reducing conditions, and the activity of this mutant is not modulated by the 
addition of reducing agents. Taken together, these data indicate that the active-site cysteine in the 
C170S-C171S mutant remains primarily reduced. To confirm this, we performed a trypsin digest 
and analyzed the peptides by mass spectrometry. The digest of untreated PRL-1-C170S-C171S 
shows disulfide-linked peptides only at equivalent intensity to background (Figure 4.2.B), 
suggesting no specific disulfide formation between the C49 and C104-containing peptides 
occurs. Conversely, the individual C49-containing peptide is exclusively detected. The MS 
spectrum for PRL-1-C170S-C171S is identical under non-reducing and reducing conditions, as 
no change in the signal for either mass is observed following addition of reducing agent.  
We next investigated the ability to oxidize PRL-1-C170S-C171S. When left untreated, 
PRL-1-C170S-C171S also runs as two bands on an SDS-PAGE gel; however, the upper band, 
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which corresponds to reduced PRL-1, is much more intense than the lower band (Figure 4.3.A). 
We attempted to oxidize PRL-1-C170S-C171S. Based on the intensity of the reduced and 
oxidized bands on SDS-PAGE, we estimated that this mutant requires at least 20-fold more 
oxidizing agent than WT (Figure 4.3.B). This finding indicates that PRL-1-C170S-C171S is 
much less susceptible to oxidation than WT. We did not attempt to quantify the reduction 
potential of this protein because, surprisingly, incubation of PRL-1-C170S-C171S with oxidizing 
agents also results in complete precipitation of the protein in one hour (data not shown). Instead 
we pursued identification of a PRL-1 variant that would allow us to determine the active-site 
reduction potential of full-length PRL-1. We investigated the role of the remaining two 
Cysteines, C98 and C99, in PRL-1 solubility. The crystal structure of PRL-1 reveals that C98 
and C99 are largely buried in the hydrophobic core of the protein, but the side chain of C98 is 
partially surface-accessible. We hypothesized that oxidation of C98 might lead to formation of a 
second disulfide bond and cause a structural transition, leading to precipitation. To investigate 
this hypothesis, we examined the available NMR and MS data more closely.  
The Cβ NMR chemical shift of a cysteine residue can be used to deduce the oxidation 
Figure 4.3. PRL-1-C170S-C171S. A. PRL-1-
C170S-C171S was run on SDS-PAGE under 
various oxidizing conditions. Under non-
reducing conditions (lane 6), C170S-C171S 
runs as two bands. In contrast to wild type, 
however, C170S-C171S is primarily reduced 
as indicated by the much greater intensity of 
the upper reduced band. Complete oxidation of 
PRL-1-C170-171S occurs near 2 mM oxidized 
DTT. B. PRL-1-WT was run on SDS-PAGE 
under the same conditions as in B. Complete 
oxidation of wild type occurs near 0.1 mM 








state of the thiol moiety. The chemical shift of an oxidized side chain (disulfide bound) should 
have a downfield shift closer to that of the Cα resonance.18 The Cβ chemical shift of C98 in 
untreated wild-type PRL-1 indicates that this residue is reduced (26.449 ppm). For comparison, 
the Cβ chemical shifts of the disulfide bound C49 and C104 residues are 35.21 ppm and 36.36 
ppm, respectively. Reduction of PRL-1 leads to a large change in Cβ chemical shifts for the C49 
and C104 residues (34.01 ppm and 29.82 ppm, respectively). Cβ chemical shift information is 
unavailable for residue C99 in the oxidized state and is absent presumably due to chemical 
exchange.15  
To further investigate the propensity of C98 and C99 to be oxidized we examined the MS 
data of wild type and PRL-1-C170S-C171S. Digested PRL-1-C170S-C171S shows a strong 
signal for the peptide containing C104 at 1712. The observed value is 2 amu below the predicted 
mass of 1714. This mass, which is shifted by -2, also is consistently observed in the spectra of 
the cross-linked species involving the C49- and C104-containing peptides (3181.3) derived from 
non-reduced wild-type PRL-1. Addition of reducing agent shifts the mass of the C104-containing 
peptide to 1714 for both wild type and PRL-1-C170S-C171S. Because the C104-containing 
peptide also includes C98 and C99, it is likely that an intra-peptide disulfide bond between C98 
and C99 is also present. MS analysis of intact PRL-1 under non-reducing conditions reveals a 
peak 4 amu below the calculated mass. This peak shifts to the expected position in the MS 
spectrum upon addition of reducing agent when no LC separation is performed. As such, it 
appears that this additional disulfide bond forms after the reducing agent is removed during the 
LC step. 




Because the MS data indicate the possibility of C98-C99 disulfide bond formation upon 
oxidation, we created the PRL-1-C98A mutant. We hypothesized that chemical oxidation by 
thiol modulating agents leads to oxidation of the C98 and C99 residues in both PRL-1-WT and 
PRL-1-C170S-C171S, which results in precipitation. Mutation of C98 mitigates this problem. 
Untreated PRL-1-C98A runs similarly to PRL-1-WT on SDS-PAGE (Figure 4.4.A, compare 
lane 1 to 4). Like wild-type PRL-1, complete oxidation of PRL-1-C98A occurs with 5 mM 
oxidized DTT and is re-reduced by the addition of a four-fold excess of reduced DTT (Figure 
4.4.A, compare lane 2 to 5 and 3 to 6). Unlike wild type, incubation of C98A with oxidizing 
agents for extended periods of time results in little to no precipitation. Consequently, PRL-1-
C98A was found to be an appropriate candidate to use for a reversible, equilibrium redox 
Figure 4.4. PRL-1-C98A. A. Lanes 1-
3 are the same samples from the gel 
shown in 4.1.A and are included for 
ease of comparison. B. The measured 
activities of PRL-1-WT and PRL-1-
C98A are equivalent within error prior 
to addition of reducing agent, and each 
is activated by the addition of 10 mM 
reduced DTT. The activity of PRL-1-
C98A under oxidizing conditions (5 
mM oxidized DTT) was equivalent to 
















titration. To ensure that this mutation has not compromised the functional or structural integrity 
of the protein, we compared the PTPase activity and NMR spectra of PRL-1-WT to PRL-1-
C98A.  
Wild type and C98A exhibit almost identical substrate turnover when assayed in 
equivalent redox conditions. PRL-1-C98A shows an equivalent level of activity when left 
untreated. Oxidation of the protein with 5 mM oxidized DTT completely abolishes the activity of 
the enzyme (data not shown), while reduction with 10 mM DTT recovers the full activity of this 
mutant, as shown by comparison to the reduced wild type and C170S-C171S mutant (Figure 
4.4.B). The percent activity of PRL-1-C98A under oxidizing conditions was determined to be 
0.05 ± 2% and was not included in the figure. Activity of the wild-type protein under oxidizing 
conditions was not measured because the formation of the precipitate precludes accurate 
measurement of the assay product. 
To verify the C98A mutation does not significantly alter the protein' structure, 1H-15N 
HSQC NMR spectra of wild type and PRL-1-C98A were collected. Comparison of the HSQC 
spectra of wild type and PRL-1-C98A reveals relatively small changes between the two variants 
(Figure 4.5.A). As such, the overall structure of PRL-1-C98A and PRL-1-WT are virtually 
identical, as indicated by the large number of peaks in common in these two spectra. Using the 
previously reported assignments for full-length oxidized PRL-1-WT, the chemical shift changes 
were mapped to the oxidized crystal structure of truncated PRL-1-WT.4,15 The significant 
chemical shift changes observed correspond to residues located near the site of the mutation 
(Figure 4.5.A, black boxes and Figure 4.5.B). The average chemical shift deviation (Δδavg) for all 
residues in PRL-1-WT and PRL-1-C98A was calculated by subtracting the chemical shift values 
of the C98A mutant from those of the wild type and was determined to be 0.07 ppm for 15N and 
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0.01 ppm for 1H. It should be noted that several new peaks appear in the spectrum of PRL-1-
C98A that are not observed for wild type. Peaks for many of the C-terminal residues in PRL-1-
WT were absent from the HSQC spectrum, likely because of line broadening due to exchange on 
the intermediate timescale. We suspect the new peaks in the PRL-1-C98A spectrum are 
resonances from the C-terminus, and their appearance may reflect a faster rate of exchange on 
which the motions at these residues occur in the PRL-1-C98A protein. Sequential backbone 
assignments of the C98A mutant and complete dynamics analysis of both are needed to confirm 
this, which is beyond the scope of this work. 
Figure 4.5. Comparisons of PRL-1-WT and C98A. A. The spectrum of untreated PRL-1-
WT (red) is overlaid with untreated PRL-1-C98A (black). Small differences in structure exist 
between these two proteins, and the residues that change significantly with mutation are 
enclosed in boxes. Unlabeled boxes enclose either new peaks in C98A (black) or unassigned 
peaks in wild type (red). B. The chemical shift changes observed between these two proteins 
were mapped to the available crystal structure of the oxidized wild type. A break in the 
structure exists between residues F70 and G73 because no information is available for D71 
and D72 residues. F70 and G73 are labeled and colored in pink to illustrate the break. For 
chemical shift mapping, the Δδ value for all assigned residues was used as the b-factor in the 
pdb file (1ZCK). Residues for which an assignment is missing in one of the two states are 
colored white. The rainbow color scale is applied with the largest changes being highlighted 
in red and insignificant changes in blue. Additionally, larger changes in chemical shift 









































As shown in the previous chapter, reduction of PRL-1 results in a conformational change, 
causing greater than 90% of the peaks in the wild-type spectrum to move. Backbone chemical 
shift assignments for both the oxidized and reduced forms were determined, which are reported 
elsewhere.15,16 The most dramatic change in the spectrum that occurs upon reduction of PRL-1 
corresponds to C49. The position of C49 in the HSQC shifts significantly upfield by more than 9 
ppm in nitrogen and 1 ppm in proton compared to the oxidized form. Figure 4.6 maps the 
observed changes in chemical shifts (Δδ) of assigned resonances to the available crystal structure 
of oxidized PRL-1. Δδ values were obtained by subtracting the chemical shift of PRL-1-C170S-
C171S from those of wild-type PRL-1, which was graphically illustrated in the previous chapter 
(Figure 3.3). A Δδavg of 0.91 ppm for 15N and 0.24 ppm for 1H was determined for these two 
forms of the protein. Parallel changes in chemical shifts are observed upon reduction of PRL-1-
C98A (data not shown). The Δδavg value was determined to be 0.72 for 15N and 0.14 for 1H by 
subtracting the chemical shifts of the reduced protein from those of the oxidized protein. This is 
Figure 4.6. Comparisons of PRL-1-WT and C170S-C171S. A. Differences in NMR 
chemical shifts between PRL-1-WT and PRL-1-C170-C171S were mapped to the crystal 
structure (as in figure 4) and displayed with the active site in front. The disulfide bound (pink 
bond) C104 and C49 are labeled. F70 and G73 are labeled to identify the break in the crystal 
structure. B. As in A, but with the active site rotated downward by approximately 90 degress 
to reveal the large number of chemical shift deviations in the majority of the protein structure, 



















in strong agreement between that observed for wild type and PRL-1-C170S-C171S and confirms 
that redox modulation at the active site in C98A parallels that of wild type. Collectively, our 
structural and functional comparisons have shown that PRL-1-C98A is an appropriate analog of 
the PRL-1 system, from which the reduction potential of the active-site disulfide bond can be 
determined. 
4.3.4. Determining the Reduction Potential of the Disulfide Bond in Full-length PRL-1 
To determine the reduction potential, oxidized PRL-1 (in the presence of 5 mM oxidized 
DTT) was gradually reduced by the addition of reduced DTT to a concentration of 200 mM. The 
peak heights of the following residues were monitored and analyzed as described: V12, R18, 
L30, T43, R47, C49, V65, L66, I80, R93, I100, A101, L114, E127, and Y152. Peak selection 
was based on spectral resolution, proximity to the disulfide bond, distance from mutation site and 
chemical exchange behavior (slow exchanging peaks only). Figure 4.7 displays a representative 
plot, depicting the results of the titration on residue C49, in which normalized peak height is 
plotted vs. half-cell potential. Similar results were obtained for all other residues and the 
chemical shifts of each residue in both states are included in Table 4.1. An average E’ value of -








Figure 4.7. Representative Plot of 
Reduction Potential Derived From 
Residue C49. The peak heights of 
residue C49 were normalized and 
plotted versus the half-cell potential 
of DTT, which was determined using 
the Nernst equation. The value 
determined for this residue was -
364.4 ± 0.7 mV. Similar results were 
obtained for other residues and are 







 The reduction potential of the active site disulfide bond in full-length PRL-1 was 
determined to be approximately -365 mV at pH 7.5. The reported reduction potentials 
determined for various cellular environments range from -320 (most reducing) to -170 mV (most 
oxidizing), the details of which have been reviewed extensively.2,19-22 Based on these values, our 
results indicate that nascent PRL-1 is rapidly oxidized inside the cell to an inactive state. The 
reduction potential is considerably lower than those reported for proteins that are known to play 
an important role in maintaining the redox state of the cell and/or specific proteins. The reduction 
potential of thioredoxin-1 (Trx-1), found in the cytoplasm and nucleus, has been reported to be -
230 mV, while that of Trx-2, found in the mitochondria, is near -330 mV.19,23 Both enzymes 
Table 4.1. Calculated Reduction Potential for PRL-1 Residuesa 
 E' (mV) ± SD δ-15N ox δ-1H ox δ-15N red δ-1H red Δδ (15N) Δδ (1H) 
V12 -366.1 0.0 126.780 9.122 126.771 9.202 0.009 -0.080 
R18 -364.6 2.0 121.848 5.764 121.919 5.837 -0.071 -0.073 
L30 -364.0 1.0 124.349 7.359 124.543 7.302 -0.194 0.057 
T43 -363.5 0.0 111.911 7.806 112.654 7.908 -0.743 -0.102 
R47 -361.8 0.0 126.631 8.861 129.143 8.896 -2.512 -0.035 
C49 -364.4 0.7 121.676 8.037 112.254 6.943 9.422 1.094 
V65 -365.2 0.0 124.996 8.563 125.651 8.570 -0.655 -0.007 
L66 -364.8 0.0 130.322 9.065 130.756 8.853 -0.434 0.212 
I80 -364.8 1.3 119.137 7.235 119.000 6.994 0.137 0.241 
R93 -364.7 2.3 118.477 7.287 118.344 7.236 0.133 0.051 
I100 -364.9 2.4 127.986 8.162 127.919 8.230 0.067 -0.068 
A101 -364.8 1.8 129.683 9.180 129.252 8.865 0.431 0.315 
L114 -365.4 2.6 116.028 7.424 117.798 7.107 -1.770 0.317 
E127 -363.9 1.6 118.621 9.219 119.105 9.187 -0.484 0.032 
Y152 -362.7 1.9 122.770 7.129 123.362 7.099 -0.592 0.030 
average -364.3 1.5             
aThe reported E’ value for each residue corresponds to the average of both the reduced and 
oxidized peak heights fit to the equation listed in the methods section. The standard deviation 
(SD) is also reported in mV. Δδ values were calculated by subtracting the chemical shift of the 
reduced species from those of the oxidized species. 
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would have a substantial fraction of protein in the active state in their respective environments, 
and Trx-1 would be able to act as a reducing agent more effectively in the nucleus. Reduction 
potentials for cytoplasmic glutaredoxins (Grx) vary depending on the primary sequence and 
range from -200 to -240 mV.24  Reduction potentials for proteins that facilitate disulfide bond 
formation in the endoplasmic reticulum have been determined to be -175 mV (protein disulfide 
isomerase; PDI) and -275 mV (regulatory disulfide of Ero1α).25,26 The role of PDI is thought to 
be to make and break disulfide bonds in target proteins and the reduction potential is appropriate 
for this enzyme in this compartment. The reduction potential of Ero1α is sufficiently negative to 
ensure oxidation and facilitate re-oxidation of PDI. To date, analysis of reduction potentials has 
been focused on a small subset of redox modulating enzymes, but measuring the reduction 
potentials of other proteins that are subject to redox regulation has recently been recognized as 
important as well. The absence of general and accurate methods for quantifying these potentials 
has precluded the ability to identify conditions in which proteins are switched on or off by 
disulfide bond formation. NMR spectroscopy has recently been shown to be a valuable tool for 
obtaining this information and was used to determine the reduction potential of Trx-1 with great 
accuracy.11 Other proteins have been studied using this method as well. Zimmerman et al. (2007) 
used NMR to determine the reduction potential of the N-terminal hSH3 domain of the immune 
cell protein ADAP (adhesion and degranulation promoting adapter protein).27 Sahu et al. (2008) 
used NMR to quantify the reduction potential of the High Mobility Group B1 (HMGB1) protein, 
which plays an important role in DNA binding as well as chemotaxis.28 In both examples, 
disulfide bond formation was shown to lead to a conformational change, which alters the 
function of the protein. The altered function of the protein also correlates with a change in 
subcellular location. Likewise, the subcellular location of PRL-1 may affect the activity of the 
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protein, although no cellular compartment is sufficiently negative to ensure activation. Even in 
the most reducing environment reported (-320 mV), nascent PRL-1 would exist primarily in an 
inactive, oxidized state (> 96%). This strongly suggests that in vivo, PRL-1 requires a 
posttranslational modification or binding partner to switch on phosphatase activity. 
The data presented earlier demonstrate the importance of the C-terminus to the 
phosphatase activity of PRL-1. The data presented here show that modification of the C-terminus 
affects the redox state of the active site, making PRL-1 much less susceptible to inactivation 
(Figure 4.4). The PRL enzymes each contain a C-terminal prenylation motif or CaaX box (C 
stands for cysteine, a represents any aliphatic residue and X corresponds to any amino acid). The 
prenylation motif directs farnesylation at the conserved CaaX box cysteine, followed by 
proteolytic cleavage of the aaX peptide and methylation of the terminal carboxyl moiety.29 
Farnesylation has been shown to occur in vivo for the PRL enzymes.30-32 In PRL-1, this 
modification occurs at C170. Based on our data, the shift in the reduction potential of the 
inactivating disulfide bond in PRL-1 to a less negative value appears to be accomplished through 
a conformational change that depends on the presence of C-terminal residues in the CaaX box. 
Because farnesylation occurs on C170 and mutation of this residue makes PRL-1 less prone to 
inactivation, we expect farnesylation will also alter the protein’s conformation and reduction 
potential of the active site disulfide bond. Because farnesylation often leads to membrane 
association and PRL-1 has been shown to localize to several membranes in vivo,4,17,30,31,33,34 the 
protein’s conformation may be altered more substantially in the context of a lipid bilayer than is 
apparent from solution studies. 
In all work published to date, the phosphatase activity of PRL-1 has been reported to be 
necessary for the promotion of cellular proliferation and motility by this protein, regardless of 
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localization.32,33,35-39 PRL-1 is typically farnesylated in cells 30-32,40 and farnesylated PRL-1 is most 
often directed to the nucleus.32,41,42 The fact that PRL-1 is most often localized to the nucleus 
seems appropriate with respect to cellular redox conditions,41 because this compartment is often 
the most reducing organelle at -320 mV.19 Based on our studies of the C-terminal mutant, it 
seems that modification at the C-terminus would raise the reduction potential sufficiently to turn 
on phosphatase activity in this environment. Interestingly, when farnesylation of PRL-1 is 
prevented in cells, the ability of this protein to promote proliferation is abrogated and its 
localization is often altered. For example, the lack of prenylation inhibits the ability of PRL-1 to 
promote invasion and motility of SW480 colon carcinoma cells and to promote HEK293 cell 
growth and migration.33,40 In these cases, it was not determined whether localization and/or 
PTPase activity is responsible for the altered phenotype. In mitotic cells, however, PRL-1 
localizes to the centrosomes and spindle apparatus independent of whether farnesylation occurs, 
and despite proper localization, farnesylation deficient mutants result in mitotic defects.32 
Interestingly, the inactive mutant produced the same result. During mitosis, the nuclear envelope 
breaks down and the reduction potential of the cell becomes approximately -240 mV.2,43,44 The 
reduction potential of unmodified PRL-1 (-365 mV) is much too low to be active in this redox 
environment. As such, farnesylation may enhance PRL-1 activity during mitosis, and this may 
explain why mitotic defects were observed with both the catalytically inactive C104 mutant and 
non-farnesylated proteins.  
PRL-1 facilitates the regeneration of damaged tissue by promoting proliferation and 
migration, notably in the liver, which has a highly reducing environment. Increased activity in 
this case may be due, at least in part, to elevated expression of the protein.45 The expression and 
phosphatase activity of PRL-1 have also been associated with many types of cancer cell 
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lines.34,41,46-48 It has been well documented that the interior of cancer cells are generally more 
reducing than their normal counterparts.49-51 Because cancer cells have aberrantly regained the 
ability to proliferate and have lost the ability to maintain redox homeostasis,2 we hypothesize that 
the redox environment in some cancer cells may be sufficiently negative to confer activity in 
PRL-1. This is supported by the fact that abolishing the activity of PRL-1 in cancer cell lines by 
transfecting them with catalytically inactive PRL mutants decreases cell viability, prevents cells 
from entering into mitosis and also inhibits anchorage independent growth.32,33 These and other 
studies collectively suggest that the active form of PRL-1 may be a good target for therapeutic 
intervention in the treatment of metastatic cancers.46 
It is clear from our in vitro studies that changes in cellular redox conditions will have a 
profound affect on the activity of PRL-1 in vivo and that modification of residues, especially at 
the C-terminus, may dramatically alter the propensity of PRL-1 to be oxidized and inactivated 
inside the cell. Given its diverse localization and multifarious roles in proliferation, 
differentiation and motility, the data presented here provides the impetus to pursue further 
studies that investigate the function of PRL-1 under distinct cellular conditions to generate a 
more accurate account of how PRL-1 is regulated in vivo and how its regulation contributes to 
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PROBING RESIDUE-SPECIFIC INTERACTIONS IN THE STABILIZATION 
OF PROTEINS USING HIGH-RESOLUTION NMR: A STUDY OF 
DISULFIDE BOND COMPENSATION 
 
5.1. INTRODUCTION 
An understanding of the forces that contribute to protein stability is crucial to the 
development of new biotechnology products having improved half-lives, shelf lives and reduced 
immunogenicity.1,2 One method commonly used to improve the stability of proteins is 
engineering cysteine residues into the primary sequence to form a new or additional disulfide 
bonds.3-5 This has proved to be important for the stabilization of antibodies.6-8 Classical theory 
suggests that disulfide bonds stabilize proteins by reducing the entropy of the unfolded state.10-12 
More recent theories propose disulfide bonds stabilize the folded state enthalpically, presumably 
through favorable local interactions or by stabilizing the packing of hydrophobic residues.14,15 
Disulfide bonds are not always beneficial. Alterations to a protein’s redox status in the form of 
disulfide exchange can disrupt a protein’s native structure and lead to enhanced aggregation by 
exposing previously buried, often hydrophobic, regions of a protein that can then associate.3,17 
Generally speaking, it is thought that disulfide bonds destabilize the folded state by restricting 
energetically favorable conformational changes.17-19 Unfortunately, very little experimental data 
to support any of the described ideas is available, which makes predicting the circumstances 
under which disulfide bond formation will stabilize or destabilize a protein fold difficult.20-23 
Currently, a set of low-resolution experiments is commonly employed to assess structural 
stability (and more recently dynamics) and this approach has proven beneficial for rapidly 
identifying stabilizing conditions for individual proteins.24-27 The methods used provide general 
information about classes of interactions or structural features in the protein. Despite the obvious 
72 
 
utility of these traditional methodologies, mechanistic understanding cannot be gleaned from 
these data sets to elucidate why stabilization is affected. Additional information about the 
contribution of individual residues can be obtained by comparing mutants to the wild-type 
protein using these methods and calculating changes in the free energy (ΔΔG) in an unfolding 
experiment.5,28 While this approach can determine whether a specific residue is required for 
folding, it does not reveal how cooperativity and conformational dynamics contribute to 
stabilization of the folded state. High-resolution or site-specific detail is required to explain why 
a protein is inherently more or less stable or is stabilized to a greater or lesser extent by specific 
solution conditions. Solution NMR studies of protein folding and unfolding are commonly 
employed to examine folding pathways,29-31 but this powerful technique has been greatly 
underutilized to examine the mechanisms of stabilization of the folded state from both the 
perspective of the packing arrangement in the protein as well as the effects of solution 
environment on the protein’s conformational ensemble. Understanding how structure and 
dynamics affect the stability of the folded state is important for generating protein therapeutics 
that better resist unfolding and aggregation. 
In the present study, the protein phosphatase of regenerating liver (PRL-1) was used as a 
model system to investigate the effects of disulfide bond formation on the protein’s stability. 
PRL-1 has two discernable stable states, one of which contains a disulfide bond (oxidized, 
inactive) and one that does not (reduced, active). Here, the disulfide bond was disrupted in 
several ways and the protein carefully examined to assess the effects these two cysteines and 
their oxidation state have on the conformation of the protein. PRL-1 serves as an excellent model 
for this purpose for several reasons. First, the catalytic Cys (C104) is highly susceptible to 
inactivation by disulfide bond formation at the active site.16,32 Our group previously assigned the 
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NMR resonances for the reduced and oxidized proteins and characterized formation of the 
disulfide bond between C104 and its partner C49.33,34 The reduction potential is approximately    
-364 mV, which indicates that this protein strongly favors the oxidized state in vitro, but 
equilibrium control of the redox state is easily modulated using a redox buffer system to generate 
the reduced form.35 Second, a major conformational change occurs upon reduction of the protein, 
providing well-resolved, site-specific measurable differences between the two states using 
solution NMR spectroscopy.35 Additionally, the structures of both reduced and oxidized PRL-1 
have been determined previously using X-ray crystallography, which facilitates interpretation of 
the changes observed in the NMR data with respect to the three-dimensional structure.13,16   
Standard low-resolution techniques (circular dichroism and static light scattering) were 
used to show that the reduced form of the protein is slightly more stable than the oxidized state. 
To understand how specific residues in the reduced form compensate for the loss of the disulfide 
bond, a series of mutants were analyzed that disrupted disulfide bond formation in distinct ways. 
The physical stability of each variant is unique with respect to the others, indicating that the 
global stability of the protein depends on a combination of local, synergistic interactions with the 
Cys side chains. High-resolution solution NMR provided site-specific and mechanistic 
information about how each interaction influences the protein’s physical stability. This analysis 
reveals several key structural components that contribute to PRL-1’s overall stability in the 
absence of disulfide bond formation. The results provide insight into how the reduced protein 








5.2.1. Protein Expression and Purification 
All PRL-1 variants were expressed and purified as previously described in the preceding 
chapters. The primer used to generate the Y53F mutant was 5’-gagtatgtgaagcaacttTtgacactactctt-
gtgg3’. Purity of the final protein samples was assessed by SDS-PAGE and protein 
concentrations were determined by UV Absorbance at 280 nm using an extinction coefficient of 
19420 M-1 cm-1. The extinction coefficient was calculated based on the reduced protein using the 
ProtParam program from ExPASy.36,37 Final samples were concentrated to 30 mg/mL and stored 
at 4 °C in 50 mM Tris-Cl, pH 7.4 with 100 mM NaCl until prior to analysis. These conditions are 
equivalent to purification conditions. All samples for NMR studies were grown on minimal 
media containing 15N-labeled ammonium chloride as the sole nitrogen source (Cambridge 
Isotopes, Andover, MA). Table 5.1 summarizes the reason for studying each mutant. The activity 
of each mutant was tested using the standard generic substrate p-nitrophenyl phosphate (pNPP) 
in a colorimetric assay previously published.35 
 
Table 5.1. Purpose of PRL-1 Mutants 
PRL-1 Variant Purpose 
Wild Type (WT) Permits chemical modification of the disulfide bond 
C104S Disrupts the disulfide bond directly; abolishes enzymatic activity 
C49S Disrupts the disulfide bond directly; retains activity 
Y53E Breaks hydrogen bond between Y53 and H103; increases 
solvent exposure of loop three 
Y53F Breaks hydrogen bond between Y53 and H103; retains apolar 
side chain 
C98Aa Control for WT that permits full oxidation (see Chapter 4) 
C170S-C171Sa Indirectly affects disulfide bond formation 
aThis chapter will not cover the stability results for the C98A and C170S-C171S 




5.2.2. Static Light Scattering (SLS) 
To assess the aggregation propensity of the various PRL-1 variants, the optical density at 
350 nm was monitored with increasing temperature. Protein samples were diluted to a final 
concentration of 1 mg/mL into 50 mM HEPES or 50 mM sodium phosphate, pH 7.5 (I=0.1) with 
or without 10 mM dithiothreitol (DTT). All data were collected on a Cary 100 UV-VIS 
spectrophotometer equipped with 12-cell changer and temperature controller. Data points were 
collected every 2 °C at a rate of 5 °C per minute from 10-85 °C. Onset temperatures were 
determined from the plots of optical density versus temperature. The data were analyzed in 
duplicate and the average of these is shown. The error bars represent one standard deviation of 
the mean. 
5.2.3. Circular Dichroism (CD) 
CD spectra at 20 and 85 °C were acquired using a Jasco J-810 spectropolarimeter 
equipped with a 6-position Peltier temperature controller from 260-190 nm using a scanning 
speed of 50 nm/min and 0.5 nm resolution. Thermal melts were also performed by monitoring 
the CD signal at 222 nm every 1 °C from 20-85 °C. The temperature was gradually increased at a 
rate of 2 °C per minute, and the sample was equilibrated for five minutes at each temperature. 
The cuvette path length was 0.1 cm. As indicated by the SLS data, aggregation of the protein 
occurs at elevated temperatures, and based on our structural analysis of the protein, this process 
is probably mediated via association of β-strands (see section 5.3). Because of this, we monitored 
the loss of α-helical content to avoid complications when fitting the data. The CD signal was 
converted to molar ellipticity using the Spectra ManagerTM software (Jasco Inc., Easton, MD). 
Tms were determined by fitting the CD curve to a sigmoidal function with Prism 5 software 
(GraphPad, La Jolla, CA). The Tm was defined by the midpoint of the sigmoidal curve. Protein 
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samples were diluted to a final concentration of 0.4 mg/mL in either 50 mM HEPES or 50 mM 
sodium phosphate, pH 7.5 (I=0.1) with or without 1 mM DTT. Ionic strength was maintained by 
the addition of sodium chloride. Two independently prepared samples were analyzed in duplicate 
(n=4) to generate error bars, which represent one standard deviation of the mean. The one-
sample t-test was used to determine statistical significance using the reduced wild type examined 
in phosphate buffer as the theoretical mean. 
5.2.4. NMR Experiments 
For structural analysis of the various PRL-1 mutants, samples were concentrated to 
approximately 1 mM (~30 mg/mL) in 50 mM sodium phosphate buffer, 100 mM NaCl, pH 6.5, 
containing 5% D2O. 1H-15N Heteronuclear Single Quantum Coherence (HSQC) spectra were 
acquired on a Bruker Avance 800 MHz spectrometer using a cryogenic, triple resonance probe 
equipped with pulse field gradients. The spectra were acquired in 8 scans with 2048 points in 1H 
and 256* increments in 15N. All spectra were obtained at 37 °C. NMRpipe38  and SPARKY39 
were used for spectral processing and data analysis. Chemical shift changes (Δδ) were calculated 
by subtracting the peak positions of the mutant protein (C104S or C49S) from the chemically 
reduced wild type. Chemical shift changes were expressed as the square root of the sum of the 
squares of chemical frequency differences in the 1H and 15N dimensions between two given 














































A change was deemed significant if Δf was greater than 33.81. This value represents the average 
line width of the reduced wild-type protein and was determined by summing the squares of the 
individual resonant line widths for 1H and 15N using Equation 1 and averaging. Line widths were 
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measured in SPARKY. 
Because the C49S mutant was significantly different in structure from the reduced wild-
type protein, 2D 1H-15N HSQCs and 3D versions of the CBCA(CO)NH, HNCACB, C(CO)NH 
and HNCO experiments were collected to obtain sequential backbone assignments. The sample 
was concentrated to approximately 1.9 mM in 50 mM sodium phosphate, pH 6.5, with 100 mM 
NaCl and 5% D2O and analyzed in a Shigemi tube. Experiments were carried out on a Varian 
Inova 800 MHz NMR spectrometer using a cryogenic, triple-resonance probe equipped with 
pulse field gradients. All spectra were obtained at 37 °C. Spectra were processed using 
NMRpipe38 and peak picked using Sparky.39 Peak lists were submitted to the PINE Server 
through NMRFAM, University of Wisconsin, Madison41 and cross-checked using the 
assignments for reduced wild type.34  
Hydrogen-deuterium (H-D) exchange experiments were conducted to assess the solvent 
accessibility of residues. Post-purification, samples were exchanged at least 105 fold in 50 mM 
sodium phosphate with 100 mM NaCl at pH 6.5 and concentrated to 25 µL immediately prior to 
the experiment. The samples were then diluted to 600 µL (approximately 1 mM protein) in 100% 
D2O in a standard NMR tube and immediately placed in the NMR spectrometer. 1H-15N HSQC 
spectra were recorded at 5, 10, 30, 60 and 120 minutes as well as 12 and 24 hours at 37 °C. Data 
was collected for the C104S, C49S and reduced C98A mutants. The C98A mutant was used in 
lieu of the wild-type protein because a wider range of redox conditions can be used with this 
mutant (see Chapter 4).35 The spectra were processed with nmrPipe38 and peak picked using 
Sparky.39 The intensity of the relevant peaks were plotted versus time and fit to an exponential 
curve with Prism 5 software (GraphPad, La Jolla, CA). Many residues could not be fit because 
they exchanged completely in 5 minutes. These residues were classified as ++. Conversely, 
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residues that could not be fit because they were fully retained after 24 hours were classified as --.  
For all NMR experiments described above, 1H chemical shifts were referenced with 
respect to an external DSS standard in D2O. Indirect referencing relative to 1H was determined 
for 15N assuming a ratio of 15N/1H = 0.101329118.42 
 
5.3. RESULTS AND DISCUSSION 
5.3.1. Physical Stability of PRL-1 
 To determine the overall physical stability of the different forms of PRL-1, CD melts and 
SLS melts were performed on each variant. For CD, a Tm was calculated by fitting the data to a 
sigmoidal curve. For SLS, the onset of the transition temperature is reported because saturation 
of the detector occurred in many cases, an indication of insoluble aggregation formation. Visible 
observation of the formation of solid material following the temperature titration indicates the 
process is not entirely reversible. For this reason, thermodynamic comparisons (ΔG 
measurements) could not be made. The data presented in this study are interpreted as a reflection 
of relative differences observed under equivalent conditions rather than as a thermodynamic 
quantity. Table 5.2 summarizes this data. The CD and SLS plots for all PRL-1 variants in 
phosphate buffer are shown in Figure 5.1. 
Several trends in the CD data were observed with the PRL-1 variants. First, the reduced 
wild-type protein is slightly more stable than the oxidized protein, with melting temperatures at 
67.8 ± 0.4 versus 65.5 ± 1.3 °C, respectively (p=0.0351). We anticipated the opposite result 
because, most often, native disulfide bonds improve the ability of proteins to resist unfolding.3-
8,10-12,14,15 To understand how the reduced protein compensates for the loss of the disulfide bond, 
the same analyses were also performed on each of the two cysteine mutants (C49S and C104S) 
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that directly prevent formation of this bond under equivalent conditions (Table 5.1).  
Table 5.2 Physical Stability of PRL-1a 
 Phosphate HEPES 
 CD SLS CD SLS 
 Tm ± SD Onset T ± SD Tm ± SD Onset T ± SD 
nrWT 65.5 1.1 59.9 0.3 60.5 2.1 53.3 0.4 
redWTbc 67.8 0.4 63.8 0.4 62.0 1.3 57.4 0.3 
redWTd 79.0e 0.7 ndf nd nd 
C49S 62.8 2.0 59.7 0.2 56.3 0.3 50.0 0.3 
redC49Sb 63.5 0.8 59.6 0.2 58.1 2.2 49.9 0.3 
C104S 76.3 1.1 72.1 0.3 64.9 2.1 59.3 0.2 
redC104Sb 76.7 1.8 73.0 0.4 62.2 1.1 59.3 0.3 
Y53E 62.3 0.4 nd nd nd 
Y53F 62.6 0.3 nd nd nd 
aAll temperatures reported are in °C 
bFor CD, reducing conditions were achieved by the addition of 1 mM DTT. For 
SLS, reducing conditions were achieved by the addition of 10 mM DTT. 
dReduced PRL-1-WT (redWT) was studied in 20 mM phosphate buffer at pH 6.5 
with equivalent ionic strength (I=0.1). All other values reported, including those for 
HEPES buffer, are at pH 7.5. 
eMelting was incomplete at the maximum temperature attainable. To determine the 
Tm, the data were fit by constraining the final plateau to a constant value typically 
observed with the other redWT samples (-15 x 106). 
fNot determined (nd) 
  
Interestingly, the C49S and C104S mutants each have a unique melting profile that is 
different from each other, as well as the reduced wild type. Compared to the chemically reduced 
wild type, C49S has a significantly lower melting temperature (62.8 ± 2.0 °C; p=0.0491), while 
the C104S mutant has a significantly higher melting temperature (76.3 ± 1.1 °C; p=0.0005). 
Such large differences between the C49S, C104S and reduced wild-type proteins were 
unexpected because, with only a single atom changed, each should mimic the reduced 
conformation of PRL-1. The fact that these mutants have a 13.5 °C separation in their physical 
stability strongly indicates that the overall stability of PRL-1 is greatly impacted by local 
interactions with the side chain moieties of the C49 and C104 residues. Similar trends in the 
aggregation propensity of PRL-1 variants were also observed by SLS. In phosphate buffer, the 
80 
 
reduced wild type was slightly less vulnerable to aggregation than the oxidized wild type 
(ΔTonset=3.8 °C). The C104S protein is the least aggregation prone (Tonset=72.1 ± 0.3 °C), while 
the C49S protein self associates most readily (Tonset=59.7 ± 0.2 °C). These data clearly show that 
stability depends on more than just disulfide bond formation at the active site. 
 Table 5.2 shows that changing the buffer system from phosphate to HEPES reduces the 
physical stability of PRL-1 for all variants studied, decreasing Tm values by 5-6 °C. Similarly, 
the aggregation propensity measured by SLS also decreases consistently by approximately 6 °C 
with the same buffer switch. Because the biological role of PRL-1 is to facilitate phosphate 
hydrolysis from a phosphotyrosine substrate, this result suggests that the decrease in physical 
stability can be attributed to whether or not the protein can bind to the buffer species, albeit too 
Figure 5.1. Physical Stability of 
PRL-1. The physical stability of 
PRL-1 was monitored by either 
CD (A) or SLS (B). Tms 
determined from the data shown 
here are summarized in Table 2. 
All data presented in this figure 
were collected in phosphate 
buffer at pH 7.5. For CD 
analysis, data points represent 
the average of two replicates of 
two independently prepared 
samples. For SLS analysis, data 
points represent the average of 




weakly in this case to determine the KD even by NMR, placing it above the mid mM range (data 
not shown). The phosphate group is expected to bind at the active site of the protein, much like 
sulfate occupies the active site in the available crystal structure of C104S (Figure 5.2.A).9,16 
HEPES (sulfonate ion) apparently does not participate in such an interaction, and each variant is 
destabilized to an equivalent extent by this buffer switch. Because both buffers were prepared to 
have equivalent ionic strengths, it is unlikely that the effect results from non-specific electrostatic 
influences, further suggesting that weak phosphate binding imparts stabilization to this protein.  
Active site binding also explains the dramatic difference in physical stability between the 
C104S and reduced wild-type proteins. The catalytic Cys in the reduced wild type exists as a 
thiolate anion at physiological pH, which is typical for this family of enzymes because of the 
Figure 5.2. Phosphate 
Stabilization of PRL-1. A. The 
active site of the C104S crystal 
structure is shown occupied by a 
sulfate ligand.9 Protein data 
bank (PDB) file 1XM2 was 
used to create this illustration.13 
B. CD melts of PRL-1-C104S 
and reduced wild type at various 
pH values in different buffer 
systems. In all cases studied, the 
ionic strength was maintained 
by the addition of NaCl. The 





surrounding partially positive microenvironment and structural organization of the active 
site.16,32 With PRL-1-C104S, the thiolate side chain has been replaced with a hydoxyl group, 
which remains protonated, eliminating the negative charge at this position. Because less charge 
repulsion is present between phosphate and the –OH group from Ser than between phosphate and 
the negatively charged thiolate anion, binding by phosphate would occur to C104S more readily 
because of the differences in charge state of the active site. This conclusion is further supported 
by the fact that the melting temperatures measured by CD for the reduced wild type and C104S 
are statistically identical in HEPES buffer (ΔTm=2.9, p=0.4207) but differ significantly in 
phosphate buffer (ΔTm=8.5 °C, p=0.0005; Table 2). Although no statistical analysis could be 
conducted on the SLS data because of the small number of replicates, similar trends were 
observed with the SLS data. The ΔTonset value for these two proteins in HEPES is considerably 
smaller than for phosphate buffer (1.9 versus 8.4 °C, respectively; Table 2), further indicating 
that phosphate binding imparts structural stability. As an alternative way of investigating the 
effect of charge repulsion on stability, the pH of the phosphate buffer was lowered to 6.5 from 
7.5 while maintaining an equivalent ionic strength. This too enhanced the physical stability of the 
reduced wild type, as measured by CD (Tm=79.1 °C). The primary phosphate species at pH 6.5 
has a -1 charge, whereas at 7.5, just over 50% of the phosphate has a -2 charge. The smaller 
degree of charge repulsion between the thiolate and singly charged phosphate ion allows the 
molecule to more readily occupy the active site and stabilize the protein. A comparison of the 
CD melts of these mutants in the different buffers is shown in Figure 5.2.B.  
Phosphate binding does not fully explain the difference in structural stability of the 
reduced forms, as the Tm values measured by CD and onset temperatures measured by SLS 
remain consistently varied for the different forms across each buffer system (Table 5.2). When 
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compared to the reduced wild-type protein in HEPES buffer, C49S consistently exhibits a lower 
melting temperature. This suggests that a specific local packing interaction involving C49 is 
perturbed in this protein that causes destabilization. The side chain of C49 is completely buried 
in the protein’s hydrophobic core in the crystal structure of PRL-1-C104S. One notable feature in 
the crystal structure of the reduced state is the presence of a completely buried hydrogen bond 
between residues Y53 and H103 (Figure 5.3).13,16 In the reduced state, this hydrogen bond forms 
between the hydroxyl from the tyrosine side chain and the imidazolium Nε of the histidine and 
has a bond length of 2.85 Å. The C49 side chain is pointed inwards towards this interaction. In 
the oxidized state, the distance between these atoms lengthens to 3.07 Å, and the angle (107°) 
further deviates from ideality (120°)43 
compared to the reduced form (113°). The C49 
side chain is disulfide bound and points away 
from these residues. There is a concomitant 
rearrangement of residues in the region 
surrounding both the active site and the Y53-
H103 hydrogen bond. Based on the small (2 
°C) difference in Tm between the reduced and 
oxidized wild-type states, the optimization of 
the hydrogen bond and concomitant packing 
rearrangement around it may compensate for 
the loss of the covalent disulfide bond. Based on this information, we hypothesized that the C49S 
mutant is destabilized because the introduction of the polar group favors greater solvent exposure 
and disrupts favorable packing interactions around the Y53-H103 hydrogen bond, despite being 
Figure 5.3. Y53-H103 Hydrogen 
Bonding in PRL-1. PDB code 1XM2 was 
used to illustrate the proximity of the Y53 
and H103 side chains.13 In the figure, the 
side chain of these residues, as well as C49 
are shown as sticks. In the oxidized crystal 
structure (PDB 1ZCK),16 the interaction 




in the reduced conformation at the active site. To test this hypothesis, we created the Y53E and 
Y53F mutants and studied their physical stability by CD. As indicated by Figure 5.1 and Table 
5.2, Y53E and Y53F have equivalent Tm values to the C49S mutant, suggesting a common mode 
of destabilization. 
5.3.2. Structural Analysis of PRL-1 
We first collected CD spectra of each PRL-1 variant to determine if substantial changes 
in the total secondary structure occur as the result of any of the mutations. The results are shown 
in Figure 5.4. Despite the significant deviations in physical stability between the reduced wild 
type, C49S and C104S proteins, the 
total secondary structure content of 
each mutant remains very similar. 
Error bars were omitted in Figure 5.4 
for presentation purposes. The values 
below 203 nm are within the standard 
deviation of each curve, whereas 
values in the α-helix and β-sheet 
regions are statistically different. 
These differences are 
disproportionately small compared to 
the differences in stability. 
Unfortunately, there is no systematic 
way to extract information from this data set to explain why the Tm values differ so substantially. 
High-resolution methods are needed to provide site-specific information capable of explaining 
Figure 5.4. CD Spectra of PRL-1 Variants. The 
secondary structure elements of the various mutants 
were analyzed by monitoring the CD signal from 
190-250 nm. The data points represent the average 
of two replicates of two independently prepared 
samples (n=4). Error bars were omitted for figure 
quality purposes. All data points below 203 nm are 
statistically identical. At 208, 218 and 222 nm, 
where absorbance for α-helix and β-sheet are 















the mechanism by which stabilization or destabilization is achieved with the introduction of 
various mutations or changes in solution conditions. We performed high-resolution solution 
NMR studies to obtain such information.  
The 1H-15N HSQC NMR experiment was used because this method selectively detects 
protons that are directly coupled to a nitrogen atom. This is particularly useful for the analysis of 
protein structure because of the repeating pattern of amides in the polypeptide backbone. A cross 
peak for each amide in the protein is observed, providing a fingerprint of the protein’s unique 
structure. This experiment serves as the basis for assessing the overall fold and dynamic behavior 
of a protein. Because chemical shift is so sensitive to an atom’s local environment, changes in a 
protein’s tertiary structure, such as those introduced by point mutations, are manifested as 
changes in the position and/or shape of the peaks in the HSQC spectrum.44 For this analysis, 
backbone NMR assignments for reduced PRL-1, which we previously published, were used to 
assign the respective mutants and provide site-specific information.35 Because of the large 
number of changes between the reduced wild-type and C49S proteins (see below), independent 
backbone assignments for C49S were also made to identify additional peaks that could not be 
deduced using the reduced PRL-1 spectra.41 
 To determine which residues are perturbed by mutations that affect disulfide bond 
formation, we first compared the HSQC spectrum of the chemically reduced wild-type protein 
with that of C104S (Figure 5.5.A). Although many of the peaks overlap, there are a number of 
significant changes observed between these two proteins, some of which are highlighted by 
boxes in the figure. To illustrate where these residues are located with respect to the mutation 
site, we mapped these changes to the available C104S crystal structure (Figure 5.5.B).13 The 
largest chemical shift deviations (blue) are observed in or near the active site (V47, W68, V102-
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C104, G109, R110, F141), which is expected because the catalytic cysteine has been modified. 
The active site is illustrated in ball and stick format for reference. Other small changes (red) are 
observed near the active site and include H23, N24, R47, E50, F70, A74 and V81. Additional 
smaller changes are present in α4-α6 (V113-V115, I133, G139-A140, L146) because a hydrogen 
bond between the active site and small loop containing F141 is perturbed. This change 
propagates, affecting the β1-containing residues V10-Y14 and β2-containing I21. On the 
opposite side of the active site, there are perturbations in two loops. Because the amides from 
these residues are already solvent exposed, the change in their chemical shift position is small. 
Residues Y53 and D54 in the flexible β2-α3 loop (loop three; L3) are slightly perturbed, as well 
as T26, which is located in loop two (L2) directly adjacent to L3. The perturbation to the Y53 
backbone is likely a result of a change in conformational dynamics revolving around the 
orientation of H103, which results from active site stabilization upon phosphate binding. Overall, 
when comparing the NMR spectra of reduced wild type to that of C104S, greater than 97% of the 
changes observed originate from the active site. This strongly suggests that a major component 
of the stability difference between the chemically reduced wild type and C104S proteins is due to 
phosphate binding and the diminished charge repulsion at the active site in the hydroxyl-
containing mutant. Moreover, previous unpublished work by the Stauffacher lab indicates that 
increasing the concentration of phosphate in solution sharpens NMR line widths throughout the 
protein but more so for the resonances associated with the active site. Because broadening of 
lines likely reflects conformational averaging, this data suggests that phosphate binding also 
shifts the dynamic equilibrium of the whole protein toward a more rigid state (data not shown). 













Figure 5.5. Chemical Shift Mapping of PRL-1. A. 1H-15N HSQC spectra of reduced of 
wild type (black) and C104S (red) are shown. Chemical shift changes (Δf) between the 
two spectra were analyzed as described in the methods section. A representative example 
from each category described below is boxed in the spectra. Black boxes highlight 
residues with Δf  < 33.8. Red boxes emphasize residues with 33.8 < Δf < 100 Hz. Blue 
boxes specify residues with 300 Hz < Δf  > 100 Hz. B. Chemical shift changes between 
reduced wild type and C104S were mapped to the available C104S (PDB 1XM2)16 crystal 
structure and color-coded as in A. The active site, Y53 and H103 residues are depicted as 
ball and sticks. Relevant regions of the protein are also labeled. C. 1H-15N HSQC spectra 
of reduced wild type (black) and C49S (red) with colored boxes highlighting chemical 
shift change from the corresponding categories. Additionally, residues with Δf > 300 Hz 
are specified by yellow boxes with black lettering. D. As in B, except changes between 
the reduced wild type and C49S are mapped. The same chemical shift change categories 
used in panel C were used in panel D (no change=black; small change=red; medium 




the choice of buffer still affects the stability of the oxidized species such that phosphate is more 
stabilizing. While studies to explain this phenomenon are beyond the scope of this work, a 
secondary phosphate interaction site has already been proposed. The C-terminal tail of PRL-1 
contains a polybasic region, which has been shown to be important for binding to phospholipid 
membranes.45 The stabilization of oxidized wild type by phosphate may be a result of an 
interaction with this region of the protein. These residues are missing from the crystal structures 
but large perturbations corresponding to these residues in the NMR spectra occur upon active site 
oxidation,35 suggesting they are organized differently in the two states. 
We next compared the NMR spectrum of the chemically reduced wild-type protein to 
that of C49S (Figure 5.5.C). Surprisingly, there are far more changes between these two protein 
forms than observed between the chemically reduced wild type and C104S. Representative large 
(yellow), medium (blue) and small (red) changes are highlighted with corresponding colored 
boxes in the figure. Again for visualization, the changes were mapped to the available C104S 
crystal structure with each residue colored according to the appropriate chemical shift change 
category (Figure 5.5.D).13 Many of the largest chemical shift changes are located in or near the 
active site (V48-E50, W68, F70-A74, H103, C104, L108-R110). Similar to the C104S-reduced 
wild type comparison, several additional perturbations to α4-α6 are observed (L114-L117, L119, 
Q131, Q135, F141 and Q145). These changes are again propagated to β1 and β2 (V10-V12). 
Because changes in α4-α6, β1 and β2 are confined to the internal face and are relatively small 
across variants with differing stabilities, we conclude that this region of the protein does not 
appear to correlate with aggregation propensity. Loop three containing Y53 is also altered. 
Interestingly, in each region of the protein described above, the number and magnitude of 
chemical shift changes are larger in C49S, and the specific residues involved in some cases 
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differ. For example, Y53 and nearby residues, especially T26, are perturbed to a much greater 
extent with the C49S mutation than with the C104S. The 1H line width of the Y53 peak increases 
from 22.7 to 53.9 Hz (137% increase), despite the fact that the average line width for all C49S 
peaks is approximately the same as that for the reduced wild type (33.05 and 31.8 Hz, 
respectively). This data supports our hypothesis that burial of the C49 side chain stabilizes the 
Y53-H103 interaction and incorporation of a polar moiety at this position increases 
conformational flexibility in this region.  
To further probe the role of the hydrogen bond between Y53 and H103, we eliminated 
the interaction by substituting Phe for Tyr. An NMR spectrum of Y53F was collected, and the 
broad line widths of the peaks indicate that this protein exists in a molten globule-like state. With 
Y53F, the Phe side chain is likely exchanging between a buried and exposed conformation of 
loop three, and consequently, the conformation of this residue and the surrounding residues is not 
restricted to a specific organization (Figure 5.6). Because the entire set of peaks is broadened to a 
similar extent in this spectrum, it appears that the Y53-H103 hydrogen bond organizes a 
Figure 5.6. 1H-15N 




Figure 5.7. Structural Comparison of C49S and Y53E. The 1H-15N HSQC spectrum of 
PRL-1-C49S (red) is overlaid with that of PRL-1-Y53E (black). The number of peaks in the 
Y53E spectrum indicates that Y53E samples multiple conformations in solution. One of these 
conformations is similar to the structure of C49S. Although, the chemical shift difference for 
Y/E53 is significant, the change is rather small (compare to Figure 5C). The small difference is 
likely a direct result of the side chain substitution. 
 
particular conformation of the protein, which has increased physical stability. Y53E was made 
because it was expected that mutation to Glu would favor a more exposed state for this region, 
due to the introduction of a charged moiety. The NMR spectrum of Y53E was collected and 
compared with that of C49S (Figure 5.7). Overall, the NMR spectrum of Y53E has many more 
peaks than would be predicted for a single stable conformation, and many of the peaks in the 
central portion of the spectrum are overlapped and unresolved. Based on the line widths, it 
appears that a mixture of two or more distinct conformations exists, possibly a set of more open 
conformers that undergo slow conformational exchange on the NMR timescale. Despite this 
complexity, critical portions of the Y53E spectrum are remarkably similar to C49S. Of 
importance is the fact that the peaks for Y53 and E53 are virtually identical. This information 
supports our hypothesis that the C49S mutation also alters the status of the Y53-H103 hydrogen 
bond. To eliminate the possibility that mutation of Y53 might alter the redox state of the protein, 







of a reducing agent does not alter the appearance of the Y53E (or Y53F) spectrum in any way 
(data not shown), indicating that the protein exists as multiple conformers independent of 
disulfide bond formation. As such, the formation of the disulfide bond appears to depend on the 
presence of the Y53-H103 bond, and the local packing organization imparted to the active site 
and L3 are a result of this interaction.  
Based on the above data and the assumption that the charge state of the active site for 
C49S and chemically reduced wild type are approximately the same, it seems that the active site 
is coupled to the rest of the protein through H103 via its hydrogen bond to Y53 in L3. Although 
more extensive structural analysis is needed to fully explain the cooperativity, the β-sheet also 
packs against the large hydrophobic surface generated by the Y53-H103 hydrogen bond. An 
unusually large number of substantial differences appear in the central β-strand (β5) located in 
the hydrophobic core of the protein variants. A101 is the central residue of this structural feature, 
and the C49S mutation causes a considerably larger change in frequency than does C104S for 
this residue when compared to the chemically reduced wild type (Δδ1H and Δδ15N for C49S are 
0.116 and 2.54 ppm, respectively; Δδ1H and Δδ15N for C104S are 0.000 and 0.073 ppm, 
respectively). To better illustrate the differences between C104S and C49S, the chemical shift 
changes observed between the NMR spectra of these two proteins were again mapped to the 
structure. The results are shown in Figure 5.8. As can be observed in Figure 5.8, the largest 
changes are observed in the central strand (β5) with residues C99, A101, V102 and H103. The 
remaining blue change is V42 in β2, and smaller changes are observed for all residues in β4. 
These changes may be a reflection of the altered packing arrangement of surrounding residues 
and/or dynamics in L3 where both C49 and Y53, which hydrogen bonds to H103 positioned at 
the edge of the active site in β5, are located. C49S, which lacks both the Y53-H103 hydrogen 
92 
 
bond and C49-C104 disulfide bond, is consistently less stable than all other forms studied, as 
indicated by its dramatically lower melting temperature in both phosphate and HEPES and 
increased propensity to aggregate. As such, increased protein aggregation is correlated with 
increased flexibility in this region of the protein. This is supported by the fact that the oxidized 
wild type, which contains the disulfide bond but lacks the hydrogen bond, is more stable than 
C49S (Table 5.3). 
In this context,22 the disulfide bond increases the stability of the protein by restricting the  
Table 5.3. Effects of Specific Bonds on PRL-1 Stabilitya 
 Decreasing Stability  ⇒⇒⇒  
 C104S Reduced WT Oxidized WT C49S 
Y53-H103 hydrogen bond Yes Yes No No 
C49-C104 disulfide bond No No Yes No 
Active site PO4 binding Yes Partial No Partial 
Tm (pH 7.5) 76.3 67.8 65.5 62.8 
aAll temperatures reported are in °C 
 
Figure 5.8. Chemical Shift Mapping of PRL-1. A. Chemical shift changes (Δf) between 
the C104S and C49S proteins is shown with the following color categories: no 
change=black; small change=red; medium change=blue; large change=yellow. Changes 
were mapped  to the available C104S  (PDB 1XM2)16 crystal structure. The NMR spectra 
are not shown.  B. As in A, except the molecule is rotated by 180° along the Y axis to 




conformational flexibility of L3 in a different manner. When comparing the reduced and 
oxidized wild type proteins,35 similar changes to the central β-sheet are observed, as well as large 
changes in α-helix two (α2). Similar changes to α2 are detected when comparing C49S to 
reduced wild type and/or C104S and can be seen in Figures 5.5.D and 5.8. Because β4 is 
composed of entirely hydrophobic residues and such sequences are prone to aggregation,46 we 
hypothesize that stable packing of L3 and α2 provide protection in the reduced state against edge 
strand initiated aggregation. Formation of the disulfide bond causes the Y53-H103 bond to 
become distorted and L3 consequently becomes more flexible, leading to slightly increased 
aggregation propensity in the oxidized state. Complete disruption of the hydrogen bond, as is the 
case with C49S, may lead to unraveling of α2, and the increased susceptibility to aggregation 
may be caused by a larger degree of β-sheet exposure. Many other groups have found that the 
proportion of β-sheet structure increases in protein aggregates, while α-helical content is 
diminished.47,48 Interestingly, full spectral CD analysis reveals that much of the β-sheet structure 
remains intact at the onset temperature. Although only a representative plot of C49S is shown in 
Figure 5.9, similar results were seen for the other PRL-1 mutants. This hypothesis is further  
 
Figure 5.9. CD Spectra of PRL-
1-C49S. The spectra shown 
represent the average of two 
replicates of two independently 
prepared samples (n=4). Error 
bars were omitted for 
presentation purposes. In this 
plot, the spectrum at 35 °C was 
shown to provide a comparison 
for the NMR studies, which were 
all performed at 37 °C. Similar 
results were obtained for the 




supported by the results of the H-D exchange NMR experiments, in which labile protons in the 
protein are exchanged with deuterons when the protein is dissolved in D2O. Only protonated  
groups generate signal in the NMR experiment, and the loss of intensity for each chemical shift 
can be monitored to determine the rate of exchange at individual positions. These rates will differ 
depending on the location of the amide in the protein and the interactions in which it participates. 
For example, based on the crystal structure, residue T56 is located near the edge of α2 and the 
amide of this residue does not participate in hydrogen bonding. As expected, the exchange rate at 
this position is very fast for all three protein forms. In contrast, W84 is located in the center of 
α3 and its amide hydrogen participates in hydrogen bonding with the carbonyl in the i-4 
position. The amide for this residue is completely retained for all three variants after 24 hours. 
As another example, the NH of L66 is pointed towards the interior of the protein and hydrogen 
bonds with the carbonyl of I45 in β3. The amide should be solvent inaccessible, and as 
anticipated, the H-D exchange data indicates that the NH of L66 is completely retained after 24 
hours as well. Although the vast majority of amides exchanged either too slowly or quickly to 
obtain quantitative values, F92, which is located in α3 close to the C-terminal end of the helix, 
exchanged at a measureable rate. The data for this residue was analyzed and is shown because 
the exchange rate for this amide could be determined for all three proteins. Only very small 
differences are observed among the three variants indicating that this portion of the structure 
behaves similarly and experiences no structural or dynamic perturbations with either Cys 
mutation. This data is summarized in Table 5.4.  
In Table 5.4, the amide half-lives determined from the exponential fit of the signal decay 
from 0-24 hours for a few representative residues are shown. The exchange rate values, although 
quantitatively determined, are a qualitative way of identifying trends in structural stability among 
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the PRL-1 variants at specific sites in the protein. 
According to the crystal structures, residue V58 is 
the central residue in α2 and the amide hydrogen 
should be buried in a hydrogen bond. It therefore 
should be less solvent accessible and exchange 
more slowly than random coil if participating in 
α-helix interactions. As can be seen with Table 
5.4, the half-life for this amide in C49S is shorter 
compared to the reduced wild type, and reduced 
wild type is shorter than the C104S protein. A 
similar trend is observed for L57, although these differences are very small. When inspecting 
residues located in β4, the edge strand, similar trends are observed, especially for residues H64 
and, to a lesser extent, D67. This data indicates these residues are more solvent exposed in C49S 
than in the reduced wild type or C104S protein and parallels the trends observed with our 
reported Tonset and Tm values. Based on these observations, it is likely that unfurling of the 
structure at L3 and α2 exposes the β-sheet and may permit edge-strand association to initiate 
aggregation. Because large protein aggregates cannot be observed using solution NMR, the 
aggregation mechanism will have to be investigated further using other methods. 
It is particularly interesting that the hydrogen bond between Y53 and H103 is better able 
to enhance stabilization of the protein than the disulfide bond. Other incidents of hydrogen bonds 
contributing substantially to the stability of proteins have been documented.28,49,50 The 
methodologies used in these studies, however, could not provide information about cooperative 
or dynamic influences resulting from disruption of the hydrogen bond and compensation effects 
Table 5.4. H-D Exchange Dataa 
  
Protein 
Region C49S redWT C104S 
T56 α2 ++b ++ ++ 
L57 α2 ++ 1.4 2.1 
V58 α2 26.8 34.2 --c 
H64 β4 26.7 42.0 54.0 
V65 β4  ++ ++ 2.1 
L66 β4 -- -- -- 
D67 β4 ++ 2.1 3.8 
W84 α3 -- -- -- 
F92 α3 28.2 24.7 21.8 
aAll data are reported as half-lives of NH  
 peak intensity in minutes. 
bCould not be fit because the NH  
 exchanges completely within 5 minutes. 
cCould not be fit because NH is  
 completely retained after 24 hours 
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could not be observed. The high-resolution approach used here shows that modification of the 
hydrogen bond causes local perturbations as well as increased dynamics in coupled regions. For 
example, because disruption of the Y53-H103 bond in PRL-1 indirectly leads to drastic changes 
in the central β-sheet, packing of these structural features must be interrelated. 
Reduction of the disulfide bond in PRL-1 causes more than 90% of the NMR chemical 
shifts to change significantly, without drastically altering the secondary structure elements.35 
This structural transition probably reflects changes not only to the conformation of the active site 
but also the interaction between Y53 and H103 and cooperative hydrophobic packing 
interactions with the β-sheet in the protein core. Although the solution NMR data reveal that 
substantial conformational changes occur in solution between the reduced and oxidized states,35 
such large differences are not apparent in the crystal structures. The majority of differences are 
located near the active site when comparing the two crystallized proteins, and these differences 
are obvious in the NMR data as well. What is not apparent in a comparison of the crystal 
structures is the importance of the small rearrangements between the β-sheet, L3 and α2 in the 
two states. Based on the crystal data, one would predict that the hydrophobic packing 
interactions in the reduced and oxidized states are largely the same,13,16 but the NMR data clearly 
show otherwise. One explanation for this discrepancy may be the absence of several residues 
from the C-terminus in the crystallized proteins. Crystallized PRL-1 was truncated at residues 
156 and 160 for the reduced and oxidized forms, respectively. Although the full-length protein 
has not been crystallized, studies from our lab previously showed that the missing residues, 
which compose the polybasic sequence, modulate the structure and activity of PRL-1, such that 
their removal abrogates disulfide bond formation.35 This result indicates an additional unique 
coupling exists in the oxidized protein that involves the tail residues. 
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5.3.3. Concluding Remarks 
This study shows that stabilization or destabilization of a protein can be achieved in the 
folded state through the collaboration of specific, local interactions. The strategies presented here 
illustrate the utility of NMR in pharmaceutical research, as they can be applied to therapeutically 
relevant proteins to identify stabilizing forces within the structure. Identification of these forces 
at atomic resolution will facilitate the rational design of improved protein therapeutics and 
biotechnology products. Furthermore, this work demonstrates that the effects of the oxidation 
state of cysteine residues on a protein’s stability derive from the overall context in which they 
reside. Understanding this relationship is valuable because it may guide disulfide bond 
engineering in protein pharmaceuticals.  
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CHAPTER 6.  
CONCLUSIONS, FUTURE WORK AND IMPLICATIONS  
FOR DRUG DESIGN 
 
6.1. MAJOR CONCLUSIONS 
 The major conclusion of this work is that the PTPase activity of PRL-1 is controlled by 
redox conditions and is dramatically affected by modification of the C-terminus. Modification of 
the C-terminus confers activity through structural rearrangement of the protein and yields a 
conformation in which disulfide bond formation is no longer apparent. In the following two 
sections, the implications these findings have for PRL-1-based drug design and understanding of 
protein stability are discussed. 
6.1.1. PRL-1 as a Novel Therapeutic Target 
PRL-1 is a unique PTPase that has gained attention over the last decade because it 
promotes cancer and metastasis, when active.1,2 Because PRL-1 is a PTPase and is subject to 
redox regulation, it follows that identification of a stable, constitutively active (reduced) form of 
PRL-1 is needed to facilitate the design of potential therapeutics by either high-throughput 
screening or structure-based drug design using solution NMR. We have clearly shown in Chapter 
2 that two of the predicted posttranslational sites of PRL-1 dramatically affect the enzyme 
activity of PRL-1, such that farnesylation at the C-terminus likely promotes catalysis, while 
phosphorylation at Y53 would inhibit it, indicating that the C170S-C171S mutant provides a 
stable, reduced and active form of PRL-1 with which inhibition assays and screening for lead 
compounds for drug design can be pursued. Our data correlates well with previously published 
biological studies that showed inhibition of farnesylation abolishes PRL-1 mediated cell growth 
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and motility and causes mitotic defects.3,4 This finding is also significant because the CaaX box 
motif is unique to the PRL enzymes and drug molecules that target the farnesylated form may 
provide a means of specificity without modifying the actions of other essential PTPases. 
Direct confirmation that farnesylation activates the enzyme is needed to validate our 
model protein for drug design. In vitro conjugation of the farnesyl group and PRL-1 has been 
observed previously but has been difficult to reproduce.5,6 Our lab has previously shown that 
PRL-1 contains a novel metal coordination center at the site of farnesylation (unpublished 
results)∗ and we suspect that metal binding interferes with the reaction. Although a number of 
metals have been found to coordinate to PRL-1, zinc coordination is likely biologically relevant 
because it is required for the farnesyl transfer reaction.7 With this in mind, I have developed a 
new method for purifying recombinant PRL-1 with zinc coordinated at the C-terminus, the 
details of which are described in Appendix E. Attempts to purify PRL-1 without metal for the 
purpose of quantifying a metal binding constant and performing in vitro farnesyl conjugation 
were unsuccessful because the protein precipitates rapidly out of solution, indicating that the 
metal ion is an important structural feature. No other groups have reported PRL-1 metal binding. 
Others have reported difficulty obtaining crystals of the full-length form, but it is not certain 
whether metal binding was a factor in these studies or not.8,9 We have not yet attempted to 
farnesylate Zn-bound PRL-1 because the reaction is quite complicated and the reagents are 
expensive. A thorough screening of assay conditions will be required to identify conditions that 
promote this modification and is well beyond the scope of this dissertation project. 
                                                
∗ This work was completed by Anthony A. Vartia. Site-directed mutagenesis in combination with 
inductively coupled plasma mass spectrometry and UV-Vis spectroscopy was used to identify 
the metal coordination site, the species present (nickel, copper, zinc) and the most likely 
coordination geometry (square planar).  
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In addition to providing a model protein for drug screening assays, the biophysical and 
biochemical assays used to characterize the full-length and C-terminally modified proteins have 
provided, for the first time, a basis for explaining some of the varied findings regarding the role 
PRL-1 plays in controlled or aberrant growth processes. For example, although PRL-1 most 
frequently promotes cellular proliferation, it also likely plays a role in differentiation under 
certain conditions. For example, elevated levels of PRL-1 have been detected in differentiated 
tissues such as the intestinal villi,10 confluent CaCo2 cells,10 the outer segments of 
photoreceptors,11 neurons and oligodendrocytes.12 This is interesting with respect to redox 
conditions because differentiated cells are generally more oxidizing than proliferating ones. In 
fact, Yu et al. (2007) showed that oxidative stress induced the expression of PRL-1 in the retina 
and a photoreceptor-derived cell line.13 Because the PRL-1 promotes several distinct phenotypic 
response (i.e. proliferation and differentiation) it is likely that this enzyme acts in multiple 
signaling pathways on a series of substrates and the cellular response may be modulated by the 
level of phosphatase activity or confinement of the protein to distinct subcellular locations. In 
Chapter 4, the reduction potential for the active site disulfide bond was calculated, which 
provides a basis for understanding how subcellular localization may regulate the phosphatase 
activity of PRL-1 in different types of cellular environments.14 Determining the differences in the 
subcellular location and/or posttranslational processing of PRL-1 expressed in terminally 
differentiated versus proliferating tissues will generate a more accurate account of how PRL-1 is 
regulated in vivo and how its regulation contributes to such diverse cellular outcomes. This 
concept has yet to be explored by any group.  
Interestingly, it is not clear whether the PTPase activity of PRL-1 is required for 
differentiation and it is possible that during differentiation, PRL-1 functions in a completely 
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unrelated way than it does during proliferation. In Chapters 3 and 4, it was shown that PRL-1 
undergoes a major conformational change upon reduction (or modification to the C-terminus) in 
that greater than 90% of the amide resonances are perturbed to a significant extent.15 When 
mapped to the available crystal structure, the perturbations are larger in number and magnitude 
in the central β-sheet located in the hydrophobic core of the protein (Figure 4.6). Such a drastic 
change in the protein’s hydrophobic core is quite unanticipated. In general, the intrinsic 
dynamics of a protein predict that changes involving flexible loops or active-site residues occur, 
and changes of this nature are indeed observed in this study. Rearrangement of a protein’s 
hydrophobic core, however, is rare.16 Even proteins with large conformational changes share 
similar hydrophobic packing interactions.9,17,18 Recently, a structural change that involves 
repacking of the protein core has been documented. In this example, virtually all of the tertiary 
contacts of the lyphotactin fold are replaced with new contacts and each of the two states have a 
unique function.16 The structural transition in PRL-1 likely reflects changes not only to the 
conformation of the active site but also the interaction of Y53 and H103 and cooperative 
hydrophobic packing interactions with the β-sheet in the protein core, which was shown with the 
work described in Chapter 5. Additional, higher-resolution NMR studies are being pursued to 
further assess alterations in direct contacts between specific residues in the two states. 
6.1.2. PRL-1 as a Model Protein to Study Protein Stability 
Chapter 5 was dedicated to studying the effects of disulfide bond formation on the 
stability of PRL-1. The results of this study are significant because they show that that the 
integrity of the native PRL-1 structure does not depend on the absence or presence of the 
disulfide bond directly, but rather on the local packing interactions among nearby side chains and 
coupling between different regions. Each Cys-modulated PRL-1 variant has a unique physical 
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stability based on retention of specific features in its three-dimensional structure. The data 
indicate the reduced form of the protein compensates for disulfide bond cleavage by a 
compilation of adjustments focused around a central hydrogen bond between Y53 and H103. 
Structural instability and aggregation is correlated with flexibility in L3 (containing Y53), and 
C49S, which lacks both the Y53-H103 hydrogen bond and disulfide bond, is less stable than the 
oxidized wild type. In this context,19 the disulfide bond increases the stability of the protein by 
restricting the conformational flexibility of L3 in a different manner. The work demonstrates that 
the effects disulfide bond formation has on a protein’s stability derive from the overall context in 
which they reside, and understanding this relationship is valuable because it may permit a more 
rational approach to disulfide bond engineering in protein pharmaceuticals. 
The other significant part of this work is how the combination of low-resolution and 
high-resolution methods gives a more detailed account of how stabilization is achieved than 
either method does alone. In this study, low-resolution methods (CD and SLS) were used to 
rapidly determine whether differences in stability between the various protein forms exist. These 
experiments are incredibly important because they facilitate rapid identification of stabilizing 
conditions for protein formulations. In this study, the hypotheses regarding the mechanism of 
protein stabilization or destabilization derived from low-resolution analysis were tested using 
high-resolution solution NMR. NMR has long been recognized as a valuable tool for structure 
determination and studying protein folding. In this work, however, NMR was used to correlate 
the observed changes in stability with specific perturbations in the structure of the folded protein 
to identify which residues are important for stabilization of the folded state. The strategies 
presented here illustrate the utility of NMR in pharmaceutical research, as they can be applied to 
therapeutically relevant proteins to identify stabilizing forces within the structure. Identification 
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of these forces at atomic resolution should further facilitate the rational design of improved 
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APPENDIX A. pNPP INDUCES OLIGOMERIZATION OF PRL-1 
 
A.1. pNPP INDUCES OLIGOMERIZATION OF PRL-1 
 In an attempt to determine Michaelis-Menten kinetic constants and compare our findings 
with those previously published, the pNPP substrate concentration was varied from 0.2-60 mM 
and the reaction was monitored over time. As can be observed in Figure A.1, PRL-1 exhibits an 
atypical kinetic profile in that the reaction is inhibited with increasing amounts of substrates in a 
non-linear fashion. This was observed for all mutants examined and a representative plot of the 
data for PRL-1-C170S-C171S is shown in 
Figure A.1.A. Because PRL-1 is generating free 
phosphate during the course of the experiment, 
which could cause feedback inhibition, attempts 
were made to precipitate excess phosphate out 
of solution by the addition of CaCl2 with little 
success due to interference with the 
measurement because of light scattering. The 
progress curve for PRL-1-C49S is also shown in 
(Figure A.1.B). It is apparent that this mutant 
behaves even more anomalously than the C-
terminal mutant, displaying a profile 
reminiscent of aggregation behavior. The visible 
range used for this assay is susceptible to 
interference from light scattering effects, and as 

























Figure A.1. PRL-1 Progress Curves. A. 
PRL-1-C170S-C171S was allowed to 
react with increasing concentrations of 
pNPP for 150 minutes and the amount of 
pNP product formed over time was 
monitored at 405 nm. B. As in A, except 
C49S was monitored. 
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such, a study to determine if oligomerization or aggregation of the protein was causing this 
atypical profile was conducted. First, the protein was incubated in the assay conditions without 
substrate and monitored over the time course of the kinetic reaction. A small amount of 
background absorbance from the protein itself was detected, but not in any significant quantity to 
cause such an anomalous progress curve (data not shown). Next the ability of pNPP to induce 
aggregation was evaluated. In this study, the 1H-15N HSQC NMR peaks of PRL-1 were 
monitored over time, and as indicated in Figure A.2 by the loss of protein signal after the 
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Figure A.2. 1H-15N HSQC NMR 
Spectra of PRL-1-WT in the 
presence of pNPP. A. WT without 
pNPP. B. WT+200 mM pNPP after 
60 minutes. To better visualize the 
drastic change in signal intensity of 
the protein, both A and B are shown 
at the same signal-to-noise level. C. 
As in B except shown closer to noise 
to see remaining signals. 0.5 mM 
PRL-1 was used in 50 mM HEPES, 
pH 7.5 (standard assay condtions). 
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The fact that the generic substrate can induce oligomerization is significant because this 
substrate has been used for all other previously reported kinetic studies of PRL-1 and PRL-3.1-3 
Unfortunately, the actual progress curves are rarely presented because discrete time point assays 
are often performed, so it is uncertain whether other groups have experienced a similar problem. 
It is shown here that above concentrations of 20 mM pNPP, aggregation can be quite significant, 
which precludes any kind of quantitative analysis. Unfortunately, Sun et al. (2005) did not report 
the range of substrate concentrations used; only that they spanned from 0.2-5 mM times the KM. 
Using this information, the concentrations could be extrapolated if the enzyme concentration is 
known. This is also not reported in their published manuscript.1 Consequently, only the relative 
activity of a given mutant at a given concentration is reported for PRL-1 for this project. In these 
experiments, the reaction is allowed to proceed and an absolute rate value is calculated using the 
molar absorptivity coefficient of p-NP. In this case, 20 mM pNPP was used because there is only 
a small degree of aggregation at this concentration (see Figure A.3) and because the enzyme is to 
inherently too slow to use smaller concentrations. Upon examining the progress curves, it is clear 
that the C170S-C171S mutant has the most activity. This value was, therefore set as the 
theoretical maximum, while the value of the inactive C104S protein was used as a theoretical 
minimum. Other groups have used a variety of other substrates to measure the kinetics of other 







Figure A.3. SDS-PAGE Analysis of 
PRL-1-WT in the Presence of 20 mM 
pNPP. The pNPP assay was allowed to 
proceed and gel samples were taken out 
at various time points up to 300 minutes. 
Once collected, non-reducing loading 
buffer was added and the sample heated 
to stop the reaction. This reaction was 
done under non-reducing conditions, 
which explains the two bands for PRL-1 
at 20 kDa. 
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PTPase family members. It is unclear whether these substrates may also induce oligomerization 
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APPENDIX B. SEQUENCE ALIGNMENT OF PRL FAMILY MEMBERS 
 
The sequence alignment of the human PRL family members is shown above. The 
sequence alignment shown is based on the results presented in Figure 1 of Sun et al. (2005). 
PRL-1 is 87% identical to PRL-2 and 79% identical to PRL-3. Overall, the three members share 
76% sequence identity with each other. 
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APPENDIX C. HIGH-FIELD SOLUTION NMR SPECTROSCOPY 






One of the most important uses of high-field solution nuclear magnetic resonance (NMR) 
in the pharmaceutical industry relies on its unique ability to examine protein-drug interactions at 
very high resolution. NMR experiments have provided crucial data to assess the ability of a small 
molecule drug to bind and modify the activity of a disease-modifying protein at a structurally 
defined binding site.1 Upon the interaction of a small molecule ligand with a protein target, a 
perturbation of the NMR spectrum occurs, and detection of the perturbation is the basis of ligand 
binding analysis by NMR. The perturbation assay is divided into two categories based on 
whether the signals from the protein target or the ligand are observed. An expanding set of NMR 
experiments is available to map either the small or macromolecule in a site-specific manner to 
chemically and physically characterize small molecule ligand interactions with protein targets. A 
significant advantage of these NMR assays is that they are useful for identifying binding partners 
from a mixture of compounds (NMR screening). Each method will be discussed in further detail 
in the appropriate sections, and a summary of the advantages and disadvantages is outlined in 
Table C.1.  
Solution NMR is often segregated into two fields. Low-field NMR is primarily utilized 
for small molecule analysis, while macromolecular studies require high-field instruments 
(greater than 500 MHz). Higher field spectrometers offer advantages for the study of both small 
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and large compounds. First, the probes accompanying higher fields allow selective detection of 
bonds or atoms to obtain site-specific information about the protein target or small molecule. 
Additionally, increased field strength improves sensitivity and provides better resolution and 
narrower line widths, which are necessary to analyze large molecules that generate many signals. 
Improved sensitivity allows lower concentrations of analytes to be detected. Although small 
molecule analysis traditionally does not require high-field spectrometers, the higher field 
instruments are advantageous because the increased resolution allows for improved ability to 
examine small molecules, specifically in the context of their interactions with macromolecules 
where they are undergoing exchange processes, which leads to line broadening.2  
Table C.1. Summary of Current NMR screening Methods 
Limits and Requirements Permits Identification of: 







Epitope Selectivity  






c   
19F Relaxation and Chemical 
Shift Perturbations unlimited 
10-6- 
10-3 
19F d   
Ligand Observed       
Relaxation Rates unlimited 
e10-6- 
10-3 none    
Diffusion Coefficients unlimited 10
-6- 
10-3 none    
Nuclear Overhauser Effects unlimited 10
-6- 
10-3 none    
Magnetization Transfer unlimited 
e10-6- 
10-3 none    
19F Relaxation and Chemical 
Shift Perturbations unlimited 
e10-6- 
10-3 
fnone    
aRequires the use of two-dimensional 1H-15N HSQC or 1H-13C HSQC experiments. 
bRequires the use of advanced pulse sequences and/or isotopic labeling strategies. 
cPartial or complete resonance assignments are required. 
d19F resonances must be assigned if more than one aromatic residue occurs in the protein. 
eCompetition based screening permits determination of a wider range of binding affinities. 





High-field solution NMR can provide supplementary or additional information about a 
binding reaction in addition to facilitating determination of the association constant between a 
drug and binding partner, as can be obtained with traditional functional assays. Most notably, 
NMR provides detailed structural information about the protein-ligand binding site, as well as 
data from which the KD value can be determined, providing a structure-activity relationship 
(SAR).3 Moreover, high-field NMR can be used to structurally characterize binding of two or 
more ligands simultaneously.4,5 The experimental setup is straightforward and provides a 
universal process, applicable to virtually any protein, for the detection of intermolecular 
interactions.4 Two unique advantages of analyzing molecular interactions by NMR are that: 1) it 
requires no target-specific assay or knowledge of the target protein’s function6 and 2) NMR 
experiments can detect species that interact weakly with each other (mM dissociation constants). 
The ability to detect direct interactions between ligand and target over a broad KD range 
illustrates the robustness of this technique.5 
In brief, high-field solution NMR offers the ability to easily evaluate the structural, 
thermodynamic and kinetic aspects of a binding reaction.7 This appendix outlines the current 
methodologies used to assess protein-ligand interactions from both the perspectives of the 
protein target and ligand molecule. Appropriate background information is provided to describe 
the NMR experiments available for assessing ligand binding and the corresponding data 
interpretation. Finally, advances in NMR technology and experimentation are presented to 
illustrate the utility of solution NMR in the identification and characterization of potential 





C.2. “PROTEIN TARGET” DETECTED METHODS 
 Most target-observed screening applications rely on chemical shift changes as indicators 
for intermolecular binding.6 This type of screening generally is referred to as a perturbation 
assay, and it is used to evaluate the resonances of the protein target as a function of ligand 
concentration in a titration experiment.8 Changes are observed upon binding because chemical 
shift reports on the local electronic environment of a nucleus. NMR commonly detects spin ½ 
nuclei (1H, 13C, 15N, 19F), and the type of nucleus is a major determinant of the chemical shift 
value.9 Additionally, the dielectric properties of the solvent, covalent or hydrogen bonds, van der 
Waals interactions and bond angles influence the electronic environment of an atom, which 
impact its chemical shift.10 Changes in NMR chemical shifts can result from any physical or 
chemical process that changes the magnetic environment of a nucleus, including dynamic 
processes such as conformational changes and solvent effects. The chemical shifts of surface 
exposed nuclei are affected by bulk solution. Proteins are virtually always analyzed in aqueous 
solution, where the main contribution to solvent effects comes from the pH and ionic species 
present. Generally, low ionic strength and slightly acidic conditions are more conducive to 
generating high-quality spectra, but the requirements for each protein are unique.11 On the 
interior of the protein, chemical shift values are dictated largely by packing interactions and bond 
geometries. Chemical shifts corresponding to regions experiencing dynamic fluctuations may be 
substantially influenced by both structure and solvent contact. When interactions occur between 
analytes in solution different values of NMR chemical shifts reflect the different nuclear 
environments undergoing exchange and depend on the nature of the exchange or binding 
process.12 A nucleus involved in a binding reaction will experience a different environment in its 
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free and bound form, generating signal that reflects the combination of both. The appearance of 
the NMR spectrum also depends on the rate at which the exchange phenomenon occurs (Figure 
C.1). A slowly exchanging system exists when the exchange occurs more slowly than the 
difference in chemical shift in frequency units. When the exchange is faster than the difference in 
chemical shift, the system is classified as a fast-exchange system. NMR experiments detect 
processes that occur on the microsecond to millisecond time scale. If the nuclear environments 
change slowly on the NMR timescale, the spectrum will capture two distinct sets of resonances 
for the free and bound states (Figure C.1.A), whereas rapidly-exchanging nuclei will produce a 
single set of resonances representing a weighted average of the chemical shifts of the free and 
bound signals (Figure C.1.C).9,12 
 
The ability to interpret a NMR spectrum becomes increasingly difficult for higher 
molecular weight species. A small molecule with relatively few atoms will produce well-
resolved, sharp NMR signals with large chemical shift dispersion (Figure C.2.A). In contrast, a 
simple one-dimensional spectrum of a protein contains thousands of signals generated by 
Figure C.1. Exchange Regimens 
Observed with NMR. A. Two 
resonances appear because the observed 
nucleus exchanges slower than the NMR 
scale. B. Nuclei that exchange on the 
intermediate time scale cannot be 
detected because they are too broad. C. 
One resonance is observed because the 
detected nucleus exchanges faster than 
the NMR time scale. The peak represents 






numerous similar chemical moieties that appear in the same regions of the spectrum. The 
presence of secondary and tertiary structure elements provides improved dispersion, 
distinguishing the chemical shifts from those of the random state as the microenvironment of a 
particular nucleus dictates its chemical shift in an extremely sensitive manner. Nonetheless, due 
to the large number of signals, one-dimensional observation typically lacks sufficient resolution 
to evaluate structure and dynamics and quantify binding (Figure C.2.B).13 Consequently, this has 
led to the development of multidimensional correlation experiments. These experiments resolve 
overlapping signals by expanding the spectrum into two or three dimensions based on different 
nuclei or differences in connectivity.12 
 
Figure C.2. Multidimensional NMR. A. 1H NMR spectrum of pNPP in 50 mM HEPES, 
pH 7.5. The two resonances at approximately 7 and 8 ppm correspond to the two aromatic 
protons. The water peak resonates at 4.703 ppm and the remaining peaks below 4 ppm 
correspond to the HEPES buffer. B. 1H NMR Spectrum of PRL-1. The peaks above 6 ppm 
are the protein’s backbone amides and side chains. The water peak resonates at 4.703 ppm 
and the remaining signals respresent the protein’s aliphatic protons. The signals are too 
numerous and overlapped to make any specific assignments. C. 1H-15N HSQC spectrum of 
PRL-1. Each peak represents a single NH group in the protein, including backbone and 
side-chain amides. Using three-dimensional correlation experiments, each peak can be 
assigned to a given amino acid in the protein sequence to yield structural information that 






Two-dimensional correlation spectroscopy refers to a class of experiments that probe the 
connectivity between nuclei. Each axis shows the chemical shift of a specific nucleus, and cross 
peaks result only for those that are correlated to each other.14 In general, the experiment can be 
applied to investigate homo or heteronuclear associations. The Heteronuclear Single Quantum 
Correlation (HSQC) experiment is particularly useful for the analysis of proteins. The 1H-15N 
HSQC experiment exploits the repeating nature of the protein’s primary sequence and three-
dimensional structure. The amide bond connects the amino acids that compose the protein 
sequence, creating a repeating series of NH groups that become chemically unique in the context 
of the protein’s tertiary structure. The experiment only detects those protons directly coupled to 
nitrogen, so the resulting spectrum lacks any overlap from proton signals associated with carbon 
(typically aromatics in the relevant ppm range).12 The spectrum displays one cross peak for every 
amide in the protein at a position characterized by its 1H and 15N chemical shifts.15 In total, the 
spectrum contains one signal for each residue except proline, which lacks an HN, two paired 
peaks generated by the asparagine and glutamine NH2 groups and additional signals from NH 
containing side chains (Figure C.2.C).7 The HSQC spectrum provides an overall map or 
fingerprint of the protein target and serves as the basis for assessing ligand binding and the 
overall fold and behavior of a protein. This experiment is fast and easily interpreted but requires 
isotopic labeling of the protein with 15N because of its low natural abundance (0.37%).10 When 
labeling is not practical, a 1H-13C version of the HSQC can be performed using unlabeled protein 
to evaluate the aliphatic protons; however, this experiment requires longer data acquisition. Both 
experiments reveal information about the protein’s structure. The 1H-15N-HSQC has the 
advantage of probing each amino acid and revealing whether the protein is folded, as the amide 
proton chemical shift distribution for each amino acid is significantly influenced by its secondary 
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structure and collapses to a narrow ppm range upon unfolding.16 Also, the 13Cα alpha and 13Cβ 
and, to a lesser extent, 1Hα chemical shifts correlate with α-helical and β-sheet secondary 
structure elements, but the spectrum is more difficult to interpret with respect to structural 
changes than the 15N version. 
The HSQC experiment is a powerful tool for binding studies because of the sensitivity of 
coupled nuclei to changes in the environment. The 1H-15N HSQC detects changes in the 
backbone amide bonds upon addition of ligand, whereas the 1H-13C HSQC detects changes in 
aliphatic and aromatic chemical shifts of the side chains. Monitoring the chemical shift changes 
as a function of ligand concentration can be performed to accurately measure the affinity 
constant between the ligand and the target (Figure C.3).7,17-19 The magnitude of the protein’s 
chemical shift change will differ depending on how the small molecule interacts with the protein. 
For example, hydrogen bonding will have a different effect on the chemical shift than covalent 
attachment.20 Knowledge of the protein’s resonance assignments reveals the residues involved in 
binding. In this case, most studies employ the 1H-15N HSQC because backbone resonances are 
more easily obtained.7 Moreover, binding site identification allows differentiation of specific 
from nonspecific binding, which is characterized by small environmental changes in the NMR 
spectrum similar to the effects of a change in temperature.21 NMR is, thus, a unique tool with the 
ability to immediately identify false positives.4 It is important to note that even if the protein 
target resonances have not been assigned, target-observed assays may still be used to identify 
ligands that bind strongly to the target and reveal whether multiple ligands bind using the same 
or different binding sites.22 In addition to detecting tight binding, this method can detect 
interactions that are as least as weak as mM binding KDs because observation of the protein 
target does not rely on tight binding to acquire bound-state information.21,23 A consequence of 
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weaker binding is that the time scale on which the ligand exchanges leads to line broadening. For 
systems exchanging on this intermediate timescale (Figure C.1.B), the line width of the protein 
resonances will sharpen as saturation binding is approached. To confirm that a ligand is binding 
in a single conformation the concentration of the ligand should be titrated until saturation is 
reached. If no change in the line width is observed, structural investigations may be complicated, 
as the ligand likely occupies the binding site in multiple conformations of comparable energy.24  
Upon the addition of ligand, the signals of those amides whose environments are 
perturbed by ligand binding change position.15 Specific binding of a small molecule and protein 
target can take place using two modes.6 A lock and key interaction of the ligand to the protein 
has little or no effect on residues that are not directly involved. Consequently, only those 
involved experience a different environment and resonate at a different frequency. Some have 
reported that as few as eight out of 107 resonances change upon compound binding.25 Induced fit 
binding leads to a conformational change, often resulting in a global change of the protein as a 
whole, where the majority of the resonances are altered.7,26 In this case, a series of experiments 
that compare chemical shift changes 
induced by a series of closely related 
ligands may be used to identify the binding 
site.20 After mapping the changes in 
chemical shifts from the titration of a first 
ligand, a second, structurally-related ligand 
differing by a functional group is added to 
the protein target. Most of the 
perturbations will parallel the changes of 
Figure C.3. Δδ  vs [ligand]. Changes in 
chemical shift are monitored over a series of 
ligand concentrations and plotted to 
determine the dissociation constant. 
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first ligand except for the resonances at the binding site. This occurs because of the proximity of 
the protein’s binding site to the substituted functional group on the ligand and because the 
magnitude of the chemical shift change depends on the ligand moiety involved with binding.7,20  
The chemical shift perturbation assay has been used extensively to identify the ligand 
binding site of many important protein targets and receptors. For example, cyclosporine A bound 
to human cyclophillin,27 interleukin-8 complexed with the N-terminal region of the human 
interleukin-8 receptor,28 the Fab fragment of IgG interacting with streptococcal protein G29 and 
NADP+ bound to the MurB enzyme30 have all been characterized using the chemical shift 
perturbation method. Importantly, these studies helped lead to the advent of the SAR (structure- 
activity relationship) by NMR method developed by S. Fesik at Abbott Laboratories.25 SAR by 
NMR detects changes in the chemical shifts of the protein target upon addition of ligands. 
Weakly interacting compounds that bind at adjacent sites on the protein target are identified and 
combined with structural information about the orientation of the bound ligands to guide a 
linked-fragment approach to generate lead drug compounds with greatly increased binding. 
Figure C.4 outlines the experimental procedure. The first step requires screening a library of 
ligands using the perturbation method with the assumption that a change in chemical shift greater 
than 0.1 ppm for at least two peaks in the spectrum constitutes a significant change and indicates 
binding.31 After hit identification, monitoring chemical shift changes as a function of ligand 
concentration in a titration experiment is performed to accurately deduce the binding constant.32 
Following identification of a binding partner to the first site, screening of related compounds is 
conducted to increase and optimize the binding affinity for that site. The same perturbation 
method is applied to identify a second low-affinity hit in the presence of the optimized first 
ligand. Following identification and optimization of the second binding site, structural data 
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obtained by additional experiments is used to determine the location and orientation of the 
protein target in complex with its two low affinity hits. Maintaining the spatial orientation of the 
compounds with respect to each other and the protein target, the ligands are synthetically linked 
together to produce the high-affinity ligand.25 
Screen for 1st Ligand
Optimize 1st Ligand







The SAR by NMR method has facilitated the development of inhibitors of proteins, for 
example, stromelysin, to combat its role in arthritis and tumor metastasis.32 Additionally, the 
methodology has supported the characterization and development of inhibitors that block DNA 
binding by the human papillomavirus E2 protein, to treat cervical cancer,33 and antagonists of 
Erm Methyltransferases to fight resistant bacteria.34 More currently, the SAR by NMR method 
Figure C.4. SAR by NMR. Binding of the first ligand is determined by detecting changes in 
the 1H-15N HSQC of the protein target upon titration of a mixture of ligands. After a binding 
ligand is identified and optimized, a mixture is screened for a second low affinity binder to an 
adjacent site on the protein target. Once optimized, the ligands are synthetically linked 
together to create one, high-affinity lead drug compound. 
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served as the primary tool for characterizing protein-ligand complexes of the Bcl-2 family, a 
class of proteins involved in the apoptotic pathways.35 Additionally, variations of this method 
have been developed and utilized recently to examine higher molecular weight proteins and 
analyze selective binding among related proteins, including SAR by NMR with 13C-labeled 
methyl groups (see section C.4.3)36 and RAMPED-UP NMR.26 RAMPED-UP NMR (Rapid 
Analysis and Multiplexing of Experimentally Discriminated Uniquely labeled Proteins using 
NMR) is an important advance, because it provides a way of simultaneously evaluating the 
specificity of a ligand for a protein among a mixture or class of proteins. Each protein target is 
labeled with one unique amino acid type and studied simultaneously in a mixture using a ligand 
titration experiment. The ability to multiplex the protein target not only increases the screening 
throughput but also reveals whether the ligand of interest will target a single family member in a 
specific manner or bind to several members from a class of proteins. 
Although the perturbation assay and SAR by NMR are powerful techniques for 
characterizing ligand-protein interactions, the size, solubility and stability of the protein, as well 
as the ability to isotopically label the protein, may limit the ability to screen for binding using the 
protein target resonances.4 The line width of NMR signals increases with increasing molecular 
weight, resulting in spectral overlap and loss of signal and resolution.37 To acquire protein 
spectra with reasonable signal-to-noise ratios in a timely manner, the protein must stay soluble at 
concentrations around 0.1-1 mM without degradation for the duration of the experiments. The 
length of the NMR experiments that detect the protein target depend on the type of experiment, 
which can last anywhere from a few minutes to several days.38 Furthermore, the 1H-15N HSQC 
requires isotopic labeling of the protein target.39 Although, the 13C nucleus occurs at 1% natural 
abundance, studies without 13C enrichment can provide valuable information, but this requires 
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longer data acquisition. Although isotopically labeled protein production can increase cost, 
labeling facilitates the observation of specific nuclei or bonds of one species. With protein target 
detected NMR, for example, because the ligand is left unlabeled, ligand resonances do not 
complicate the protein target spectrum, eliminating the need for spectral subtraction (difference 
spectroscopy) (see section C.3.1.c).40 15N and 13C isotopic labeling permits the assignment of 
backbone amides using a series of three-dimensional NMR experiments.13,16,38 A description of 
how assignments are completed is beyond the scope of this paper, and a detailed discussion of 
the topic can be found elsewhere.38 Completion of sequential assignments is necessary to obtain 
structural information about the protein target’s binding site and can be used to develop structure 
activity relationships. As the size of the protein increases, resonance assignments become more 
difficult to obtain, and as such, different labeling strategies are used to facilitate the evaluation of 
larger protein targets with molecular weights greater than 30,000 kDa (see section C.4.3).  
Target observation also may result in lower throughput as a result of more time-
consuming, multidimensional spectral analysis and the need to deconvolute hits from a small 
molecule compound library.4 Selecting an optimal mixture size from the library to be screened 
will have a great impact on the efficiency of the perturbation assay. A comprehensive review of 
the determinants has been presented by Mercier and Powers.41 The time needed to deconvolute 
hits from a mixture depends largely on the number of compounds in a mixture but also on the 
physicochemical properties of the mixture’s components. For example, the main goals to achieve 
when selecting a compound mixture include minimizing reactivity and interactions of 
compounds, achieving structural diversity, maximizing solubility, and preserving constant 
physical properties (pH and ionic strength). Deconvoluting mixtures of ligands also has been 
addressed by an automated system in which 306 individual compounds were screened for 
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binding to a 15N-labeled target. This robotic sample preparation, in conjunction with the 
automated data acquisition and analysis tool is applicable to many systems. It can be used to 
evaluate a large number of ligand-protein interactions without the need to deconvolute hits from 
the larger library.42,43    
An alternative approach to minimizing the spectral complexity of proteins is to introduce 
a spin probe. 19F is a unique spin ½ nucleus that can be incorporated into a protein at Tyr, Phe, 
His, or Trp residues using selective labeling techniques.44 Aromatic residues are useful probes of 
structural integrity and binding because, respectively, they are often buried in the hydrophobic 
core of the proteins and/or located at the interface of intermolecular interactions.45 Several useful 
properties of the 19F nucleus make it an ideal label for NMR studies, which have been described 
previously.46,47 First, 19F is present at 100% natural abundance and has 83% of the sensitivity of 
1H providing a reasonable alternative to 1H NMR. Next, 19F incorporation generally produces no 
dramatic structural effects when substituted for hydrogen in an amino acid side chain. Although, 
19F is substantial larger than 1H, the two have similar covalent radii (1.3Å for 19F and 1.2Å for 
1H).46 Third, the considerably different dipole moment means that fluorine lone pair electrons 
primarily control the 19F chemical shift, resulting in a 100-fold larger chemical shift range than 
1H. This also makes the nucleus especially responsive to local changes in van der Waals 
environments, electrostatic fields and hydrogen bonding.47 As such, small chemical shift 
perturbations are easily detected in one-dimensional 19F spectra. Finally, 19F does not occur 
naturally in proteins so no background signals complicate the spectrum. A protein labeled with 
19F-labeled amino acid will exhibit NMR peaks due only to the label, not to the backbone of the 
protein permitting the use of simple one-dimensional NMR experiments to detect changes in the 
protein structure upon addition of ligand. Because one-dimensional experiments are faster, 19F 
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NMR studies can be performed with lower protein concentrations, and thus, spectral acquisition 
is shorter than traditional protein detection techniques. Furthermore, 19F-NMR can be used to 
examine structural aspects of much higher molecular weight proteins, which traditional 
multidimensional NMR experiments fail to resolve. For example, selective 19F labeling and 
subsequent 19F NMR analysis of the 497 residue XIAP (X-linked inhibitor of apoptosis protein) 
with and without the Smac peptide revealed the interaction of the peptide to protein in a 2:1 ratio 
and the ability of the Smac peptide to inhibit the interaction of XIAP with its downstream 
partner.48,49 Additionally, in an investigation of inhibitors to the anti-apoptotic protein Bcl-xL 
(181 amino acids), selective 19F-Phe labeling was used to obtain supplementary structural 
constraints for defining the orientation of the inhibitor in the Bcl-xL-inhibitor complex.45  
 
C.3. LIGAND DETECTED METHODS 
Ligand observation experiments offer a useful alternative to protein target detection for 
larger proteins or those that oligomerize in solution at higher concentrations23 or have no suitable 
expression host that permits isotopic labeling.21 The use of simple one-dimensional spectra and 
ability to screen mixtures without deconvolution, results in higher throughput and its use as a 
well-suited primary screening technique.4 Ligand examination has the technical advantage of 
requiring a smaller amount of unlabeled protein9 and may be used to identify the binding epitope 
of the ligand.4 Furthermore, the size of the protein target does not limit this technique, and in 
many examples, larger proteins provide better sensitivity because binding of a large protein 
causes a more distinguishable change to the observable NMR signals.3 This broader approach to 
NMR screening relies on either detection of an altered hydrodynamic property of the ligand upon 
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addition of protein target or exchange-mediated transfer of bound state information to the free 
state.50  
C.3.1. Hydrodynamic Property Experiments 
The NMR spectral properties of proteins and small molecules differ because of 
differences in hydrodynamic properties, which affect the translational and rotational mobility of 
a molecule in solution. Experiments in this category exploit the fact that a bound ligand 
transiently adopts the NMR properties characteristic of a large protein target, which are manifest 
in the spectrum of the ligand.21,40  
C.3.1.a. Relaxation Experiments 
Comparison of the ligand’s relaxation rate in the presence and absence of the protein 
target represents the most well-established class of NMR binding assays. Relaxation reflects the 
hydrodynamic radius and rotational tumbling rate of species in solution.9,21,23 Following delivery 
of a rf-pulse of energy, the system is perturbed and must re-establish its equilibrium by 
dissipating the absorbed energy supplied by the pulse. This loss occurs by transferring energy to 
either its surroundings or to other spins. Relaxation simply implies the movement of bulk nuclear 
magnetization towards equilibrium and occurs through two distinct mechanisms. Thermal 
equilibrium governs the recovery of magnetization in line with the magnetic field, meaning that 
the nuclear spin exchanges energy, in the form of heat, with its surroundings (lattice) to return to 
its ground state.39 The rate at which relaxation proceeds via the spin-lattice mechanism is called 
R1 and effectively occurs at a similar rate for small and large molecules.10 The second 
mechanism by which energy is transferred is more complex but fundamentally depends on the 
size of the molecule, such that relaxation proceeds more rapidly with increasing size.51 After an 
rf-pulse, the bulk magnetization becomes perpendicular to the magnetic field (transverse plane). 
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Although the pulse initially aligns the nuclei in the same plane, spin diffusion ensues and the 
transfer of energy from one spin to another spin (dipolar coupling) proceeds until the net 
magnetization dissipates to zero (Figure C.5).10 The rate at which relaxation occurs via the spin-
spin mechanism is called R2 (transverse relaxation) and occurs much faster for large, slowly 
tumbling molecules.51 The rate of transfer strongly depends on the chemical environments of the 
different nuclei and how efficiently the nuclei exchange energy; the larger the molecule, the 
more efficient the exchange and the faster the rate of relaxation.37 
  
Figure C.6. Nuclear Relaxation. A. Longitudinal Relaxation (Spin-Lattice Relaxation). 
After an rf-pulse of energy is applied to the nuclei in solution, the atoms must relax back to 
their equilibrium position in line with the z-axis by releasing energy in the form of heat to its 
surroundings. B. Transverse Relaxation (Spin-Spin Relaxation). After an rf-pulse of energy 
is applied to the nuclei, the signals corresponding to the different nuclei fan out away from 
the y-axis at different rates due to chemical shift dispersion and diffusion and the transfer of 
energy from one spin to another spin, which proceeds until the net magnetization becomes 
zero. For small molecules the rate of transverse relaxation often equals the rate of longitudinal 
relaxation because there lacks sufficient interaction between the atoms to permit the transfer 
of excitation energy. For larger molecules, especially proteins, the rate of transverse 
relaxation is generally faster than longitudinal relaxation because the transfer of energy 







Additionally, the rate of transverse relaxation determines the line width of the observed 
resonances. Line width is directly proportional to the rate of spin-spin relaxation (line 
width=R2/π), which is a consequence of detecting the NMR signal in the transverse plane, 
perpendicular to the magnetic field. Transverse relaxation governs the rate at which the signal or 
Free Induction Decay (FID) falls off, such that a large R2 results in a FID that decays rapidly. 
Therefore, upon Fourier transformation to the frequency domain, faster relaxing species produce 
broader, less resolved peaks in the spectral window.10  
When a small molecule binds to a large molecule, the small molecule transiently 
possesses similar NMR properties as the large molecule and assumes fast transverse relaxation 
rates leading to spectral line broadening of the small molecule signal.9 The extent of ligand 
binding and size of the protein target directly correlates with line width changes.52 As such, 
larger proteins usually produce stronger effects, increasing the sensitivity of the experiment.3 For 
ligands with weaker dissociation constants (1-10 mM) to smaller protein targets, it is difficult to 
obtain reproducible and reliable line-broadening data, while binding to a larger protein (greater 
than 60 kDa) with the same affinity for the ligand is easily detected.53 The most basic method to 
evaluate binding in this manner involves the acquisition of a ligand spectrum (or mixture of 
compounds) in the absence and presence of a protein target, from which the differences in line 
shape and relaxation rates are determined. Enhanced transverse relaxation of ligand upon the 
addition of the protein target indicates the transient formation of a bound complex.21,23,54 For 
example, relaxation experiments were used to obtain information regarding the interaction of the 
FK506/FKBP complex (FK506-binding protein) with its downstream target calcineurin to 
improve the structure-based design of immunosuppressive agents. By detecting relaxation 
differences in different regions of the FK506/FKBP complex upon binding to calcineurin, the 
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region of the complex that interacts with the protein target was identified, which was important 
because the immunophilin/drug complex (FKBP/FK506 respectively), not the drug or protein 
alone, inhibits an immune response.55  
Differential line broadening assays form the basis of the SHAPES screening method. A 
small but diverse library known as the SHAPES library is screened against any protein target of 
interest. The library consists of molecular shapes found commonly among commercially 
available therapeutics.53 This method is similar in concept to the SAR by NMR technique. Once 
two shapes have been identified as weak binders by differential line broadening assays, a non-
binding shape is used to link the two binding components to yield a higher affinity lead 
compound. To demonstrate the value of the SHAPES screening method, molecules from the 
SHAPES library were screened against p38 MAP kinase, an important protein target involved in 
cellular responses to external stress signals. The p38 MAP kinase served as a model protein 
target with which the utility of the SHAPES method could be established, because several 
inhibitors of p38 had been developed previously. SHAPES screening was utilized to discover a 
unique tri-substituted imidazole lead compound. The hit came from the same family of drugs as 
other p38 inhibitors that have important anti-inflammatory effects. The effectiveness of SHAPES 
screening against p38 MAP kinase indicates its potential to be applied to other novel protein 
targets to develop inhibitors to their function.53  
Although most ligand screening methods rely on 1H-NMR, the favorable NMR properties 
of the fluorine nucleus make 19F-NMR an extremely useful method for detecting the binding of 
fluorinated compounds to a target.3,56 The properties of fluorine that make it useful for protein 
target detected screening apply to ligand-detected methods as well. Most notably, the 
extraordinary sensitivity of 19F to its environment and local shielding effects means that its 
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resonances are dispersed over a large chemical shift range and it is extremely sensitive to 
relaxation changes caused by binding, which can provide more resolution than 1H-NMR 
relaxation experiments. Furthermore, because 19F does not occur naturally in proteins, no 
background signals complicate the one-dimensional spectrum, which eliminates the need for 
difference spectroscopy (see below).4 Most NMR solvent and buffer components lack fluorine 
moieties, which means buffers and solvents also do not interfere with data acquisition.57 
Additionally, the broad chemical shift dispersion allows the use of large compound libraries 
minimizing overlap of individual ligand resonances.21 Although protons are found more 
ubiquitously,4 approximately 12% of compounds (equating to 200,000 compounds) in the 
Available Chemical Directory of Screening Compounds58 and 17% of the MDDR database45 
contain fluorine moieties, making it quite possible to obtain a 19F-containing lead compound 
without resorting to special synthetic efforts.57 For example, 19F-NMR has been used to 
characterize the multifunctional calcium-dependent Calmodulin protein bound to the fluorinated 
antipsychotic inhibitor, trifluoperazine (TFP) to determine that TFP binding can occur without 
calcium present.59,60 Additionally, fluorine incorporation often improves the pharmacokinetic 
properties and potency of the drug.21,45 Binding interactions between the plasma protein human 
serum albumin (HSA) and drugs can have detrimental effects on the drug’s pharmacokinetic 
properties. 19F-NMR has been used to report on specific interactions between HSA and 
fluorinated dugs prior to lengthy pharmacokinetic studies.61 This has recently been applied to the 
interactions between niflumic acid (a potent analgesic anti-inflammatory drug prescribed for 
rheumatoid arthritis) and HAS, providing insight into its pharmacokinetic and toxicological 
properties.62 19F NMR also has been applied to detect metabolism of cytochrome P450 
substrates.63 Cytochrome P450 enzymes are largely responsible for drug metabolism, and 
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analysis of fluorinated drug interactions with cytochrome P450 enzymes by NMR can be used to 
avoid adverse pharmacodynamic effects resulting from the accumulation of metabolites. 
Additionally, 19F-NMR facilitated the determination of the metal to substrate distances and 
geometries within the active site of P450s, providing valuable structural information for drug 
optimization.64 Quantitative information about substrate turnover by enzymes, including P450s, 
can be obtained using the recently developed 3-FABS (three Fluorine Atoms for Biochemical 
Screening) technique. The substrate is labeled with a CF3 moiety and detecting by using 19F 
NMR. The substrate and product concentrations are monitored as a function of time to determine 
inhibition constants.65-67 For a more extensive analysis of ligand-detected 19F-NMR methods, a 
comprehensive review recently published is recommended.68 
Another useful but less common spin probe used for analyzing protein-ligand interactions 
is 31P.  31P can be used to evaluate enzyme activity and inhibition. Screening for inhibitors can be 
conducted using this unique nucleus when the enzyme binds a phosphorylated cofactor, which 
would be perturbed by interactions with ligand molecules. A family of small molecule inhibitors 
of Ras was examined for their ability to stabilize the inactive Ras conformation by monitoring 
the 31P signals from the bound GTP.69  
C.3.1.b. Diffusion Experiments 
Comparison of the ligand’s diffusion coefficient, which reflects the translational mobility 
of the molecule, in the presence and absence of the protein target, may be used to accurately 
examine intermolecular interactions between protein targets and ligands. Lin, Shapiro, and 
Wareing illustrated the use of diffusion-edited NMR (affinity NMR) spectroscopy for screening 
compound libraries in 1997.70-72 The spectral differences upon the addition of protein target 
result from the inverse dependence of diffusion coefficients on the hydrodynamic radius of small 
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and large molecules. Diffusion experiments follow the same basic principles as relaxation 
experiments but rely on differences in translational instead of rotational motion. The small 
molecule transiently adopts the properties of the large molecule and, as such, exhibits a decrease 
in translational diffusion, which can be readily assessed by pulsed-field gradient NMR.73 
Because the signal intensity of the ligand resonances depends strongly on the strength of the 
gradient pulse, diffusion-edited NMR experiments distinguish between molecules that interact 
with the protein target and those that do not by increasing the strength of the gradient pulse, 
which selects for resonances from bound species (Diffusion Encoded Spectroscopy-
DECODES).22,74 The Diffusion Ordered Spectroscopy (DOSY) experiment extrapolates the one-
dimensional chemical shift information into a pseudo-second dimension of diffusion coefficients 
and eliminates the need for deconvolution of the signals from a mixture of ligands.75,76 A change 
in the second dimension indicates binding in a straightforward manner, as the data acquisition 
does not differ from simple one-dimensional experiments because the second dimension encodes 
a property of the molecule, not a nucleus.52 As with relaxation experiments, diffusion 
experiments can be used to examine compound mixtures or libraries for protein target 
interactions in a powerful, high-throughput manner. This method has been applied to the 
identification of peptide compounds that bind to vancomycin to study antibiotic resistance. 
Vancomycin is a potent antibiotic for streptococcal and staphylococcal bacterial infections 
because it specifically binds to the carboxy-terminal D-Ala-D-Ala sequence of the bacterial 
peptidoglycan, inhibiting cell wall synthesis. Antibiotic resistance results because of a 
substitution to one of the amino acids in the target bacterial cell wall, which inhibits binding of 
vancomycin. The ability to study binding interactions between vancomycin (or its derivatives) 
and peptides that mimic the bacterial cell wall will facilitate the development of additional agents 
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that may overcome bacterial resistance. In this example, the limits of diffusion-edited NMR were 
challenged because the vancomycin receptor was only three times the size of the peptides tested. 
The results obtained, however, produced a spectrum with adequate resolution to identify 
interacting ligands.77 
C.3.1.c. Difference Spectroscopy 
Relaxation and diffusion experiments have great utility, but both experiments require the 
use of spectral subtraction (difference spectroscopy), which can have disadvantages. When 
examining smaller proteins, the signal intensity from the protein approaches that of the ligand, 
and the protein resonances may overlap in the region of the ligand signals, such that they obscure 
the signal from the ligand. Consequently, a large excess of ligand is required to ensure ligand 
observation. Most studies of this nature require a minimum of ten-fold ligand molar excess.21 
The experimental setup requires a one-dimensional spectrum of the protein alone and subsequent 
subtraction of the protein resonances from a spectrum of ligand in the presence of protein target. 
Subtraction of the resonances may lead to artifacts in the resulting spectrum when the protein’s 
chemical shifts change upon binding. Relaxation and diffusion filtering eliminates the signals of 
the protein target and bound ligands and simplifies the subtraction process, minimizing the 
number of artifacts observed.74 Relaxation filtered experiments employ the use of spin-locks, 
while diffusion filtered experiments utilize pulsed field gradients to attenuate the protein target 
and bound ligand signals. These edited experiments work because the rotational or translational 
motion properties of the bound ligand transfer to the detected free ligand. To detect binding, a 
spectrum of the ligand in the presence of the protein target is subtracted from a spectrum of the 
ligand in the absence of the protein target. If the ligand interacts with the protein, the resulting 
difference spectrum should resemble that of the ligand alone with decreased signal intensities. 
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For ligands that do not bind to the protein target, the resonances will be completely eliminated 
upon subtraction.  
Both relaxation and diffusion experiments require a fast-exchange regimen between the 
ligand and the protein target. If a ligand briefly exchanges into another environment by binding 
to a protein and obtains a very different chemical shift during NMR detection, the signals from 
the ligand will dramatically decrease and broaden. The accumulation of these exchange events 
with time leads to destructive interference in the FID and loss of signal. Slowly exchanging 
nuclei cause these errors to accumulate and result in broad NMR signals indistinguishable from 
the noise. Fast-exchanging nuclei will average out these errors and produce one resonance 
line.10,39 This limits the technique to weakly binding ligands in rapid exchange, and 
consequently, these experiments cannot differentiate the nature of the binding reaction (specific 
from non-specific binding),78 leading to more frequent detection of false positives.3,21 On the 
other hand, because relaxation and diffusion experiments rely on detection of the ligand 
resonances, the size, composition and oligomeric status of the protein target are essentially 
unlimited, which is advantageous over protein target detected methods.23 Furthermore, the extent 
of ligand binding and size of the protein target bound directly correlates to line width changes.52 
As such, larger proteins usually produce stronger effects, increasing the sensitivity of relaxation 
experiments.3,53 Additionally, there is no need for multidimensional or correlation experiments, 
simplifying the experimental setup. 
C.3.2. Exchange Transferred NOEs 
To determine the specific conformation of weak to medium affinity ligands when bound 
to a large protein target, the one- and two-dimensional exchange transferred NOE experiments 
(etNOE) have been used extensively.52,79 Like relaxation and diffusion-based experiments, the 
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use of the transferred nuclear Overhauser effects (NOEs) also depends on the ability of the 
ligand to acquire the relaxation properties of the protein target.50 Upon binding of a ligand to a 
protein target, the NOEs observed for the free ligand change because the molecule retains a 
“memory” of its bound state properties. The ligand acquires distinct magnetic properties while 
bound to the protein, which are retained even when the complex dissociates.80 
Direct magnetic interactions between nuclear dipoles located close to each other in space 
result in dipolar coupling, leading to time-dependent mutual cross-relaxation. These time-
dependent dipolar couplings provide an important source of nuclear relaxation in solution. They 
also provide incoherent magnetization transfer pathways that result in direct through-space 
interactions between nuclei called nuclear Overhauser effects (NOEs). Experimental observation 
of the NOE requires a change in signal intensity from one spin after the perturbation of a nearby 
spin with radio-frequency excitation. The rate constants governing cross-relaxation depend on 
the distance between two nuclei and the rotational mobility of the vector connecting the two 
atoms.22,54 NOEs are sensitive probes of short-range, through-space, intramolecular and 
intermolecular interactions,9 because the intensity of the NOE falls off rapidly with increasing 
distance (1/r6).37 As such, the NOE provides relative spatial information for structure 
determination, and allows the use of solution NMR to examine the interactions between nuclei 
that are not necessarily covalently bound but are within five angstroms of each other.22 
Differences in Brownian motions of the molecular structure also intimately reflect alterations in 
NOE patterns. For rapidly tumbling small molecules, two-dimensional 1H-1H nuclear Overhauser 
spectroscopy (NOESY) experiments result in negative NOE cross peaks with weak intensity. For 
slowly tumbling large molecules, stronger positive cross peaks result.6,9,22 The differences in sign 
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and intensity of the NOE serve as the basis for extracting information about binding from etNOE 
experiments.  
When a ligand binds to the protein target, the ligand protons experience additional dipole-
dipole interactions from the protein’s protons. In addition, the ligand transiently adopts the 
tumbling properties of the large protein target. Detection of binding relies on intraligand NOEs 
that develop in the bound state, where the dipole-dipole interaction caused by the decreased 
molecular tumbling rate occurs much more efficiently than in the free state. As such, positive 
NOE cross peaks for small molecules in the presence of the protein target clearly indicate 
binding. Unbound ligand molecules produce weak, negative NOE cross peaks typical of small 
molecules. These so-called exchange transferred NOEs have great utility in the examination of 
the interactions between ligands and protein targets.3,9,22,54,79 etNOEs were used to examine the 
interactions between the antibody SM3 and the aberrantly glycosylated MUC-1 protein (which is 
associated with breast cancer) because specificity of the SM3 antibody to cancerous MUC-1 
glycoproteins may result from decreased carbohydrate chain length or a conformational change. 
etNOES were used to determine the conformation of differentially glycosylated MUC-1 peptides 
bound to the SM3 antibody and found that the less glycosylated form is bound preferentially 
because the peptide acquires a more knob-like structure. The ability to determine the 
conformation of the MUC-1 peptides bound to SM3 has facilitated the development of SM3 for 
diagnostic and therapeutic purposes.81  
Once a ligand has been confirmed to bind to a protein by methods such as etNOEs, two 
recently developed techniques may be used to facilitate identification of the bound ligand’s 
orientation without the need for complete structure determination of the protein-ligand complex 
under investigation. The INPHARMA (Protein Mediated Interligand NOEs for Pharmacophore 
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Mapping) method was developed to investigate the binding orientation of a competing ligand 
when a structure of a similar protein-ligand complex is known.82 Interligand NOEs are used to 
gain information about the binding mode of one ligand with respect to the other. Interligand 
NOEs arise between the known binder and new compound, which are used to determine the 
orientation of the new complex without the need for complete structure identification. The SAR 
by ILOEs (interligand nuclear Overhauser effect) approach uses etNOEs to identify small 
molecule ligands bound to the protein target simultaneously in close proximity to each other. 
Interligand NOEs then are used to provide information about the orientation of ligands, which 
subsequently may be linked to yield a high-affinity lead compound in the correct conformation.83 
The SAR by ILOEs approach is advantageous over the SAR by NMR method previously 
described because it provides information about the relative orientation of the two compounds in 
the binding pocket without needing to solve the structure of the ternary complex.80  
Limitations to the etNOE method’s utility include the sensitivity of the 1H-1H NOESY 
experiment itself. The low-sensitivity of the two-dimensional homonuclear NOE experiment 
requires that relatively long acquisition times are used to provide spectra of sufficient quality and 
precludes the high-throughput analysis of large libraries of compounds.3,7 Furthermore, the 
spectrum contains strong diagonal peaks that prohibit the observation of cross peaks between 
ligand resonances having similar chemical shifts. The strong diagonal peaks may also introduce 
noise or baseline problems that interfere with the observation of weak cross peaks.52 An 
additional constraint is that the transferred-NOE experiment most efficiently characterizes 
ligands with a KD value in the µM to mM range. To observe changes in NOEs, the dissociation 
of the ligand must occur quickly enough such that a sufficient percentage of the free ligand will 
remember the bound state and generate intense, positive NOE cross peaks. If the on rate is too 
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slow (much slower than diffusion allows), the transfer NOE will be too weak for detection.6,23 
The dissociation constants of slowly exchanging systems can be determined using the etNOE 
experiment but requires a complex mathematical treatment, which has been reviewed previously 
and is beyond the scope of this paper.80,84 This limits the transfer NOE technique to weakly 
binding ligands in fast-exchange and, as such, requires large ligand concentrations in excess of 
the protein target (10:1-20:1 ligand:target ratio). This large ratio introduces the possibility of 
secondary binding, which may hamper unambiguous interpretation of the results. Also, 
compounds of limited solubility can aggregate in solution and exhibit large positive NOE cross 
peaks in the absence of the protein target, producing false positives.9,52,85 False positives are 
easily identified by examining control samples containing only the small molecules. 
Nonetheless, the transferred NOE method has great advantages because of its ability to generate 
information on both the binding affinity and the geometry of the ligand in the bound state from 
the same experiment. etNOE experiments are often employed as one of the final steps in the 
SAR by NMR method, when sequential assignments of the labeled protein target are known, to 
determine the orientation of two adjacently bound ligands to a protein target.25 Although it is 
possible to attain even higher resolution information when coupled with sequential assignments, 
the transferred NOE method always retains the important advantage of being able to provide 
structural information about ligands interacting with unlabeled protein targets of unlimited 
molecular weight.  
C.3.3. Exchange-Mediated Saturation Transfer Experiments 
 The second category of ligand-detected methods relies on exchange-mediated transfer of 
another type of bound-state information to the free state.50 The basis of this type of NMR 
experiment is similar to transferred NOE experiments in that magnetization transfer can occur 
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between ligand and target through NOEs.23,86 The difference from etNOE experiments is the fact 
that detection of binding does not rely on the bound ligand exhibiting transient relaxation 
properties of the protein target. Instead, the protein target is saturated with rf-energy, which is 
transferred to an exchanging ligand to affect the one-dimensional proton signal intensities of the 
ligand. The Saturation Transfer Difference (STD) experiment utilizes this form of magnetization 
transfer in conjunction with difference spectroscopy and manifests the binding interaction as an 
apparent decrease in signal intensity of the ligand. The STD experiment is advantageous because 
it provides more sensitivity than previously described ligand-detected methods and may be used 
to quantify binding affinities between ligand and target and identify the binding epitope of the 
ligand.87 
STD experiments require the application of a train of selective radio-frequency pulses 
until the protons in the protein target can no longer absorb any more energy (saturation). Ligands 
that come in close contact with the target receive part of this saturation via intermolecular 1H-1H 
cross relaxation pathways, which results in a decrease in the ligand’s line intensity. An apparent 
decrease in the one-dimensional signal intensity of the ligand-resonances upon subtraction of a 
reference spectrum (lacking target saturation, and as such, magnetization transfer) accurately 
indicates binding of the ligand to the protein target.21 STD studies often employ extremely low, 
undetectable concentrations of the target, and ideally the resulting difference spectrum contains 
only ligand signals corresponding to protons making NOE contacts with the protein; however, 
for studies requiring high concentration of the protein target, relaxation filters may be applied to 
suppress the signals from the protein.3,54 Differences in the observed signal intensities of the 
resonances from atoms in the ligand indicate which moieties are embedded in the protein-ligand 
interface. Because the magnetization transfer depends on the distance between the ligand and 
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protein target, proximal interaction leads to more efficient transfer of saturation, which in turn 
leads to a greater loss of signal, allowing identification of the ligand’s binding epitope with the 
difference spectrum.3 This method was used to characterize the binding epitope of the cyclic 
RGD peptides that inhibit fibrinogen binding to integrins to prevent platelet aggregation and to 
permit optimization of these peptides as potential drug candidates. Conformational changes of 
the RGD peptide significantly impact selectivity for specific integrins involved in clot formation, 
and the appropriate conformation was identified to selectively target these peptides to the correct 
integrin type.88 When used with isotopic labeling strategies (See Advances in NMR; Isotopic 
Labeling), STD NMR can identify the ligand binding epitope and the amino acid composition of 
the ligand-binding site simultaneously. This setup forms the basis of the SOS-NMR experiment 
(Structural information using Overhauser effects and Selective labeling). SOS utilizes STD NMR 
to examine a ligand complexed to a series of selectively protonated protein target samples to 
characterize the amino acid composition of the ligand-binding site, while concomitantly 
identifying the ligand binding epitope.89 
 The STD experiment offers more sensitivity than relaxation, diffusion, and transfer NOE 
experiments.52 The increased sensitivity depends on the ability to selectively pulse the protons of 
the protein target and the ability of the pulse to saturate all of its spins. Typically, the radio-
frequency pulse used to saturate the protein resonances occurs at ppm values that lack ligand 
signals in the outermost region of the spectrum (typically below -2 or above 10 ppm). Because 
the pulse only perturbs selective protons of the protein target, the saturation must transfer to the 
rest of the protein signals via dipolar interactions and, as such, depends on the protein’s ability to 
transfer energy. STD NMR is ideally suited for protein targets of 30,000 molecular weight or 
greater, because the saturation disperses more quickly to the other protons of the protein target 
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that were not directly perturbed by the selective radio-frequency pulse. The larger the protein, the 
more efficient transfer of magnetization is to other nuclei, including the bound ligand, making 
this technique an extremely useful alternative to protein target detected methods for species of 
large molecular weight.21,23,87 Additionally, the better sensitivity of the STD experiment means 
that these experiments require even smaller concentrations of the protein target; however, 
optimal setup, use, and interpretation of the STD experiments require some familiarity with the 
exchange processes at work, and as such, some prior knowledge the protein target’s structure or 
function.  
Ligands with KD values in the range of 10-8-10-3 are ideally suited for STD methods. For 
extremely weak binders, too many protein target molecules will lack a ligand in the binding site 
to achieve detectable signal by STD. For tight binders, the exchange occurs so infrequently that 
the pool of free-ligand is barely influenced by its visit to the saturated protein target and relaxes 
back to equilibrium before it is released from the protein. The population of saturated ligands 
will not influence the total ligand magnetization to produce a measurable STD signal.21 Despite 
these limitations, a broad range of binding constants can be evaluated. By expressing the signal 
intensity of the STD spectrum as a fraction of the intensity of an unsaturated reference spectrum 
[(I0-Isat)/I0], the binding affinity can be calculated. In the preceding equation, the intensity of the 
reference peak is I0 and the intensity of the peak after saturation is Isat. A value of 0.5 
corresponds to 50% saturation of the ligands (equating to 50% of the ligands in exchange with 
the protein target).86 This value is then multiplied by the ligand:protein ratio to generate the STD 
factor. For a series of ligand concentrations, plotting the STD factor versus ligand concentration 
generates a curve from which the KD value is determined. The ability to accurately quantify 
binding constants is a unique advantage of this NMR method. 
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An important adaptation of the STD method is the waterLOGSY (water-ligand observed 
via gradient spectroscopy) experiment.90,91 The aim of both methods is to transfer magnetization 
to the bound ligand and detect differences in the spectrum of the free ligand. Where the STD 
method achieves this by directly saturating the protein, the waterLOGSY method accomplishes 
transfer indirectly through excitation of the bulk water magnetization. The excited water interacts 
with the protein-ligand complex transferring the magnetization, which is subsequently retained 
by the ligand after it dissociates. Bound ligand directly interacts with bound water molecules 
within the binding site via cross-relaxation mechanisms. Alternatively, labile protons (NH and 
OH groups) in the protein target exchange with bulk water and acquire the saturated 
magnetization previously applied. Then the magnetization is propagated to the free ligand when 
the water molecules interact directly with the bound ligand at the protein-ligand interface via the 
same types of intermolecular cross-relaxation mechanisms.21 In both of these cases, the 
magnetization transfer pathway conserves the sign of the magnetization from the bulk water and, 
as such, non-binding compounds appear with opposite sign compared to the water signal. 
Nonbinders and binders are easily discriminated from each other in a mixture because they give 
waterLOGSY signals of opposite sign.21,91 False positives may be observed if magnetization is 
transferred directly to the free ligand via chemical exchange of bulk water with exchangeable 
ligand protons. The exchangeable proton resonances, when visible, may complicate the 
interpretation of waterLOGSY data. To overcome this problem, a waterLOGSY spectrum for the 
free ligands without protein target can be collected as a control.21 Like all ligand-based screening 
methods, the waterLOGSY experiment is limited to the detection of weakly binding ligands in 
the low µM range. Ligands with a tighter affinity will stay bound to the protein too long and 
relax back to their original state before dissociating. An important advantage of the 
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waterLOGSY method is that it is much more sensitive than other ligand-detected methods. This 
may be attributed to the large excess of solvent available and the large number of exchangeable 
protons in a protein-ligand complex. The exceptional sensitivity of this method permits the use 
of nanomolar concentrations of unlabeled protein target, making it a powerful method for 
primary screening of compounds that bind to therapeutically relevant protein targets.91 
 
C.4. ADVANCES IN NMR 
 Many recent advances in solution NMR have served as tools to overcome the limitations 
encountered with each screening methodology discussed. Advances in instrumentation and 
innovative experimental protocols (pulse sequences) have been utilized to overcome the 
problems of fast relaxing signals and lack of resolution with higher molecular weight proteins. 
Isotopic labeling strategies have facilitated the study of higher molecular weight protein targets 
(up to 900,000 kDa) by decreasing the number of observable signals and reducing spectral 
crowding. In addition, computational methods have improved the amount of information gleaned 
from limited NMR data sets. The development of competition experiments has expanded the 
range of binding affinities that can be evaluated by ligand-detected screening methods. These 
advances have contributed to a more extensive use of NMR as a high-throughput screening tool. 
C.4.1. Instrumentation Advances 
Instrumentation development has rapidly improved the quality of data available from 
NMR experiments, especially the development of higher frequency spectrometers. Increasing the 
magnetic field strength simplifies complex or overlapped spectra by generating more dispersion 
along the observed chemical shift axis, because the chemical shift dispersion increases linearly 
with field strength, while the line widths of aliphatic protons and carbons remain unchanged.12 
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Higher field strength not only resolves overlapping signals but also increases the NMR 
sensitivity because stronger magnets achieve better signal-to-noise, increasing roughly as the 3/2 
power of the magnetic field.39 For example, moving from a 400 MHz spectrometer to an 800 
MHz spectrometer increases the sensitivity by a factor of approximately three and resolution by a 
factor of two. Because of this, field strengths of 14.1 Tesla (600 MHz) and above are routinely 
utilized for drug screening and development. Additionally, magnets with proton resonance 
frequencies up to 1 GHz are becoming available and are employed currently for the study of 
higher molecular weight protein targets.92 Because of the increase in signal-to-noise, better 
spectra can be recorded in less time using less material. This has greatly improved the quality, 
speed, and resolution of data acquired for protein target structure determination and ligand 
interactions.16 
Increasing the sensitivity of the NMR signals observed may be accomplished by either an 
increase in the signals or decrease in noise. Increasing the sample concentration or improving the 
field strength can enhance the signal-to-noise by directly increasing the intensity of the 
resonances. Cryogenically cooled probes (probes which have had their electronics cooled to 20-
25 K) greatly diminish the level of thermal noise, increasing the signal to noise ratio by a factor 
of three or more and, consequently, improving the sensitivity of the NMR experiment.92 This is 
important because a three-fold enhancement in sensitivity corresponds to approximately a ten-
fold shorter experiment time or a three-fold decrease in the protein concentration needed to 
achieve the same signal-to-noise with a room temperature probe.3 A cryogenic probe can 
effectively convert a lower field instrument (500 MHz) to the equivalence of a higher field 
instrument (800 MHz) at a greatly reduced cost compared to obtaining a higher field 
spectrometer. It should be noted that the signal-to-noise in a cryogenic probe depends strongly 
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on the conductivity and dielectric losses of the solution, such that an increase in ionic strength 
corresponds to an increase in noise. At approximately 100 mM salt concentration in a standard 5 
mm tube, the signal-to-noise advantage over a conventional room temperature probe begins to 
diminish.93-96 This can be overcome by using a narrow diameter tube, which positions the ions in 
a region with the lowest electric field; however, the sample concentration must be increased to 
account for the decrease in volume being analyzed. Using a cryogenic probe with low ionic 
strength solutions, 2D 1H-15N HSQC spectra can be obtained in a few hours on protein samples 
as low as 50 µM. This advance has facilitated high-throughput analysis of binding interactions, 
because minimizing the protein concentration permits a greater number of compounds to be 
screened simultaneously: 100 compounds at 50 µM each may be used while keeping the total 
concentration of added components to 5 mM. This increases the throughput of the NMR 
screening assay by ten fold, because earlier studies used concentrations of one millimolar protein 
target and were limited to ten compounds in each mixture, allowing a maximum throughput of 
1000 compounds per day. Using this strategy, more than 10,000 compounds can be screened in 
one day, greatly facilitating the drug discovery process.16,92,97 This can be an advantage when 
examining systems with very low hit rates.41  
C.4.2. Pulse Sequence Improvements 
The greatest limitation of early protein target observed NMR screening was the inability 
to observe higher molecular weight protein targets because the relaxation mechanisms of the 
larger proteins cause lines to broaden and signals to disappear; however, the introduction of 
Tansverse Relaxation Optimized SpectroscopY (TROSY) has supported the investigation of 
many protein targets up to a molecular weight of 100 kDa.98,99 Protein target NMR screening 
studies require well-resolved, high-quality spectra to determine the involvement of specific 
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residues in the binding reaction. The slower tumbling of larger proteins results in very efficient 
spin-spin relaxation between protons and primarily affects transverse relaxation processes. This 
effect is reflected in the line widths of the observed resonances, making these basic spectral 
requirements harder to fulfill.92 The TROSY technique reduces signal loss due to increased 
relaxation rates and consequent line broadening by exploiting the differential relaxation effects 
arising from chemical shift anisotropy (CSA) and dipole-dipole couplings, which are quite 
significant at higher magnetic fields (greater than 500 MHz). The measurement of these two 
phenomena using an uncoupled 1H-15N HSQC spectrum results in four differently shaped peaks, 
only one of which is sharp and narrow. The TROSY protocol detects only the sharp, narrow peak 
resulting in a better-resolved NMR spectrum for higher molecular weight protein targets.16,22,98 
Dipole-dipole couplings arise in proteins independent of the field strength, while CSA increases 
at higher fields. Consequently, an optimal field strength exists at which the rate in transverse 
relaxation in TROSY experiments approaches zero (1 GHz).9 As such, the increase in sensitivity 
due to the TROSY pulse sequence is more pronounced at higher field,3,16 further illustrating the 
importance of higher field instruments. With TROSY, the molecular size of proteins accessible 
for detailed NMR investigations has been extended several fold. The approach may be applied to 
a variety of NMR experiments, including two- and three-dimensional experiments used for 
sequential assignments to identify important residues of the protein target involved in binding.13 
To fully benefit from the line narrowing effects of TROSY, other relaxation mechanisms should 
be suppressed. These mechanisms include proton-proton dipolar relaxation between NH and CH 
protons and intermediate exchange broadening due to segmental motion. Deuteration of the 




 Cross Relaxation-Enhance Polarization Transfer (CRINEPT) and Cross Relaxation-
Induced Polarization Transfer (CRIPT) experiments can yield up to a three-fold signal-to-noise 
enhancement for amide groups and have been applied to a 110 kDa protein100 and 900 kDa 
protein complex.101 In a correlation experiment such as the 1H-15N HSQC, the pulse sequence 
includes a step in which transfer of the magnetization of a sensitive nucleus (1H) to an insensitive 
nucleus (15N) via spin-spin couplings takes place (Insensitive Nuclei Enhanced by Polarization 
Transfer; INEPT). This key step has been incorporated into many of the multidimensional NMR 
experiments used for sequential assignments and structure determination. The efficiency of the 
INEPT sequences depends on the strength of the magnetization of the sensitive nuclei, and as 
such, also depends on the transverse relaxation rate (an increase in R2 causes rapid deterioration 
of the magnetization). For protein targets with molecular weights beyond 100 kDa, transverse 
relaxation during the transfer time may become a limiting factor because the magnetization of a 
fast relaxing 1H signal is relatively short lived and cannot transfer its magnetization to the 
bonded 15N. CRINEPT and CRIPT experiments utilize cross-relaxation pathways (NOEs) to 
transfer the magnetization to the 15N nucleus. An increase in molecular weight increases the 
efficiency of cross-relaxation pathways, increasing the sensitivity of the experiment for larger 
protein targets. The CRINEPT and CRIPT experiments permit high-resolution analysis of 
membrane bound protein targets and protein targets that oligomerize in solution.7,100 
While TROSY based experiments address the relaxation and resolution difficulties of 
higher molecular weight proteins, the problem of resonance overlap due to a large number of 
amino acids and corresponding backbone amides remains a major obstacle for resonance 
assignment and chemical shift perturbation studies. The Solvent Exposed Amide-TROSY (SEA-
TROSY) experiment provides a modification of the 1H-15N correlation experiments to reduce the 
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problem of resonance overlap in very large proteins. This type of pulse sequence assumes that 
only the amides exposed to the solvent contribute to the intermolecular interactions involved in 
binding, so that those buried in the core of the protein may be eliminated and ignored. After a 
partially or completely deuterated protein sample (see next section) is dissolved in water, the 
labile deuterons near the surface of the protein will exchange rapidly with protons from the 
aqueous bulk solution. The pulse sequence manipulates the rf-energy in such a way as to 
eliminate any magnetization generated from amide protons, without modifying the water signal. 
The water magnetization exchanges with exposed amide protons, which can be detected with a 
TROSY-type correlation experiment. This eliminates any signals that may result from amides in 
the core of the protein. The resulting spectrum contains fewer resonances with peaks for only the 
amides near the surface of the protein, which then may be monitored upon the addition of small 
molecule ligands to examine interactions between ligands and surface residues.102 
C.4.3. Isotopic Labeling Strategies 
Many newly emerging isotope-labeling techniques address the limitations of examining 
large protein targets by solution NMR. Specifically, the overlap of NMR signals from large 
protein targets precludes full interpretation of the spectral data, and selective isotopic labeling 
strategies can permit observation of only specific moieties, reducing the number of signals and 
decreasing spectral crowding.103 For example, the use of deuteration at non-exchangeable sites 
(aliphatic sites) in combination with uniformly 13C- and 15N-labeling dramatically improves the 
quality of NMR spectra of larger proteins. Expressing the protein in partially or completely 
deuterated growth media followed by purification in protonated buffers causes most of the 
deuterated amides at the surface of the protein to be replaced by protons, permitting the 1H-15N 
HSQC to be utilized for screening.22 Replacing protons in the core of a large protein with 
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deuterons not only improves spectral overlap by decreasing the number of observable signals but 
also results in a narrowing of the remaining proton signals,22 increasing the overall quality of the 
spectra obtained. This effect occurs because deuteration results in a considerable reduction in the 
proton spin density, which decreases proton spin-spin interactions and, therefore, the overall 
relaxation rate of the protein target.104 Additionally, the inclusion of specifically protonated 
amino acids or amino acid precursors in D2O growth media permits selective retention of protons 
at aliphatic resiudes (Ala, Val, Leu, Ile) or aromatic side chains (Phe, Tyr), which yields 
important structural information about protein target hydrophobic cores.105-107 Phe and Tyr side 
chains are often located at binding interfaces as well,103 and as such, protonation at these specific 
residues may be used to detect direct binding of a ligand. 
Selective 13C-labeling of Val, Leu and Ile methyl groups and subsequent 1H-13C HSQC 
chemical shift perturbation assays results in a three-fold increase in sensitivity compared to the 
1H-15N experiment.36 This labeling strategy, of course, improves the molecular weight limit of 
the protein target and has been used to study proteins with as many as 723 amino acids.108 More 
importantly, 13C-methyl labeling greatly simplifies the 1H-13C HSQC spectrum of the protein 
target and makes it amenable to implementation in high-throughput protocols. Additionally, the 
increase in signal-to-noise of the 1H-13C cross peaks shortens the required acquisition time and 
permits a lower concentration of protein to be used, facilitating the screening of many ligand 
mixtures in one day.7 13C-methyl labeling utilizes 13C-labeled amino acid precursors instead of 
13C-labeled glucose, making the cost of protein preparation comparable to uniform 15N-
labeling.36 
With prior knowledge of the structure or function of a protein, a variety of 15N- and 13C-
labeling techniques can be used to simplify the spectrum observed upon addition of ligand to 
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provide information about a specific region of interest in the protein target. Selective enrichment, 
applicable to many naturally occurring amino acids, is accomplished using supplemented media 
with one or more specific 15N-amino acids.109 For example, the specific 15N labeling of active 
site residues simplifies the 1H-15N HSQC perturbation assay. With knowledge of the protein 
target’s function unique amino acid sequences can be selectively labeled and used to detect 
binding using a simple approach. 13C and 15N labeling of two consecutive amino acids 
respectively (13C-X, 15N-Y) in the active site of the protein target will yield only one signal or a 
limited number of signals in a 13C-15N-1H three-dimensional correlation experiment (HNCO),38 
provided that only one or a limited number of the chosen amino acid pairs occur in the protein 
sequence. This particular labeling strategy facilitates the identification of ligand binding to a 
selective site without the need for sequence specific assignments because only adjoined 13C-15N 
labeled nuclei are detected with the HNCO experiment (see Figure 3).110 In another application, 
prior knowledge of the protein’s structure or function can guide segmental 13C and 15N-labeling 
of multidomain protein targets via trans-splicing111,112 or chemical ligation techniques.113 This 
reduces the number of observed signals in the correlation experiments, simplifies the analysis of 
chemical shifts upon titration of ligand and permits the evaluation of multidomain proteins in 
their native form. Selective 15N-labeling of specific amino acids is an additional approach that 
facilitates evaluation of larger molecular weight proteins as well as multidomain proteins. This 
type of labeling scheme also permits structural investigations of proteins that undergo allosteric 
regulation. For example, induced conformational changes of the acetylcholine binding protein 
(AChBP) pentamer were studied by selectively labeling Cys residues in the protein with 15N. 
Conformational changes in the Cys-loop distant from the binding site were observed upon the 
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addition of ACh, which confirmed the important regulatory role of the Cys-loop to AChBP 
function.114 
C.4.4. Computational Methodologies 
When full structure determination by NMR is not practical, computational strategies can 
be used to generate structural information about the protein-ligand complex to guide drug 
development using a limited amount of NMR data. NMR-DOC115 (Nuclear Magnetic Resonance 
DOcking of Compounds) can be used to develop models of the ligand bound to the protein target 
once the residues involved in binding have been identified. To determine important residues 
involved in binding, selective isotopic labeling is performed to observe a small number of key 
residues in the binding site, eliminating the need for complete sequential assignments during the 
screening process. Using a previously determined x-ray or solution structure of the protein as a 
starting point and experimentally measured intermolecular NOEs that arise between the ligand 
and the selectively labeled protein, models are developed that dock the ligand in the binding site. 
Selective labeling simplifies interpretation of the NOE spectra because fewer signals are present. 
This method has great utility because it can be used to examine higher molecular weight proteins 
with only a few NMR experiments and limited data analysis.  
NMR-SOLVE115 (Structurally Oriented Library Valency Engineering) is a very useful 
alternative to the SAR by NMR method of drug screening because it is applied to different 
protein targets that belong to a class of proteins related by binding site properties 
(pharmacofamily), as opposed to one protein target at a time. Proteins are classified into families 
based on common structural and functional features. Those from the same family typically share 
similar attributes, which may be exploited to narrow the search space to more rapidly identify 
high-affinity lead compounds. With NMR-SOLVE, the development of high-affinity ligands is 
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tailored to the family of protein targets related by the presence of a common binding site adjacent 
to a variable binding site.116 A known binder (often a cofactor) and its interactions with the 
common binding site are first studied by protein-detected NMR to identify important residues 
involved in binding. Common ligand mimics that bind with low affinity to a model member of 
the protein-family are then investigated by the same means. Intermolecular NOEs that develop 
between the ligand and the common and variable binding sites are used to develop NMR-DOC 
models based on the previously determined structure of the reference family member. The model 
of the low affinity ligand bound to the common binding site is then used to design a linker from 
which various molecular fragments can be added. Because the protein family selected has the 
same geometric relationship between the common and variable sites, the addition of various 
molecular fragments to the linker yields a compound library tailored to a given protein family 
without specific knowledge of their three-dimensional structure.115 Once the compound library 
has been constructed, screening of additional family members may be performed using other 
methods with a higher probability of finding a high-affinity (nanomolar) hit. This approach may 
prove to be an important drug design strategy in the post-genomics era.9 
The protein-ligand NOE matching117 method was developed in order to bypass the 
requirement of backbone resonance assignments of a protein’s binding site in order to determine 
the location, orientation, and internal conformation (binding pose) of a ligand bound to the 
protein. The binding pose of the complex can be determined at high-resolution using isotope-
filtered NMR experiments118 but may be difficult to accomplish in a reasonable time frame, as 
the time-consuming task of assigning binding site residues for each protein-ligand complex 
studied does not support repetitive cycles of structure-based ligand design. In this method, trial 
binding poses are scored based on matching an experimental pattern of intermolecular protein-
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ligand NOEs to predicted NOE patterns based on theoretical calculations. Trial protein-ligand 
binding poses are generated by any suitable computational docking method and are based on a 
previously determined structure (either X-ray or NMR) of a protein target of interest. For each 
binding pose, the intermolecular NOE pattern is predicted and matched to the experimental 
patterns. The scoring is based on a fast, deterministic algorithm, making it suitable for scoring a 
large number of trials in a short amount of time. Only the proton assignments for the bound 
ligand are required, making this a useful alternative to traditional methods when a structure of 
the unbound protein is available.117 
C.4.5. Competition Experiments 
 While it is possible to examine a wide range of binding affinities by NMR, ligand-
detected NMR screening has been expanded further to detect strongly binding ligands with slow 
dissociation rates by the use of competition assays.  The inability to observe tightly bound 
ligands directly results from the need to distinguish the ligand and target signals by exploiting 
size-dependent effects. Ligand-based screening methods detect only the free ligand signals and 
require rapid exchange between free and bound forms. To detect high-affinity ligands, 
competition-based experiments have been developed that rely on 1H or 19F relaxation and the 
STD NMR or waterLOGSY experiments because these methods are amenable to high-
throughput protocols in which mixtures of compounds can be screened simultaneously.58,119-
120,121  
Competition-based experiments utilize a reporter ligand that is in rapid exchange between 
free and bound forms with the protein target of interest.21 Tight binding by another compound 
results in displacement of the reporter.4 Displacement is manifested as a shift of the reporter 
compound’s NMR parameters toward those of the free state.21 Fluorine moieties on the reporter 
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molecule are especially useful because they facilitate the rapid high-throughput screening of 
large chemical mixtures against the protein target of interest because of the absence of overlap 
with signals from the mixtures to be screened.58 Competition experiments permit the detection of 
high-affinity molecules, significantly expanding the KD range amenable to ligand-based NMR 
screening to include high-affinity ligands. 
 
C.5. CONCLUSIONS 
High-field NMR is a powerful tool for the investigation of transiently forming 
complexes, and has become increasingly useful as the methodologies available to study these 
complexes expand. Methodologies are available to assess protein-ligand interactions from either 
the perspective of the protein target or the ligand molecule. They take advantage of the 
differences in the fundamental properties of small and large molecules as well as the presence of 
unique connectivities or atoms within the molecules to selectively detect binding. Advances in 
NMR technology and experimentation have greatly increased the size of molecules that can be 
analyzed, as well as increasing the throughput, sensitivity and resolution of the technique. As a 
result, high-field solution NMR plays a significant role in the identification of binding partners 
and the physicochemical characterization of protein-ligand interactions and has been applied 
successfully to advance pharmaceutical research. NMR’s unique ability to examine weak 
interactions and to structurally characterize binding events has substantially improved rational 
drug design and development and the analysis of potential therapeutics to protein targets. Given 
the versatility of high-field NMR and the continual innovation of the drug evaluation process, 
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STABILITY OF PRL-1-C98A AND PRL-1-C170S-C171S 
 
Table D.1 Physical Stability of PRL-1a 
 Phosphate HEPES 
 CD SLS CD SLS 
 Tm ± SD Onset T ± SD Tm ± SD Onset T ± SD 
nrWT 65.5 1.1 59.9 0.3 60.5 2.1 53.3 0.4 
redWTbc 67.8 0.4 63.8 0.4 62.0 1.3 57.4 0.3 
redWTd 79.0e 0.7 ndf nd nd 
C49S 62.8 2.0 59.7 0.2 56.3 0.3 50.0 0.3 
C104S 76.3 1.1 72.1 0.3 64.9 2.1 59.3 0.2 
Y53E 62.3 0.4 nd nd nd 
Y53F 62.6 0.3 nd nd nd 
oxC98A 64.5 0.6 59.4 0.3 64.7 1.6 59.9 0.3 
redC98A 65.1 0.6 63.5 0.3 64.2 1.8 60.9 0.3 
oxC170S-171S 70.2 0.5 68.6 0.3 60.1 0.1 56.6 0.4 
redC170S-171S 70.4 0.5 72.6 0.3 67.4 2.4 60.0 0.3 
aAll temperatures reported are in °C 
bFor CD, reducing conditions were achieved by the addition of 1 mM DTT. For SLS, 
reducing conditions were achieved by the addition of 10 mM DTT.  
cCD and/or SLS were also used to study the physical stability of PRL-1 mutants under 
both reducing and nonreducing conditions, although no differences were detected. 
This data for this is not shown. 
dReduced PRL-1-WT (redWT) was studied in 20 mM phosphate buffer at pH 6.5 with 
equivalent ionic strength (I=100 mM). All other values reported, including those for 
HEPES buffer, are at pH 7.5. 
eMelting was incomplete at the maximum temperature attainable and the data was 
extrapolated to determine the Tm.  
fNot determined 
 
Table D.1 includes the SLS and CD onset and melting temperatures for all PRL-1 
variants examined in the stability study (Chapter 5).  
 In all conditions examined, the reduced and oxidized C98A mutants have virtually no 
differences in their physical stabilities as measured by CD or SLS. This is not unexpected 
because the differences between the reduce and oxidized wild types are, although statistically 
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different from each other, extremely small (2.1 °C) compared to other differences observed (i.e. 
8.5 °C difference for C104S and reduced wild type). Inconsistent with all other mutants 
examined, however, phosphate does not stabilize the conformation of C98A to any reasonable 
extent. The reason for this observation is not clear but may have to do with local changes in the 
protein structure or dynamics when comparing the oxidized wild type and reduce wild type. 
As expected, there is no difference in Tm values between the reduced and untreated 
C170S-C171S mutant assayed under phosphate buffered conditions. Interestingly though, the 
untreated mutant was slightly less stable than the reduced mutant as judged by SLS in either 
buffer or by CD in HEPES buffer. The reason for this is unclear, but it may be due to the 
transient ability of the active site to form the disulfide bond. This is supported by the fact that 
C170S-C171S is less stable than the C104S mutant but more stable than the reduced wild type, 
possibly because C170S-C171S is less capable of forming the disulfide bond than the reduced 
wild type. Furthermore, the C104S mutant, which is incapable of forming the disulfide bond, is 
the most stable species. The fact that there was no difference observed by CD in phosphate may 
be because the buffer can bind the active site and slows down these conformational changes. 
Although highly speculative, this data collectively suggests that dynamic exchange of the 
disulfide bond is destabilizing. Construction of the C104S-C170S-C171S triple mutant may be 





APPENDIX E.  
PURIFICATION OF Zn-BOUND PRL-1 
 
PRL-1 is normally expressed as a His6-tagged fusion protein to permit purification by  
immobilized metal ion affinity chromatography (IMAC). The tag is cleaved by Factor Xa and 
then separated from the protein by passing the sample back over the IMAC column. Although 
the purification scheme for the zinc version of PRL-1 is the same in concept, a few minor 
adjustments were made to accommodate changes in protein solubility. First, the cells are lysed 
using a French press in Buffer A (50 mM Tris-HCl, pH 7.5 with 100 mM NaCl and 10 mM 
imidazole) and subsequently 
centrifuged at 21,000 x g to 
pellet out insoluble debris 
(Figure E.1, lane 1). Using a 
batch method for purification, 
the soluble cell lysates were 
then incubated with 
approximately 3 mL of 
iminodiacetic acid (IDA) 
chelating IMAC resin charged 
with 100 mM ZnSO4 for at least 











Figure E.1. Zn-PRL-1 Purification Scheme. Lane 1: 
soluble cell lysate. Lane 2: flow through from cell 
lysate. Lane 3: flow through from Buffer A wash. 
Lane 4: flow through from Buffer B wash. Lane 5-8: 
elution fractions 1-4. Lane 9: dialyzed sample that was 
subsequently treated with Factor Xa to remove the 
purification tag. Lane 10: Biorad protein standards. 
His6-tagged PRL-1 runs at approximately 25 kDa. 
Untagged PRL-1 runs just below 20. 
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(lane 2). The resin with protein bound was washed with 25 mL of Buffer A five times (lane 3). 
The resin was then rinsed with 25 mL of Buffer B (50 mM Tris-HCl, pH 7.5 with 200 mM NaCl 
and 40 mM imidazole) three times to minimize the number of nonspecific protein contaminants 
(lane 4). Elution was accomplished in 10 mL using Buffer C, repeating four times times (50 mM 
Tris-HCl, pH 7.5 with 200 mM NaCl, 500 mM imdazole, 100 µM ZnCl2) (lanes 5-8). The 
fractions were pooled together and a slow dialysis procedure was used to remove the imidazole 
from solution (lane 9). The 30-40 mL protein sample was dialyzed in 4 L of buffer containing 
250 mM imidazole for 1 hr, followed by subsequent dialysis steps with decreasing amounts of 
imidazole  (250, 150, 75, 10 then 0 mM). Dialysis was performed in 50 mM Tris-Cl, pH 7.5 with 
100 mM NaCl. The affinity tag was cleaved with factor Xa overnight and subsequently purified 
by size exclusion on a G75 column in 50 mM sodium phosphate, pH 6.5 with 100 mM NaCl, the 
next morning to ensure separation of the final cleaved product from any uncleaved sample 
remaining. Figure E.1 shows the SDS-PAGE gel corresponding to the first-day purification 
procedure to illustrate the efficiency of the method.  
The final samples were concentrated and exchanged 105 fold into 50 mM HEPES, pH 7.5 
for pNPP activity assays as described in the previous sections. The relative activities of the Zn-
bound PRL-1 and Ni-bound PRL-1 under both reducing and nonreducing conditions are 
essentially identical (data not shown), indicating that the majority of the protein is oxidized even 
though zinc lacks any specific redox active properties. 1H-15N HSQC NMR comparisons of the 
Zn-bound (0.5 mM) and Ni-bound (0.5 mM) PRL-1 forms are shown in Figure E.2. The 
diagnostic C49 NMR peak corresponding to reduced Zn-PRL-1 is not visible in this spectrum 
and a peak is observed close to the position of C49 in the oxidized state, further supporting our 
hypothesis that Zn-bound PRL-1 is primarily oxidized. Although some significant differences are 
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present between the two spectra, the two protein forms share the same general topology. 
Reduction of Zn-bound PRL-1 leads to large conformational differences that parallel those 
observed for the Ni-bound species both in the magnitude and number of changes, but also in the 
residues involved. Detailed chemical shift analysis cannot be conducted at this time because 
sequential backbone assignments are needed to clarify some of the larger differences between the 
two species. Collectively this information indicates that zinc binding in PRL-1 does not grossly 
affect the activity or structure when compared the nickel counter part. 
 
 Figure E.2. Overlay of 1H-15N HSQC Spectra of Zn- and Ni-PRL-1-WT. Both samples 
were collected under identical solution conditions at the same concentration. The C49 
residues are highlighted by a thick black box and the place where the corresponding C49 
peak in the reduced state should be located is demarked as well. Some of the larger changes 
between the two species are emphasized with the thinner black boxes. Some of these peaks 
correspond to previously unassignable C-terminal peaks, which are expected to deviate 
between these two forms because metal binding is accomplished by residues in this region. 
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